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MODELING AND DOSE SCHEDULE DESIGN FOR CYCLE-SPECIFIC
CHEMOTHERAPEUTICS
Jeffry Alan Florian Jr., PhD
University of Pittsburgh, 2008
Model-based optimal control has been used to synthesize chemotherapy treatment schedules.
Constraints on drug delivery or states are used to maintain drug administration within
toxicity limits, and the objective function usually minimizes the tumor volume at a
prespecified final time. These solutions predict a characteristic 3-phase treatment profile:
maximum initial drug delivery; a non-dosing period; and the remainder of the drug delivered
at the end of the treatment window. Ethically, however, a doctor cannot allow a tumor to
grow untreated, thereby invalidating the controller formulation. Dose schedule development,
therefore, requires an alternative formulation to obtain clinically relevant dosing schedules.
Dose schedule design for the therapeutic tamoxifen (TM) was investigated using nonlinear
model predictive control (NMPC) and a tumor regression reference trajectory. Performance
was dependent on accurate incorporation of the pharmacodynamic (PD) effect, and the
desired trajectory was tracked. The techniques evaluated could be adapted to other
therapeutics administered over regular intervals, though alterations to the objective function
would be necessary for clinical implementation
More detailed cell-level tumor growth models were investigated using population balance
equations. Individual cell cycle states were included within the model, as were saturating
growth rates representative of Gompertzian growth seen from solid tumors. Open-loop
simulations involving two cycle specific therapeutics (S- and M -phase active) questioned
iv
the simultaneous administration of therapeutics which predicted the largest final tumor
volumes. These results require additional investigation, as does the accuracy of the bilinear
PD effect structure.
A physiologically-based pharmacokinetic (PBPK) model for systemic docetaxel (Doc)
disposition in SCID mice was developed based on collected plasma, tumor, and tissue
concentration data. This model was scaled to humans and compared against patient Doc
plasma data from several clinical trials as well as Doc plasma predictions from other models
in the literature. A low-order neutrophil model from the literature was tailored to patient
neutrophil samples from the clinical study. The human-scaled PBPK Doc and neutrophil
PD models were combined and used to evaluate Doc regimens from the literature. Finally, a
NMPC was synthesized based on the PBPK and PD models and used to develop clinically-
relevant dosing regimens under PD constraints.
v
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1.0 INTRODUCTION
Cancer is a collection of diseases resulting from a series of genetic mutations that is
characterized by an imbalance between cell proliferation and apoptosis, or programmed cell
death [9]. Currently, cancer is the leading cause of death in adult Americans under the age
of 85 and is expected to claim over 565,650 lives in 2008 [10]. In addition, the total disease
burden, including treatment costs and loss of productivity, was estimated at $219.2 billion in
2007, providing both societal and monetary reasons for improving cancer treatment regimens
[10].
Current cancer treatment modalities include surgical excision of the tumor mass whenever
possible, site-specific treatments (i.e., radiation or photodynamic therapy) when the tumor
is localized but not resectable, and systemic administration of a chemotherapeutic agent
(that is commonly cytotoxic). The last modality is commonly employed as a single agent,
in combination with additional chemotherapeutics, or in conjunction with one or more of
the previously mentioned treatment modalities. Systemic chemotherapeutic treatments have
numerous advantages, such as an ability to eliminate undetected metastases and doses that
can be taken without hospital visits in the case of oral medication. Systemic treatments also
have failings, however, the most notable of which is a lack of selectivity in targeting tumor
cells. Chemotherapeutics affect all rapidly proliferating cell types in a patient, including
gastrointestinal, epithelial, and hematopoietic stem cells, the destruction of which results in
the most common toxicities encountered during treatment with cytotoxic agents. The degree
to which these toxicity effects can be tolerated are determined in extensive preclinical and
clinical trials, during which pharmacokinetic (plasma drug concentration and metabolites)
and pharmacodynamic (tumor regression and toxicity) data are collected.
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However, the goal of these trials is not on developing the true optimal dose regimen.
Rather, protocols focus on demonstrating efficacy and establishing the maximum tolerated
dose of the drug while using the same schedule previously used for drugs with similar
mechanisms of action. Due to monetary, time, and ethical restrictions, as well as the
combinatorial nature of the problem, all feasible dosing schedules, drug dosing levels, and
dosing combinations cannot be evaluated in clinical trials. Simulations, on the other hand,
provide a low-cost alternative for evaluating the plethora of possible dosing schedules and
determining which, if any, could theoretically increase treatment efficacy and/or patient
quality of life if implemented in the clinic. Three components are essential in developing these
simulations as shown schematically in Figure 1.1: (i) a pharmacokinetic (PK) model for the
delivered drug; (ii) a pharmacodynamic (PD) model for the drug effect (toxicity and/or
tumor response); and (iii) a model-based algorithm for calculating candidate treatment
regimens based on the constructed models, implemented constraints, and objective function.
Following administration of a therapeutic, concentrations of the drug in the plasma and
throughout the system will be observed to increase, then decrease back to homeostatic values
(or zero) over time. In turn, drug in the system will result in a number of downstream PD
effects, including, but not limited to, tumor regression, reduction in circulating neutrophil
count, and decreased body weight. In the context of control systems, this connectivity is
considered as an open-loop system, where an administered input results in a downstream
system effect. When the resulting effect information is used to alter the input, this is
considered a closed-loop system [11]. In a clinical context, the clinician serves this role,
evaluating the patient outcome of a treatment and making informed alterations to the dosing
level accordingly. Usually, the clinician will only make decisions regarding alterations to the
dosing level or continuation of the treatment. Alterations to the dosing schedule are avoided
due to FDA regulations, the complexity of the problem, and limited experimental evidence
regarding increased efficacy resulting from dose schedule alterations.
Alternatively, decisions on input changes can be established using PK and PD model
approximations of the patient, a controller framework, and an objective function that
optimizes performance according to model-predicted PD effects and/or actual patient
measurements by manipulating available inputs. The state of the system (current patient
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measurements) and desired output are both provided to the algorithm; based upon a user-
defined objective function, the input alterations which minimize the objective function
are found and will either be administered to the patient (true in an absolute close-loop
implementation) or, for the case of chemotherapeutic treatment, will be examined off-line
and administered to the patient on the following treatment visit if accepted.
1.1 PHARMACOKINETIC MODELS
Pharmacokinetics describes the time course of distribution, absorption, metabolism, and
excretion for an administered drug [12, 13]. In addition, PK aids in determining the route
of drug administration and dosing level. Finally, it is a necessary precursor to drug approval
by the FDA [14]. Three types of PK models, ranging from simplest to most complex, are
described in the literature: (i) non-compartmental models; (ii) compartmental models; and
(iii) physiologically-based pharmacokinetic (PBPK) models.
The simplest and most commonly employed PK analytical tool is non-compartmental
modeling. This modeling technique uses statistically-based methods to calculate patient
relevant metrics such as drug clearance and drug exposure based upon an area under the
curve (AUC) calculation. This approach provides information regarding individual patient
data and may be predictive of population metrics across other studies involving the same
compound. However, each altered experimental variable (e.g., dosing schedules, infusion
duration, dosing levels, etc.) reduces the likelihood of accurate extrapolation of non-
compartmental model results. This type of analysis accompanies a majority of clinical trials
in the country and is commonly employed as a means of finding correlations between two
measures, such as patient toxicity and clearance or patient survival and AUC [15].
Another type of PK modeling, the compartmental approach, uses ordinary differential
equations (ODEs) coupled via a compartmental structure to relate drug input to drug
concentration output as a function of time. A generic compartmental PK model with
intravenous drug infusion and clearance from the central compartment is shown in Figure 1.2
(solid line). Additional compartments may be added to account for lumped-tissue absorption
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and release dynamics which may affect plasma PK (dotted lines and compartments,
Figure 1.2). Alternatively, these models can be appended with additional compartments
to describe drug deposition in other tissues and/or tumor (dashed-lines and compartments,
Figure 1.2) if the necessary drug concentration versus time data for that tissue was obtained.
Transfer rates between remote compartments and the central compartment, as well as the
elimination rate from the central compartment, are assumed to be linear with respect to
drug concentration, though nonlinear relationships, such as Michaelis-Menten kinetics, may
also be employed. Finally, central compartment volume scales plasma concentration and can
be used to estimate tissue distribution and protein binding for the drug in question.
Compartmental modeling is the second most common PK modeling technique, and the
developed models can be fit not only to individual data, but to sampled data from an
entire population [16]. Furthermore, these population models may be either representative
of the population PK or capable of predicting individual PK based on patient specific
measures directly affecting parameters within the population PK model [16]. Population
PK models are constructed from multiple individual data sets, with parameter values and
distributions capable of describing the intra- and inter-individual PK variability observed
from the population [17, 18, 19]. On the other hand, these models can also be predictive of
individual PK profiles by including patient covariates, such as age, gender, liver function,
etc., within parameter calculations [2, 20, 21, 22, 23, 24, 25, 26, 27, 28]. Many standard
analytical programs in the community such as NONMEM, ADAPT II, and WinNonlin have
pre-made structures for the generation and analysis of low-order compartmental structures
[29, 30]. Finally, these models can also be used for calculating the same clinically important
parameters (AUC, clearance, etc.) as non-compartmental models.
Compartmental models have a few disadvantages, however. A key shortcoming is that the
model structure represents neither the anatomy nor the physiology of the species in question.
Furthermore, the estimated parameters have limited physiological significance, representing
a mathematical fit to the data rather than individual absorption and clearance dynamics
encountered within the subject. Also, the model structure is dosing route dependent. To
account for separate administration routes, not only are additional compartments necessary,
but the entire model structure and parameters may need to be reevaluated. Finally,
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the allometric scale-up for these models from animals to humans, which is the primary
treatment group of interest, may prove unreliable if the modeled drug displays long term
tissue retention, is delivered orally, or as additional tissues are incorporated within the
compartmental model [31, 32, 33]. These shortcomings can be addressed by developing a
PBPK model.
PBPK models use knowledge of the anatomy and physiology of the studied species
to develop a PK model that accurately describes plasma, tissue, and, in some cases,
tumor concentrations, following drug delivery. These models have found extensive use in
toxicology studies [34, 35], delivery of anesthetics [36, 37, 38], treating diabetes [39, 40],
and, more recently, in describing chemotherapeutic distribution [5, 41, 42, 43]. An example
PBPK structure is shown in Figure 1.3. Individual tissue compartments are represented by
ordinary differential equations (ODEs); one equation represents a perfusion-limited tissue,
with additional sub-compartments (and equations) included for diffusion-limited tissues.
Individual tissues are included based on deposition areas of interest and available data,
while the remaining tissues can be lumped together into an “other” compartment (also
described as “carcass”, “peripheral”, or “remainder” depending on the investigating group
and species in question) as a first step in reducing model complexity and the number of
parameters requiring estimation. Drugs are administered via intravenous injection (into the
venous compartment), administered orally (into the gut), inhaled (necessitating a pulmonary
compartment in addition to the lungs), injected subcutaneously (into a skin compartment),
or injected intramuscularly (through the muscle compartment).
For single equation tissue structures, plasma-to-tissue partition relationships are included
within these models by introducing partition coefficients that alter the drug concentration in
blood flowing out of tissues. Elimination from these tissues, whether metabolic or excretory,
is introduced as either linear or nonlinear elimination rates based upon the unbound
concentration of drug within the respective tissue. The metabolic rates are often obtained
from in vitro experiments, while more macroscopic elimination pathways are based on in
vivo collection of urine and feces. The concentration of drug leaving a tissue may be further
altered due to binding kinetics, which introduce additional nonlinearities or dynamics into the
PBPK model and are often not fully evaluated during model development (e.g., extrapolated
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model behavior may predict unrealistic PK results). On the other hand, when tissues are
represented as multiple ODEs, the volume of the tissue is divided between all compartments
utilizing a vascular fraction parameter obtained from the literature or estimated from
experimental data. Transport between compartments can be governed by either a single
transfer rate, driven by the concentration gradient between the two compartments, or by
unidirectional transport rates between compartments, often necessary when the transport
dynamics for a drug within a tissue is governed by non-gradient mechanisms, such as active
transport and internal binding. In the latter case, the vascular fraction and exit transit rate
may not be estimated independently, requiring prior knowledge or strict bounds on one of
those parameters, typically the vascular fraction. Metabolism and excretory dynamics are
included within the interstitial compartment of these models, and parameter values can be
obtained either from in vitro studies or by estimating the parameters to fit experimental
data.
Two main disadvantages of PBPK models are the amount of data necessary to estimate
parameters and validate the model as well as the complexity of the system compared to more
traditional compartmental models. Tissue volumes, blood flow rates, vascular fractions in
tissues, intra-tissue exchange rates, and clearance rates for the drug are all required for
constructing this type of model. Fortunately, average values for many of these parameters
can be obtained from the literature (i.e., blood flow rates and blood volume fractions) [1];
other parameters, such as tissue volumes, are collected during the course of a detailed PK
study (lacking this, average values are also obtainable from the literature). The remaining
parameters have to be estimated using the study data. Despite the complexity and data-
intensive nature of PBPK models, they have proven reliable in predicting plasma profiles
following model scale-up to larger species [5, 37, 41, 44, 45].
1.2 PHARMACODYNAMIC MODELS
PD describes the effect that the drug has on the system, where this effect may be desirable
(e.g., tumor regression) or harmful (e.g., manifestation of toxicity). Ideally, PD models
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would be PK-driven (Figure 1.1b), incorporating drug concentrations within the specific
tissue or at the site of action [46]. Currently, such measurements are rarely obtainable in
the clinic and can only be estimated using PK models incorporating tissue compartments,
though non-invasive imaging techniques may address this limitation in the future. More
often, PK-driven PD effect is estimated based on plasma drug concentrations. As the plasma
concentration may have different dynamics than the tumor drug concentration, the use of
plasma concentration may lead to over- or under-prediction of actual drug effect [47].
For cases involving chemotherapeutic PD effect, realistic PD representations may account
for cell surface receptor density and kinetics, internal signaling cascades, or intracellular drug
transport following exposure to a therapeutic. Such models, however, require substantial
amounts of data to properly describe these biologic pathways and the robust interdependency
that exists between them. Due to the complexity of biological systems, mechanistic
models for PD effect are often not explored, instead settling for macroscopic relationships
capable of describing the observed PD outcomes. Here, a number of simple, causal
relationships (i.e., linear, log-linear, Michaelis-Menten, etc.) have been explored in the
literature. These typically relate a PK profile to observed PD effects including tumor
response [48, 49], neutrophil and leukocyte toxicity [3, 50, 51], diabetes [39, 52, 53, 54],
human immunodeficiency virus treatment [55, 56, 57], and depth of anesthesia [58, 59, 60],
to name a few.
Common cancer PD models describe anti-tumor effect as being proportional to a bilinear
combination of the affected tumor population and the plasma drug concentration [61]. This
relationship is also primarily employed in predicting the apoptosis of healthy proliferating
cells for toxicity predictions. More complicated functions, such as Michaelis-Menten kinetics,
indirect response models, sigmoidal models (e.g., Hill functions), or a necessary threshold
plasma drug concentration, can also be employed for modeling PD effects [46, 62, 63, 64].
While the bulk of model-based cancer treatment has focused on tumor models and the
subsequent inclusion of drug effect, others have addressed the treatment problem through
the incorporation of suitable toxicity models for the delivered drug [65, 66]. Summaries of
both approaches are discussed below.
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1.2.1 Tumor Growth Models
Tumor modeling approaches can be grouped into two categories: homogeneous and
heterogeneous. The basic homogeneous tumor model is a single, linear ODE characterizing
exponential growth with a single parameter governing the doubling time of the tumor.
This model accurately describes blood-born cancer progressions (e.g., leukemia), but over
predicts the growth progression of solid tumors except over very short windows (e.g., one
doubling) [67]. A slightly more complex nonlinear ODE representation is the Gompertz
equation, which has been shown to accurately describe clinical data for a wide range of solid
tumors [68, 69]. The two parameter Gompertz equation predicts saturating tumor growth
as the total tumor volume approaches a preset “plateau” volume. As an approximation
to the Gompertz equation, Simeoni et al. have constructed models that “switch” growth
profiles at a predefined tumor volume [49]. This “switch” alters the growth profile from
exponential to linear or continues the exponential progression at a slower doubling time. This
model structure is useful for describing tumor growth over multiple doubling times where
a single exponential model cannot accurately model the data. The anti-tumor PD effect of
administered drugs is incorporated as a bilinear term, that is, a product of drug concentration
and the total tumor mass present scaled by an estimated drug effect rate [70]. However,
assuming an equal drug effect on the entire tumor population may result in an over-estimate
of anti-tumor effect, especially as radiation and most chemotherapeutics are more effective
during specific phases of the cell-cycle [71]. Incorporating cell phase information within
the model structure, therefore, would allow for a more biologically relevant incorporation of
treatment effect and increased model accuracy in response to treatment.
Cell-cycle models seek to describe the biological phase progression of cells. There are
five identified cell phases, corresponding to growth (G1), DNA replication (S), mitotic
preparation (G2), mitosis (M), and quiescence (Q) as shown in Figure 1.4. Actively
proliferating cells progress through the cell division loop (G1 toM and back toG1), while non-
cycling (i.e., the chemotherapy or radiation insensitive population) reside in the quiescent Q-
phase [72]. Cell phases are typically resolved by a combination of proliferation, DNA, or RNA
staining; however, it is often difficult to resolve individual phase fractions for all five phases
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of the cell-cycle [4]. Therefore, constructing a model with explicit representation of all phases
would be overparameterized, thereby leading to high parameter sensitivity and uncertainty.
Grouping cell phases together reduces the amount of information necessary to model the
system in this framework while simultaneously reducing overall model complexity. Smith
and Martin have reduced the cell-cycle model to its basic component, namely proliferating
and quiescent cells [48, 73]. This two ODE model better incorporates drug effects targeting
proliferating cells, however, most chemotherapeutics target proliferation mechanisms specific
to certain phases of the cell-cycle. A number of models have been developed [74, 75, 76, 77]
to describe either G1−, S−, orM -phase (the latter being a combination of G2- andM -phase
cells, hereafter referred to solely asM -phase within this dissertation) specific drug effects with
varying degrees of complexity (e.g., additional equations for All of these models have linear
transition rates between phases that can only return exponential tumor volume progression
at the macroscopic scale when left untreated. The introduction of saturating phase-transition
rates, similar in philosophy to the Gompertz model, or the selective accumulation of cells in
a non-cycling compartment, Q, overcomes this limitation. Such models maintain cell-cycle
specific information while amassing cells in either Q or a lumped G-phase [78, 79, 80]. These
models are often sufficient for describing bulk tumor data observed clinically; however, these
models simplify reality by assuming that the tumor is composed of lumped populations
of cells. In actuality, these cells have individual transition rates, are exposed to various
concentrations of drugs dependent on an erratic vascular network, and may not be actively
dividing depending on their overall location within the tumor and nutrient availability.
One class of models that accounts for the heterogeneous properties of tumors is
population balance equation (PBE) models. These models incorporate internal cellular
properties (e.g., age, mass, or DNA content) and allow for distributed progression through
cell phases and drug effect [80, 81, 82, 83, 84, 85, 86]. The discussion of this class of tumor
models will be explored in greater depth in Chapter 3. An alternative structure, the cell
ensemble model, uses equations to define each cell with parameters fixed from a preset
distribution [87]. Such models are simpler for a high number of intracellular properties, but
are ill-suited for handling cell division, an essential component of tumor progression. Spatial
inhomogeneity of the tumor may also be essential for predicting tumor invasiveness and
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drug concentration throughout the tumor [88, 89, 90, 91, 92, 93]. Studies have demonstrated
that many chemotherapeutics have difficulty traversing the leaky internal vascular networks
of tumors, with a majority of exposure occurring in the outer periphery of a tumor mass.
While this may be ideal from a treatment perspective, as these cells are actively proliferating,
failure to account for internal spatial diffusion limitations of chemotherapeutic compounds
(not to mention essential nutrients such as oxygen and glucose) can lead to inaccurate model
predictions.
Cell automata models and fractal simulations take the cellular tumor model to its
penultimate conclusion, representing each cell individually while accounting for invasive
migration, predicting metastases, and constructing an appropriate vascular network for the
simulated tumor [94, 95, 96, 97, 98]. Other factors influencing tumor growth, such as external
pressure effects, acquired drug resistance, and gene mutations perpetuating tumor growth
provide additional information, allowing for a more physiological representation of tumor
progression [87, 99, 100, 101, 102, 103]. While all this information would improve model
predictions, data on a per patient basis, or a per animal basis in the preclinical setting, would
be difficult, at best, to collect. Distributions for phase transitions and drug effects could be
obtained from collected data, but the exact tumor geometry with internal necrosis cannot
be determined exactly except by destructive biopsy. An important question to consider,
then, is whether control based on a less detailed but identifiable model is sufficient for dose
scheduling purposes.
1.2.2 Toxicity Models
Eliminating the tumor mass is not the only concern during chemotherapy, as the drugs
employed also adversely affect healthy proliferating cells. Common toxicities encountered
during the course of chemotherapy include diarrhea, dizziness, bleeding, nausea, vomiting,
mucositis, and myelosuppression, with different toxicities manifesting depending on the
drug(s) and treatment regimens employed [104]. While maximum dosing limits provide
one means of avoiding excessive patient toxicity, patients must still be monitored during
a treatment cycle because of inter-patient variability in drug clearance and sensitivity.
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Clinicians assess toxicity on a discrete, graded scale from 0-4, with higher grades correlating
with worse toxicity [104]. Additional discrete measures, such as discrete events of vomiting
and diarrhea introduce another element of complexity in toxicity model development, as well
as subjective classification associated with some toxicity measures (such as dizziness or skin
irritation).
One approach to toxicity modeling involves identifying those subsets of patients more
prone to toxicity and treating them in a less aggressive manner [105, 106]. Others include
developing heuristic relationships between a toxicity grade and dose administered, drug
plasma concentration area under the curve, or time that plasma drug concentration exceeds
a therapeutic value [107, 108, 109]. These relationships provide clinicians with trends and
likelihood of toxicity, though the uncertainly on such models precludes them from serving as
strict toxicity predictors during treatment. Such models do, however, allow for a continuous
formulation of discretely graded variables, facilitating downstream controller design if the
toxicity measure is indeed the primary toxicity associated with the drug. Combining both
ideas, most toxicity model development has focused on measures that are easily obtainable
and already continuous, such as the decrease in platelets, leukocytes, and/or neutrophils
following chemotherapeutic treatment [3, 50, 51, 110, 111, 112]. Control algorithms that
incorporate models for neutrophil or leukocyte proliferation and drug effect can develop
drug schedules that minimize patient toxicity (possibly avoiding other toxicities as well) while
simultaneously minimizing overall tumor volume [3, 75, 111, 113]. Secondary toxicities may
still manifest in such regimens, but by avoiding the primary toxicity it should be theoretically
possible to maintain secondary toxicities within acceptable treatment bounds.
The simplest model for healthy proliferating cells uses the same equations as those used
to represent short-term tumor growth or the progression of hematologic cancers. Using either
traditional exponential or linear cell-cycle models with adjusted growth rates and appended
elimination or apoptotic rates, it is possible to represent leukocyte progression and treatment
response over short windows in time. However, these models are either unstable or cannot
guarantee convergence back to the original steady state (i.e., will not maintain a steady state
cell population in the absence of treatment). Replacing the production rate of cells in the
progenitor compartment with a constant (rather than the product of progenitor cells and
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a rate) allows for stability of the system and baseline recovery. A typical compartmental
neutrophil model without feedback is shown in Figure 1.5a, along with a representative
neutrophil time course after administration of a myelosuppressive drug in Figure 1.5b [114,
115]. The structure consists of: (i) a progenitor compartment where drug effect (Edrug)
occurs; (ii) intermediate compartments between progenitor and circulating cells representing
cell maturation, where the cells are unaffected by the drug; and (iii) a circulating neutrophil
compartment that has elimination due to natural cell death but is otherwise unaffected
by the drug. Figure 1.5b shows a delayed drop in circulating cell count following drug
exposure (bolus at t = 0) as affected cells progress to the circulation; proliferating cells,
and eventually the circulating population, return to baseline following treatment. Models
of this type, however, fail to account for the internal biological control loop that regulates
circulating hematopoietic cell count and demonstrates baseline cell count overshoot following
treatment.
An important compound in regulating neutrophil count is granulocyte colony stimulating
factor (GCS-F), which promotes the proliferation of hematopoietic stem cells by binding to
and activating the GCS-F receptor. In addition, GCS-F binds to circulating neutrophils,
which has no effect on neutrophil production. This interaction between circulating neu-
trophils and GCS-F results in an equilibrium cell count and systemic GCS-F concentration.
If the baseline cell count of circulating neutrophils falls, such as from a chemotherapeutic
treatment, the concentration of unbound GCS-F will increase resulting in an upregulation
of hematopoietic stem cell division. Similarly, neutrophil counts above baseline decrease
the concentration of bound GCS-F and subsequently downregulate hematopoietic stem
cell division. As GCS-F plasma concentrations are not often obtained during treatment,
many groups have developed neutrophil feedback models based on the circulating neutrophil
count. A low-order model developed by Karlsson and coauthors [3] has model states as
described above in addition to a nonlinear feedback mechanism dependent on circulating
neutrophil deviation from the homeostatic value. Similar neutrophil models have been
developed by Zamboni et al. [50] and Minami et al. [109], though the model output in these
cases was percentage decrease in neutrophil count rather the absolute neutrophil count.
More complicated model structures depicting the entire process of human granulopoiesis
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incorporate multiple feedback loops, including the effects of granulocyte macrophage
colony stimulating factor (GMCS-F), individual drug effects on each subpopulation of
precursor cells, and nonlinear transition rates dependent on circulating GCS-F and GMCS-F
concentration [51, 66]. Such models are able to capture more rapid alterations in circulating
neutrophil counts and are useful for describing population or subpopulation behavior during
a chemotherapeutic trial; however, these models require more parameters than less complex
neutrophil models and are difficult to tailor to individual patients.
A final item is the location of chemotherapeutic effect relative to the measurement of
the effect. As previously mentioned, chemotherapeutics target cellular machinery which is
upregulated during cell growth and cell division. This allows for preferential selection of
tumor cells versus the majority of other cells in the body (under the assumption that tumor
cells proliferate more rapidly than healthy cells), though other rapidly proliferating cells,
such as hematopoietic stem cells, are simultaneously affected by the treatment. Circulating
neutrophils and post-mitotic neutrophils undergoing differentiation, however, do not proceed
through the cell-cycle and are not affected by the administration of chemotherapeutics.
Rather, the upstream precursors will undergo apoptosis or growth inhibition which will,
in turn, reduce circulating neutrophil count after a period of 3-5 days (the approximate
maturation time for neutrophils). Observed fluctuations in circulating neutrophil count,
therefore, are a delayed observation of the actual drug effect. More thorough model structures
accounting for differentiation states of hematopoietic cells and cell phase can also be found
in the literature [51, 66], although the large number of model parameters would hinder the
ability to adapt such models for individual patient treatment based on sparse data collection.
Neutrophil toxicity models have been developed for a number of therapeutics including
pemetrexed, docetaxel (Doc), paclitaxel, etoposide, vinflunine, irinotecan, 2’-deoxy 2’-
methylidenecytidine, topotecan, epirubicin, and 5-fluorouracil [3, 50, 110, 111, 116].
Typically, these models were developed based on individual neutrophil counts and were
used to construct representative population models of neutrophil progression following
treatment. Karlsson and coauthors have updated the model parameters to include patient-
specific measures such as α-1 acid glycoprotein (AAG), body surface area (BSA), patient
weight, and albumin levels, in order to develop prospective individual neutrophil progression
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predictions for patients [106]. Results applied to Doc demonstrated that the most important
patient parameters included AAG, BSA, and CYP3A enzyme level [106]. Scholz and
coauthors used a more involved leukocyte model to investigate the treatment outcomes of a
cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) regimen [66]. These studies
focused on defining drug PD parameter profiles representative of patients at high (elderly
patients), medium, and low risk for neutrophil toxicity following treatment. Using these
groups, subgroup leukocyte progression was simulated and necessary regimen alterations to
the cyclophosphamide dose to maintain acceptable toxicity levels were evaluated [66]. To our
knowledge, prospective evaluation of alternative dosing regimens have not been investigated
using these models in the literature.
1.3 CONTROLLER ALGORITHMS
Model-based control is currently considered the state-of-the-art in the field of process control
and is the technique focused on solely within this dissertation. A generic representation of
this technique is shown in Equations (1.1)-(1.4):
min
u(t)
F (x(tf ), x(t), u(t)) (1.1)
s.t. x˙(t) = g(x(t), u(t)) (1.2)
A1 ≥ u(t) ≥ A2 (1.3)
B1 ≥ x(t) ≥ B2 (1.4)
This control technique uses an explicit representation of the system as a model (Equa-
tions (1.2)) to make decisions on how to change the manipulated variable (u(t)) in
order to obtain a desired outcome (based upon the formulation of the objective function,
F (x(tf ), x(t), u(t))). Objective function terms typically include some combination of
penalties (weights) on the state values (x(t)), input magnitude or energy (u(t)), and final
time state values (x(tf )) of the system over the optimization horizon. Input changes
are accomplished while satisfying both input (Equation (1.3)) and state (Equation (1.4))
constraints, which may be either strict equality or inequality relationships and are specifically
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chosen for the system. This technique has been applied across a range of fields, and a
comprehensive list of areas where model-based control has been applied is beyond the scope
of this dissertation. Instead, discussion will focus on the implementation of this technique
specifically for the cancer treatment problem
Cancer treatment design has been investigated using a variety of control techniques,
including optimal control theory [65, 75, 117, 118, 119, 120, 121], control vector param-
eterization [122, 123], nonlinear model predictive control (NMPC) [79, 80], and mixed-
integer linear/nonlinear programming (MILP/MINLP) [64]. Lumped tumor models (i.e., the
exponential and Gompertz) coupled with a bilinear kill term have been investigated using
optimal control theory in order to minimize a tumor volume at a final time allowing for
the continuous administration of a therapeutic. Such dose scheduling approaches, however,
have failed to account for the constraints commonly encountered in a clinical setting. First,
intravenous (IV) chemotherapeutic administration often occurs during clinical hours, and
drugs taken orally at home should be scheduled during the day (e.g., the patient will
not routinely wake up in the middle of the night to take a pill). Furthermore, many
chemotherapeutics administered IV will not be administered continuously for extended
periods of time due to drug toxicity. For pills taken on regular intervals (i.e., daily or
weekly administration), the model predictive control framework can be used to develop
the dosing schedule [79, 80]. Evaluation of drug schedules over non-regular intervals (i.e.,
stochastic weekday decisions), however, may require more complex controller algorithms such
as MILP/MINLP [64].
The implemented objective function must also be chosen carefully to ensure the existence
of solutions which are both nontrivial and clinically relevant. For an objective function based
on the final-time tumor volume and an underlying exponential or Gompertz tumor growth
model with bilinear drug effect, the solutions returned by the controller will be clinically
indistinguishable but numerically different (final tumor volume differences of <1%) [124].
Also, for the above listed objective function, the algorithm predicts a characteristic treatment
profile: maximum initial drug delivery, followed by a non-dosing period, with the remainder
of the drug delivered at the end of the treatment window [63]. Ethically, however, a doctor
cannot allow a tumor to grow untreated, thereby invalidating the controller formulation.
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In addition, bulk dosing at the end of the cycle, instead of at the beginning, prohibits
dosing immediately after the treatment design window due to patient toxicity. Dose schedule
development, therefore, requires either an alternative objective function, PD effect, clinical
constraints, or model structure to obtain useful scheduling results. A more suitable model
structure for dose schedule development would include the cell-cycle [75, 117, 118, 125],
which more accurately captures the phase specificity of drug action, and/or a toxicity model
[3, 75, 111, 113] to ensure dosing safety and provide an additional measure of treatment
efficacy.
Dose schedule development has been investigated using a number of tumor growth model
structures, including lumped models [63, 67], cell-cycle models with cycle-specific treatment
effects [75, 80, 125], and tumor growth models with subpopulations of susceptible and
resistant cells [117, 118]. The inclusion of a toxicity model within the controller formulation,
not just input bounds or limits on the total drug administered over a cycle, however, is
limited to a few studies from the literature. Fister and Panetta investigated the case of both
healthy and cancerous cells proliferating at different growth rates while subjected to a cycle-
specific chemotherapeutic [65]. Using an optimal control algorithm with an output objective
of maximizing both total drug delivered and the final quantity of healthy cells remaining, the
results demonstrated that the therapeutic should be administered preferentially towards the
end of the simulation, again neglecting ethical issues and downstream toxicity. Afenya used
an optimal control formulation to determine the minimum time necessary to switch between
administration of the drug (e.g., drug delivery was either “on” or “off”) in the presence
of two concurrent cell populations: (i) healthy; and (ii) cancerous proliferating cells [113].
Results demonstrated that by shortening the time between dose administration, overall cycle
time could be reduced by 1-2 weeks without adverse toxicity effects, a result that is termed
“dose-dense” therapy currently practiced clinically in breast cancer treatment [70]. Finally,
Harrold et al. combined a nonlinear PK model for the therapeutic, 9-nitrocamptothecin
(9NC), with a switched exponential model for tumor progression and bilinear PD effect on
tumor regression [124]. A toxicity model altered the body weight of the mouse in response
to 9NC administration, and the resulting objective function was set to minimize the final
tumor volume subject to output constraints on the body weight of the mouse throughout
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the treatment. The model of body weight response to therapy was inexact, not to mention
non-ideal as a toxicity dosing metric (body weight alterations would manifest after intestinal
damage had already taken effect), and this dramatically impacted the dosing schedule design,
illustrating the importance of accurate toxicity models [124].
The investigation of closed-loop solutions to dose schedule development may often be too
specific to the problem being modeled (i.e., highly sensitive to model parameters, narrow
dosing windows, etc.). Furthermore, the solutions obtained from such formulations are highly
dependent on the objective function and system constraints, and the true “optimal” solution
may be numerically indistinguishable from a number of other more clinically implementable
solutions. Given all possible degrees of freedom in clinical implementation of a control
algorithm, it may be useful to begin dose schedule evaluation in an open-loop framework.
Open-loop studies based on cultured tumor cell dynamics have also been investigated,
focusing on the ideal treatment interval to maximize cell death [84, 126], ensure statistical
elimination of the tumor [127], or prevent the development of resistance [85]. Using more
involved PBE representations for tumor proliferation, all of these models were consistent
in predicting drug delivery with increased frequency compared to normal clinical treatment
(approximately cycles of 12 hours). Lacking within these studies were evaluations on how
uncertainty in parameter mean values may alter treatment, in vivo validation of the proposed
cell fraction distribution oscillations exploited during treatment, or an accompanying toxicity
model to assess whether the increased frequency of doses were clinically acceptable. Other
open-loop studies by Dyson et al. [84] and Sherer et al. [86] used concurrent models for
the proliferation of cancerous and healthy proliferating cells exposed to the same drug
concentration. Rather than investigating dose level alteration, these studies focused on the
delivery intervals of chemotherapeutics to maximize tumor elimination, again, attempting
to exploit oscillations in cell-cycle fractions induced following treatment with cycle-specific
therapeutics. Results from both of these studies concluded that the window of delivery
for improving anti-tumor effect while sparing healthy proliferating cells was too narrow to
exploit in a clinical setting, though no validation of the healthy proliferating cells within an
in vivo setting was provided.
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1.4 DISSERTATION OVERVIEW
Dose schedule development, balancing patient quality of life and treatment efficacy, should be
feasible by incorporating coupled drug PK and PD effect models within a control algorithm.
Chapter 2 focuses on the development of a compartmental PK model for the G-phase specific
chemotherapeutic, tamoxifen (TM), and its active metabolite, 4-hydroxytamoxifen (HTM).
This PK data is used for developing a series of tumor growth models which differ in growth
dynamics structure (saturating versus non-saturating growth behavior) and complexity
(lumped approximation versus representations of individual cell-cycle phases). These coupled
PK/PD models were then incorporated within a nonlinear MPC (NMPC) framework to
determine in mice the daily doses of TM necessary to follow a predefined tumor regression
trajectory.
Chapter 3 explores the development of more complicated and biologically-relevant tumor
growth models using population balance equations (PBEs). Cell cycle models were developed
using either age or mass as intrinsic variables; models were then updated to display
saturating dynamics commonly observed during solid tumor growth. Theoretical weekly
repeating treatment regimens involving an S- and M -phase therapeutic were investigated,
and simulation results are discussed with comparisons to protocols in clinical practice.
Furthermore, the ability to induce cell phase oscillations in vivo and the need for increased
PD model accuracy is addressed.
Chapter 4 focuses on the PBPK model developed for the chemotherapeutic Doc in
severe combined immunodeficient (SCID) mice. This PBPK model extended an existing
PBPK model in the literature by including additional tissue compartments, providing
predictions on Doc PK within implanted SKOV-3 tumor xenografts, and simplifying the
original nonlinear structure through the addition of multiple subcompartments with linear
transfer rates. Chapter 5 covers the subsequent scale-up of the this model to humans, along
with comparisons against an existing PBPK [5] and patient-specific population PK [2] models
from the literature. Additional investigations are performed exploring Doc tumor predictions
over various treatment schedules, patient body weight, tumor flow rates, and tumor volumes.
Chapter 6 updates the neutrophil toxicity model developed by Friberg et al. [3] for Doc.
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Actual PK profiles for the patients were used in estimating new parameters, while the original
model was developed using PK profile predictions from the population PK model developed
by Bruno and coauthors [2]. Attempts to fit neutrophil profiles on alternative Doc schedules
were unsuccessful, however, necessitating a structural change to the neutrophil toxicity
model. Average patient Doc PK and neutrophil progression parameters were combined
with an NMPC algorithm and discrete toxicity constraints to evaluate if alternative Doc
schedules may allow for the increased delivery of Doc. Alterations to the dosing regimen were
investigated for the entire population set to determine those subjects especially susceptible
or non-susceptible to toxicity under the new Doc regimen. Separate regimens were developed
for these patients, representative of those groups at high and low risk, respectively. Finally,
Chapter 7 discusses conclusions drawn from these model development and dose schedule
design studies, along with recommendations for future research areas involving tumor and
neutrophil response models.
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2.0 TAMOXIFEN
This chapter focues on designing a coupled PK/PD model and a control algorithm for the
chemotherapeutic, tamoxifen (TM), which is used in the treatment of estrogen receptor
positive (ER+) breast cancer. Both the parent compound and its active metabolite, 4-
hydroxytamoxifen (HTM), function through competitive binding to the estrogen receptor
preventing receptor activation by estrogen. Inhibition of receptor activation results in an
accumulation of the affected cells in G1-phase due to growth signal truncation. While neither
TM nor HTM directly induce apoptosis, the accumulation of cells in G1 results in “cellular
stress,” and activates intracellular apoptotic pathways [128].
TM was the drug drug due to extensive clinical implementation, properties of the drug,
and characteristics of the dosing regimen. First, TM has been extensively evaluated in
preclinical and clinical studies, providing data for the construction of reliable PK and PD
models which should, in turn, improve algorithm accuracy. Also, as previously mentioned,
TM is classified as a “cycle-specific” chemotherapeutic, and there was interest in evaluating
if TM dosing efficacy could be improved with a more mechanistically motivated PD effect.
Furthermore, TM has well documented toxicity and can be taken within accepted dosing
levels daily for up to 5 years. Dosing constraints could easily be incorporated within a
NMPC algorithm which simultaneously handles dosing over regular intervals. A final note
is that while other selective estrogen receptor modulators (SERMs) have been developed,
TM remains a first-line drug for ER+ breast cancer treatment and combination therapy.
As other SERMs become more predominant, however, the same methodology of developing
PK and PD models followed by algorithm deployment could be implemented for developing
dosing regimens.
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2.1 METHODS
Pharmacokinetic data were obtained from Robinson et al. [129]. In that study, a single large
dose of TM (200
mg
kg
) was administered orally (in 0.1 mL peanut oil) to non-tumor-bearing,
ovariectomized, athymic mice, and plasma samples were taken at 0, 3, 6, 12, 24, 48, 72, and
96 hours after dosing. Plasma samples were purified using chromatography; concentrations
of TM, HTM, and N-desmethyltamoxifen were determined via comparison to a standard
curve and the resulting plasma concentrations represented the averaged values from three
mice.
Tumor volume data for PD modeling were obtained from Conley et al. [130]. The study
protocol involved athymic mice with human ER+ MCF-7 xenografts and estradiol pellets
implanted subcutaneously at day 0. Stratified groups were dosed daily via oral gavage with
7.5, 15, 30, or 60
mg
kg
TM dissolved in 0.1 mL of sterile water (vehicle had no significant
effect on tumor growth). Doses were given once a day for five consecutive days followed by
two days off, beginning on day 12 of the study. This seven-day pattern was repeated three
times. Twice each week, tumor volumes were calculated from a digital caliper measurement
of tumor length and width, assuming an ellipsoidal tumor of volume `w
2
2
(` = longest tumor
axis, w = shortest tumor axis perpendicular to `).
2.2 TAMOXIFEN PK
The PK of the oral agent TM, and its active metabolite HTM, were modeled using the
first-order parent/metabolite with oral dosing compartmental structure in Figure 2.1.
A TM dose is administered orally, and the parent compound is absorbed from the
gastro-intestinal tract (dynamics approximated with the two initial compartments). After
absorption, circulating TM can be removed from the system (including conversion to
metabolites such as tamoxifen N-oxide, N-desmethyltamoxifen, and others) or converted
to HTM. Circulating HTM is also removed from the system. Of the metabolites, only HTM
and N-desmethyltamoxifen appear in plasma at detectable concentrations [128]. Affinity
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studies have shown N-desmethyltamoxifen binds with estrogen receptors at 1
50
the affinity
of TM and 1
1250
the affinity of HTM [128]. As such, only TM and HTM are postulated to
contribute a significant anti-tumor effect.
The following equations describe the TM and HTM PK:
dX0
dt
= −k01X0 + u(t)
dX1
dt
= −k12X1 + k01X0
dX2
dt
= −kcl2X2 − k23X2 + k12X1
dX3
dt
= −kcl3X3 + k23X2 (2.1)
Y1 =
X2
V
Y2 =
X3
V
Here X2 and X3 correspond to TM and HTM mass in plasma (µg), respectively, while X0
and X1 denote TM mass in the two initial compartments. V is the central compartment
volume for the parent compound and metabolite (mL), and ki denote transfer rates (
1
hr
).
Variables Y1 and Y2 represent the measured plasma concentrations of TM and HTM (
µg
mL).
The parameters in equations (2.1) were fit by minimizing the squared difference between
model predictions and data obtained from non-tumor bearing athymic mice [129] and
the resulting parameter values are summarized in Table 2.1. Model predictions for both
compounds can be seen in Figure 2.2.
The PK model is able to capture the dynamic profile of the data with only a slight
over-prediction of TM concentration at t = 24 hours. Additional compartments or
delays could be incorporated into the TM model to more accurately fit the data at the
cost of increased number of parameters, decreased parameter confidence, and increased
mathematical complexity.
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Figure 2.1: 4-compartment linear model for plasma concentrations of TM and HTM after
oral dosing
Table 2.1: PK parameter values for the oral dosing of TM.
Parameter Value
k01 (
1
hr
) 0.048 ± 0.006
k12 (
1
hr
) 0.993 ± 0.062
k23 (
1
hr
) 35.932 ± 0.821
kcl2 (
1
hr
) 1.145 ± 0.214
kcl3 (
1
hr
) 39.525 ± 1.119
V1 (mL) 8.592 ± 0.723
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2.3 TAMOXIFEN TUMOR MODEL AND PD
Tumor growth models which explicitly track the fraction of the cell population in each
cell phase are typically referred to as cell-cycle models. In contrast to traditional single
state lumped-compartment models (i.e, exponential and Gompertz [63, 69]), these models
introduce additional states to represent phases of the cell-cycle. These state and parameter
additions allow for direct incorporation of cycle-specific chemotherapeutic effect and typically
involve the coupling of two or more linear ordinary differential equations (ODEs). However,
linear cell-cycle models cannot simultaneously capture the rapid initial rate of tumor
proliferation and the declining rate of growth observed at larger tumor volumes, although
they do return predictions accurate over short time intervals. One solution is to model tumor
growth with the GM, a structure that lumps cell phases into one homogeneous population,
N (with units mm3). The GM displays saturating growth dynamics as N → θ, the plateau
population which the tumor asymptotically approaches (mm3), and is represented by the
following ODE:
dN
dt
=
1
τ
N ln
(
θ
N
)
(2.2)
The parameter τ is the pseudo-doubling time (hr) for the tumor. The GM is capable of
describing tumor growth dynamics, but the single-state system does not model cell-phase
progression of the lumped population [69]. This loss of information is especially relevant
as many anticancer compounds primarily affect cells during specific phases of the cell-cycle
(e.g. paclitaxel, G2/M ; topotecan, S; and tamoxifen, G1) [48, 74, 131]. Combining cell-cycle
data with a saturating growth rate yielded the SCM, which accurately captures saturating
tumor growth dynamics while modeling the overall solid tumor as a collection of three cell
phases [79]:
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Figure 2.2: Actual (circles) vs. simulated (lines) PK for TM (top) and HTM (bottom) after
a 200
mg
kg
oral dose of TM. Each data point represents mean plasma concentrations from
three mice; error bars are ± 1 standard deviation.
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dXG
dt
= −kGSXG ln
(
θ
N
)
+ 2kMGXM ln
(
θ
N
)
(2.3)
dXS
dt
= −kSMXS + kGSXG ln
(
θ
N
)
(2.4)
dXM
dt
= −kMGXM ln
(
θ
N
)
+ kSMXS (2.5)
N = XG +XS +XM (2.6)
Here Xi corresponds to the volume (mm
3) of cells in the G (growing), S (DNA synthesis),
or M (mitosis) phases (assuming constant cell volume and 106 cells = 1 mm3); kij’s denote
transfer rates from cell phase i to phase j ( 1
hr
); and θ is defined as above. The three states
correspond to cells in G (Q+G1), S, orM (G2+M) phases of the cell-cycle which can be seen
in Figure 2.4a. These groupings were based on flow cytometry analysis of DNA content using
propidium iodine as a fluorescent marker [132]. Cell phases containing equivalent amounts
of DNA have the same fluorescence and are indistinguishable from one another. Such is the
case with Q and G1-phase, where one copy of DNA is present, and G2 and M -phase, where
there is twice the DNA content [133]. S-phase falls into the intermediate region between
Q/G1- and G2/M -phase groupings. A typical flow cytometry result with DNA staining is
shown in Figure 2.4b. Figure 2.3 shows both the overall five-compartment cell-cycle model
and the reduced three-compartment cell-cycle model.
The SCM predicts 90% of the cells in the tumor are within G-phase for tumor volumes
exceeding 50 mm3 [79]. This results in dynamic behavior analogous to a single-lumped
ODE model, such as the GM, with all cells located within a single phase. As TM and its
active metabolites (primarily HTM) affect G1-phase cells and not the quiescent Q-phase cells
lumped within the state, the chemotherapeutic effect of tamoxifen is misrepresented in both
the GM and SCM. These two models both incorporate non-susceptible cells (all phases except
G1 and Q-phase cells, respectively) within the effected cell population, possibly leading to
an over prediction of the actual chemotherapeutic effect. One possible solution involves
partitioning the G-phase cell equation into separate equations for Q and G1-phase cells, as
follows:
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Figure 2.3: The five phases of the cell-cycle: Q (quiescent), G1 (growth), S (DNA
replication), G2 (mitotic preparation), M (mitosis). Two cell-cycles models are developed:
(i) a three-phase model considering G (lumped Q and G1), S, and M (lumped G2 and M)
which is resolvable using DNA labeling and flow cytometry; or (ii) a four-phase structure
with Q, G1, S, andM (lumped G2 andM) which is resolvable using DNA and RNA labeling
and subsequent flow cytometry.
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dXQ
dt
= −kQGXQ + kGQXG1 (2.7)
dXG1
dt
= kQGXQ − kGQXG1 − kGSXG1 ln
(
θ
N
)
+2kMGXM (2.8)
dXS
dt
= −kSMXS + kGSXG1 ln
(
θ
N
)
(2.9)
dXM
dt
= −kMGXM + kSMXS (2.10)
N = XQ +XG1 +XS +XM (2.11)
Here,XS andXM are defined as before, whileXQ andXG1 represent the volume of tumor cells
(mm3) in the Q (quiescent) or G1 (growth) phase, respectively. Additional rate constants,
kij, have been introduced, and θ is still the plateau population which the tumor approaches
asymptotically (mm3). The saturating term from Equation (2.5) has been replaced with
a linear exchange rate parameter in Equation (2.10) because a nonlinear term in M -phase
was not required to reproduce saturating dynamics with the QCM. Furthermore, there is
limited biological evidence to support a variable transition rate during M -phase. Exchange
rates between the quiescent and growth phases were assumed to be linear with respect to
population volume, and all cells resulting from mitosis were assumed to start in G1-phase
rather than distributing between Q and G1-phase. This assumption eliminates the need for
an additional distribution parameter which is poorly defined and for which little information
is available in the literature.
Finally, it should be noted that cell-cycle information discriminating between Q and G1-
phases can be obtained by labeling tumor cells for both DNA and RNA content. Labeling
for DNA preserves the separation between Q/G1, S, and G2/M -phase cells, while labeling
the cells for RNA content using acridine orange distinguishes RNA-rich G1-phase cells from
quiescent cells in Q-phase [4] (Figure 2.4c). Figure 2.4a shows the four-compartment cell-
cycle model governed by Equations (2.7)-(2.10). The SCM results when Q and G1 are
grouped into one lumped phase, while the GM results from the combination of all five
phases.
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Table 2.2: Parameter values for the tumor growth models: QCM, SCM, and GM.
Parameter Value
QCM SCM GM
kQG (
1
hr
) 0.0066 — —
kGQ (
1
hr
) 0.0561 — —
kGS (
1
hr
) 0.0083 0.0013 —
kSM (
1
hr
) 0.0790 0.0390 —
kMG (
1
hr
) 0.0413 0.0169 —
1
τ
( 1
hr
) — — 0.0010
θ (mm3) 104 104 104
Table 2.3: Calculated kD’s from the four TM dose groups using tumor growth models; µ1−j
and σ1−j represent the mean and standard deviation, respectively, of the lowest TM dose
through the jth lowest TM dose.
TM Dose kD
(
mL
µg hr
)
QCM GM SCM
7.5
mg
kg
0.0299 0.0049 0.0051
15
mg
kg
0.0398 0.0052 0.0061
30
mg
kg
0.0439 0.0043 0.0055
60
mg
kg
0.0340 0.0027 0.0035
µ1−3 ± σ1−3 0.0379 ± 0.0072 0.0048 ± 0.0004 0.0056 ± 0.0004
µ1−4 ± σ1−4 0.0369 ± 0.0062 0.0043 ± 0.0011 0.0051 ± 0.0010
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Figure 2.4: The cell-cycle (a) and typical flow cytometry results from DNA staining alone
(b) or combination DNA and RNA staining (c). By staining for DNA it is possible to resolve
three groupings of cells ((G, S, and M) which can be modeled using three state equations
(Equations (2.3)-(2.5)). Simultaneously staining for both DNA and RNA content allows for
independent resolution of the Q- and G1-phases, and the overall population can be modeled
using four state equations (Equations (2.7)-(2.10)). Figures adapted from Shapiro et al. [4].
Identifiable phases of the cell-cycle from combination staining for DNA and RNA content
followed by flow cytometry (left) and typical flow cytometry result from DNA staining alone
(upper right). The Q/G1 grouping could be further separated by staining for RNA content.
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Figure 2.5: Measured tumor volumes (circles; mean from 20 untreated mice) for MCF-7
human ER+ breast cancer xenografts growing in athymic nude mice and simulated tumor
size (lines) as a function of time for QCM (dash-dot), SCM (solid, overlay on dash-dot), and
GM (dashed, overlay on dash-dot) models. Error bars represent a 95% confidence interval
(CI) for measured tumor volumes.
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Values for the parameters in the GM, SCM, and QCM were obtained by minimizing
the squared difference between model predictions and animal data [130]. Parameter values
are summarized in Table 2.2. All three models provide virtually identical predictions of the
control tumor growth data (Figure 2.5) and the sum squared errors in fitting the data were
similar (13.95 for the QCM and 13.98 for both the SCM and GM). The AIC, traditionally
used to trade off model complexity versus improvements in model accuracy, is given by [134]:
AIC = n ln
(
SSE
n
)
+ 2 · p (2.12)
Here, SSE is the sum squared error between the data and the model prediction at the
measurement points, n is the number of data points, and p is the number of parameters
in the model; a lower AIC value indicates the model that better balances accuracy and
complexity. Since the number of data points used (n = 17) and the SSE for all models were
equivalent, the left-hand term in Equation (2.12) was equal for all three models. However, the
QCM had five parameters, two more than the SCM and four more than the GM, so an AIC
analysis clearly favored the GM, the least complex model structure. This result was expected
since the GM accurately predicts bulk tumor growth dynamics, and additional parameters,
which increase the AIC value, do not provide sufficient improvement in dynamic fit to offset
the AIC increase. However, the improved biological correspondence should provide superior
controller performance by more accurately accounting for the targeted effect of TM and
HTM in the G1-phase of the cell-cycle [135].
A common method for incorporating drug effect in a tumor growth model involves
introducing a bilinear kill term into the set of differential equations [63]. Conceptually,
the bilinear structure implies that increases in either plasma drug concentration or in
susceptible tumor populations will result in a greater treatment effect. For a cycle-specific
chemotherapeutic, this bilinear kill term is introduced into the model equation that contains
the cell-phase of drug action. As TM and HTM primarily affect cells within G1 and not all
of the model structures contain explicit G1-phase representation, the bilinear kill term was
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included in the most applicable phase (Equations (2.8), (2.3), and (2.2), from the QCM,
SCM, and GM, respectively). The new equations are given by:
dXG1
dt
= kQGXQ − kGQXG1 − kGSXG1 ln
(
θ
N
)
2kMGXM − kDXG1
(
[TM ]
V
+
c[HTM ]
V
)
(2.13)
dXG
dt
= −kGXG ln
(
θ
N
)
+ 2kMXM ln
(
θ
N
)
−kDXG
(
[TM ]
V
+
c[HTM ]
V
)
(2.14)
dN
dt
=
1
τ
N ln
(
θ
N
)
− kDN
(
[TM ]
V
+
c[HTM ]
V
)
(2.15)
Here kD is the drug-induced apoptotic rate (
mL
µg hr
), V is the distribution volume for the
compounds (mL), [TM] and [HTM] correspond to the mass of TM and HTM in the plasma,
respectively, and c represents the relative anti-tumor effectiveness of TM vs. HTM. Because
treatment dependent tumor reduction depends on the binding of TM and HTM to an estrogen
receptor, c can be approximated as the binding affinity ratio of HTM to TM. Previous
experiments have determined HTM to possess a binding affinity 25-50 times that of TM
[128] so the constant c was set to 25 for these studies, possibly underestimating HTM anti-
tumor effect.
Using tumor growth parameters listed in Table 2.2 and previously identified pharma-
cokinetic parameters [79], kD values for the QCM were determined individually for the four
different TM treatment groups (7.5, 15, 30, and 60
mg
kg
TM per dose) by minimizing the
squared difference between tumor data and model predictions. Individual kD values at
each TM dose for all three models are shown in Table 2.3. For both the SCM and GM, kD
estimates were consistent for the three lower TM dosing levels (7.5, 15, and 30
mg
kg
TM) while
the estimated kD corresponding to TM doses of 60
mg
kg
were significantly lower. Estimating
an average kD value from all four doses decreased the mean parameter value by 10% while
doubling the associated standard deviation. It was postulated that at the highest doses of
TM the receptor binding was saturated, resulting in no further increase in tumor death.
Hence, subsequent controller studies were limited to a dosing range of 0 ≤ u(t) ≤ 30mg
kg
TM
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per day to maintain kD linearity, where u(t) is the amount of TM delivered in a bolus dose
per day.
In contrast, kD predictions for the QCM agreed well across all four TM dose levels,
and inclusion of the kD estimated from the 60
mg
kg
TM dose reduced parametric variability.
Using this model, there is no evidence that kD saturated since the estimated kD for the
lowest dose level (7.5
mg
kg
TM) was smaller than that of the 60
mg
kg
TM dose level. Based
on these results, the acceptable dosing range for TM was set at 0 ≤ u(t) ≤ 60mg
kg
per
day for controller studies. Although the long term survival of mice on daily TM dosing
beyond 40
mg
kg
TM daily dosing has not been evaluated, the increased dosing range is deemed
acceptable since closed-loop tumor treatment simulations rarely exceeded doses of 40
mg
kg
TM
and simulated treatment length was under 2 years [136]. Figure 2.6 shows the ability of the
pharmacodynamic models to fit tumor growth data during treatment. Although Conley et
al. [130] did not demonstrate long term survival of mice on daily TM dosing, other authors
[136] have shown mouse longevity for up to 2 years at 40
mg
kg
daily dosing, thereby validating
the dosing range used here as within acceptable toxicity limits.
The model over-predicts drug effect for doses of 15 and 30
mg
kg
, however these over-
predictions do not seriously impact overall tumor growth predictions over the 60 day period.
A portion of this mismatch results from fixing the unperturbed tumor growth kinetics, which
were different even among stratified groups. For example, at day twelve for 30
mg
kg
dosing
(Figure 2.6, bottom) the predicted tumor size is greater than the measured tumor size on day
12 before drug is administered. In addition, tumor growth kinetics after drug administration
(after day 30) are noticeably less than predicted, possibly representative of a lingering drug
effect. The model with fixed parameters cannot predict this variation and can only minimize
total deviations over the remaining tumor data. Still, the model predicts the qualitative
shape of drug-altered tumor growth and model predictions remain within the 95% confidence
intervals. Furthermore, it should be noted that the error bars on tumor size measurements
are significantly broader than the prediction errors.
While each model structure possesses similar bilinear drug effect terms, the dynamic
structures have varying degrees of cell-phase complexity, and the affected cell population
differs in each model. All three models predict treatment related changes within the
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Figure 2.6: Measured MCF-7 tumor xenograft data from tumor-bearing athymic mice (circles
with a 95% CI) vs. QCM (dash-dot), SCM (solid, overlay on dash-dot), and GM (dashed,
overlay on dash-dot) model predictions. TM doses were administered starting on day 10
(dots, bottom) for five consecutive days, followed by two days off.
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prediction errors of the experimental data and within close agreement of each another.
This was expected because similar behavior was observed previously using the SCM [79].
When the drug effect was incorporated in a cell phase known to be incorrect (i.e. M - or
S-phase), the model returned pharmacodynamic predictions of tumor growth equivalent to
those obtained with drug effect incorporated in the biologically-correct phase [79]. Hence,
some knowledge of cell-cycle phase-specific effects is required a priori because an accurate
fit to experimental pharmacodynamic data does not guarantee a correct model structure for
drug effect.
2.4 TAMOXIFEN CONTROLLER SYNTHESIS
NMPC has been employed in a number of industrial processes [137], however, it has not
been applied to the cancer dosing problem despite its readily adaptable structure. The
general form of the NMPC algorithm is shown below and contains three distinct parts: (i)
an objective function; (ii) state equations; and (iii) input and state constraints.
min
∆u(k:k+m−1|k)
‖Γy [R(k + 1 : k + p : k)− Y (k + 1 : k + p|k)] ‖22
+‖Γu∆u(k : k +m− 1|k)‖22 (2.16)
x˙ = f(x, u) (2.17)
umin ≤ u(t) ≤ umax (2.18)
xmin ≤ x(t) ≤ xmax (2.19)
The objective function (Equation (6.12)) serves as the metric for deciding the ideal doses
to implement over a predicted horizon in time. For the above two-norm squared objective
function [138], the controller minimizes the sum of two terms. The first is an error term
calculating differences between predicted future tumor volume, Y (k + 1 : k + p|k) (model
predicted future values of N as a function of future drug dosing predictions), and a desired
tumor volume reference trajectory, R(k+1 : k+p|k) where the index, k, denotes information
at the present time. The second term is a noise-suppression term limiting magnitude changes
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in the dosing level, ∆u(k : k + m − 1|k). A ∆u formulation implies that the controller
calculates alterations in dose level and not absolute dose magnitude. Furthermore, a ∆u
formulation of the NMPC algorithm allows for implicit integration ensuring the controller
will converge to the desired reference trajectory without offset. The state equations,
Equation (2.17) (i.e., PK and PD equations) serve as the process model, allowing explicit
prediction of future system behavior based on m controller-predicted dosing alterations over
the prediction horizon, p, where m ≤ p. The constraints, Equations (2.18) and (2.19), ensure
that both the input (dosing level) and states (drug within tissues or plasma), respectively, do
not exceed clinically-imposed bounds. A schematic representation of NMPC implementation
is shown in Figure 2.7.
At each point in time, the controller predicts a series of m changes from the current
dosing level based upon measurements currently available at time, k. For all future days
beyond m − 1 until p, the algorithm makes no change in the administered dose. Based on
the tumor volume predicted (Y (k + 1 : k + p|k)) over the following p days, the controller
compares these values to a desired reference volume (R(k + 1 : k + p|k)) and calculates a
weighted sum-squared error, with weighting matrix, Γy. Concurrently, the weighted sum of
squared input manipulations, with weighting parameter, Γu, is calculated and added to the
penalty for deviation from the reference trajectory. By evaluating changes to this objective
function value based on m input alterations, inputs which minimize the objective function
can be determined. It should be noted that changes in ∆u affect the predicted Y through
the PK and PD equations (Equation (2.17)). The first such calculated input is implemented,
the resulting output is measured one step forward in time, and the entire procedure repeats.
Such a NMPC algorithm was constructed for the daily dosing of a “simulated mouse”
having states based on PK equations described previously and pharmacodynamics governed
by the QCM (Equations (2.7), (2.13), (2.9), and (2.10)). A daily dose of 13.4
mg
kg
maintained
a pseudo-steady state xenograft tumor size of 100 mm3. It should be noted that daily
TM administration via oral gavage is the engineering equivalent of a bolus. While NMPC
typically employs a continuous input profile with step changes at update intervals (dashed,
bottom), many chemotherapeutics are administered orally and can be mathematically
represented as a bolus (solid, vertical). Doses were scheduled as bolus inputs, but are
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past tumor volume measurements
Y(k+1), future tumor 
volume prediction    Reference       
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R(k+1)
past doses prediction horizon, p
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∆u(k:k+1|k)
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  Time
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Figure 2.7: NMPC algorithm implementation schematic; as shown, m = 2, p = 6. Based on a
current tumor volume measurement, the controller predicts m dosing alterations to minimize
Equation 2.16 over p future days. While NMPC typically employs a continuous input
profile with step changes at update intervals (dashed, bottom), many chemotherapeutics
are administered as pills, mathematically represented as a bolus (solid, vertical). Doses were
scheduled as bolus inputs, but are graphed as steps for easier viewing.
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graphed as steps in Figure 2.8 for visual clarity. The weighting matrices Γy and Γu establish
the relative importance of setpoint tracking error and manipulated variable movement,
respectively. In the present work, these matrices were set to Γy = 1 and Γu = 0 for all
simulations to emphasize reference tracking without regard to penalties for altering dosing
level. Simulations were performed in MATLAB ( c©2005, The MathWorks, Natick, MA) and
optimizations called the fmincon function.
Taking the “simulated mouse” as the QCM (plant), three NMPC controllers were
designed from the QCM, SCM, and GM (models), respectively. The controller based on
the QCM (QCMC) was the nominal case where the plant and model are identical while
controllers for the SCM and GM represent structural plant-model mismatch. The controllers
designed from the SCM (SCMC) and GM (GMC) were initialized at equivalent tumor
volumes to the plant (100 mm3) resulting in steady-state inputs of 13.7 and 12.5
mg
kg
,
respectively. This initialization restricted the available dosing range (0 ≤ U(k|k) ≤ 59.7mg
kg
for the SCMC and 0.9 ≤ U(k|k) ≤ 60mg
kg
for the GMC), but this truncation was acceptable
because the doses in the eliminated range were not routinely used in closed-loop simulations.
Closed-loop simulations were compared for two test cases: (i) a three-step tumor
reduction trajectory with 30% reduction in reference tumor volume every 28 days; and
(ii) a large tumor reduction step with biweekly volume updates. In the three-step tracking
case study (Figure 2.8), both the SCMC and the GMC had indistinguishable performance,
but were sluggish compared to the nominal controller (QCMC). The mismatch controllers
predicted lower initial drug delivery (though overall drug delivery differed by only 3%).
Initial trajectory crossing (rise time) for each controller was equivalent following each step
(44, 69, and 96 days, respectively), but the SCMC and GMC both displayed undershoot
which persisted until the beginning of the next tumor volume reduction step.
The results from the biweekly tumor volume update case study are shown in Figure 2.9.
The nominal controller settles to the reference trajectory after 28 days and delivers
substantially less drug (total dose of 3067
mg
kg
TM vs. 4270 and 4240
mg
kg
TM for the SCMC
and GMC, respectively). Comparing total drug delivery in this case is not particularly
informative, as both mismatched controllers displayed “ringing” (alternating inputs between
the maximum and minimal allowable dose) behavior around the desired reference trajectory.
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Figure 2.8: Tumor volume (top), reference volume (dotted, top) and TM dose representation
(bottom) as a function of time. Tuning parameters for all three controllers (QCMC, solid;
SCMC, dash-dot; GMC, dashed) were m = 1 and p = 8.
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This may have resulted from the input/output relationship at low tumor volumes which
required large alterations in dosing to obtain small changes in tumor volume. Both SCMC
and GMC results demonstrate that failure to explicitly represent the susceptible G1-phase
results in decreased controller performance and erroneous results.
2.5 CLINICAL APPLICABILITY
While these initial studies demonstrated that an NMPC algorithm could be used to track
tumor response, this is not equivalent to improving treatment efficacy. First, reducing
tumor volume along a prespecified trajectory may be viewed as unethical within the medical
community, especially if it is possible to decrease tumor volume at a more rapid rate while
satisfying toxicity constraints. Model results display tumor regression beneath the specified
reference trajectory, followed by a reduction in dose, and subsequent regrowth of the tumor,
to return to the specified reference trajectory. However, it has already been discussed that
objective functions based solely on minimizing tumor volume at a final time point lead to
clinically infeasible and unethical results as well. Inclusion of both measures in a properly
weighted scheme or updating the reference trajectory are two alternatives, however, the more
pressing issue is the implication of these results. In minimizing the final tumor volume with
no cumulative toxicity constraint, the algorithm would predict maximum drug delivery at
every dosing opportunity. Even for tamoxifen, which is given at the median dose for years,
this is an unacceptable dosing prediction manifesting from an inaccuracy in the toxicity
model.
Assuming this model could be scaled to humans, controller difficulties observed with
sparse feedback information would be compounded even further. While tumor volume
measurements can be obtained in the preclinical setting, where tumors are implanted
subcutaneously on animal flanks, a majority of human tumors are located internally which
requires expensive imaging that may not provide conclusive tumor size information. Also,
clinical practice seeks to surgically remove accessible tumor masses whenever possible. Due
to tumor volume being an unavailable feedback measure and unreliable therapy metric,
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Figure 2.9: Tumor volume (top), reference volume (dotted, top, 10 mm3), and TM dose
representation (bottom) as a function of time. Tumor volumes are measured biweekly under
NMPC and tuning parameters for all three controllers (QCMC, solid; SCMC, dash-dot;
GMC, dashed) were m = 1 and p = 21.
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alternative objective function metrics, such as targeted drug plasma concentrations [121],
plasma drug concentration area under the curve, and white blood cell count may need to be
substituted in place of reducing overall tumor volume. The appropriate metric, however, will
likely be drug dependent and ideally correlate with the ultimate goal of cancer treatment,
namely survival.
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3.0 PBE TUMOR MODELS
Chemotherapeutics are often treated as having a lumped tumor effect, however, the growth
state and exposure for individual cancer cells ultimately determines the response of the tumor
to treatment. It was postulated that the TM treatment outcomes were a result of having
lumped cell-cycle phase transition rates. Such lumped models treat all cells within a given
cell phase as having equivalent drug exposure and phase transition rates. Apoptotic response
is often modeled as a bilinear combination of drug concentration and susceptible population
size, premultiplied by a rate constant corresponding to drug activity and tumor sensitivity.
However, a tumor is a heterogeneous population of cells with drug exposures dependent
on the surrounding vasculature for systemically delivered drugs [139]. Furthermore, drug-
induced apoptosis may be a function of period of exposure or point of exposure within a cell
phase. Even radiation therapy displays an apoptotic effect dually dependent on cell phase
(increased susceptibility during G2/M phase) and cellular oxygen concentration (increased
probability of free radical formation) [140].
An alternative modeling structure that accounts for distributed properties in a cell
population is the aptly named, cell population balance model. This mathematical
formulation allows for distributed internal properties (e.g. mass, age, DNA, protein) among
a population, including the partitioning of intracellular compounds following cell division.
The general form for a population balance equation (PBE) is shown below:
∂N(t, i, e)
∂t
+∇i · I˙N +∇e · E˙N = κ
Here, N represents the average number density of the cell population, i refers to internal
cell properties (e.g., mass, age, DNA), e refers to external cell properties (e.g., spatial
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coordinates), I˙ and E˙ refer to the rate of change of cell properties, and κ denotes intensity
functions such as mitosis and phase transition.
While the original cell population description dates back to Fredrickson, Ramkrishna,
and Tsuchiya [141], these models have recently seen increased use in bio-processes [142,
143, 144, 145, 146] and chemotherapeutic schedule development [80, 81, 82, 83, 84, 85, 86,
147]. Historically, the primary limitations on cell PBE implementation were the numerical
complexity of the partial integro-differential equations resulting from model development
and difficulty in determining partition and transition functions and single-cell growth rates.
However, with the development of numerical algorithms capable of accurately approximating
PBE solutions [144], along with experimental advances for evaluating cellular properties,
PBEs represent a viable option for modeling intracellular states as distributed properties
among a cell population.
3.1 PBE MODEL DEVELOPMENT
There are two common formulations for the cell population balance models which differ
by the choice of internal coordinates. Models with intracellular properties that obey mass
conservation are referred to as mass-structured, while age distribution models differentiate
between cells of different ages within the system. Both model structures have been explored
for chemotherapeutic schedule development [80, 81, 82, 83, 84, 85, 86, 147] and bioreactor
applications, specifically the modeling of yeast cultures for single-phase, single-variable [142]
and multi-phase, single variable [143, 144, 145, 146] cases with environmental coupling to
the extracellular environment.
For implementation based on the three cell-cycle model in Figure 3.1, a mass structured
model would require information on phase transition rates, a partitioning function for
allocating cell properties following cell division, and single-cell growth rates for each phase.
A model based solely on mass as the intrinsic variable would be unable to account for cell
distributions within a quiescent phase (Q) where mass accumulation is theoretically zero [72].
Finally, a mass structured cell-cycle model does not allow for explicit period of drug exposure
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Figure 3.1: The five phases of the cell-cycle: Q (quiescent), G1 (growth), S (DNA
replication), G2 (mitotic preparation), M (mitosis). Two cell-cycles models are developed:
(i) a three-phase model considering G (lumped Q and G1), S, and M (lumped G2 and M)
which is resolvable using DNA labeling and flow cytometry; or (ii) a four-phase structure
with Q, G1, S, andM (lumped G2 andM) which is resolvable using DNA and RNA labeling
and subsequent flow cytometry.
51
calculation. Despite these limitations, a mass-structured model has proven advantageous for
yeast bioreactors because the intrinsic variable, mass, is a measurable quantity and is passed
from cell phase to cell phase.
Age-based models offer several advantages over mass structured cell population models
even though age is not an available measure from a cell population. First, single cell rates of
change for age correspond to unity, eliminating the need for experimentally determining three
growth equations. Second, mass structured models formulate as partial integro-differential
equations, a function of property partitioning following cell division, while age structured
models result in simpler partial differential equations with an integral boundary condition.
This integral boundary condition results from the accumulation of newborn cells, all of which
possess an initial age of zero. Subsequently, calculation of a partition function is no longer
required since age is not partitioned following cell division. Finally, tracking the internal
property, age, allows for direct calculation of the period of drug exposure for any portion of
the population. Drug-kill rates need not be constant throughout a cell phase, representative
of complex interactions between a chemotherapeutic, intracellular targets, and the induction
of apoptosis. For classes of problems where the dynamic effect of interest (tumor kill) is
period or point of exposure dependent, an age structured model is both less complex and
more relevant.
Both age- and mass-structured cell-cycle tumor growth PBEs were investigated. Addi-
tional model developments focused on extending both PBE model structures to account for
saturating tumor growth dynamics.
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3.2 MASS-STRUCTURED CELL CYCLE TUMOR GROWTH PBE
For the three cell phases, G, S, and M , the cell phase population density is given by NG,
NS, and NM , respectively. The complete PBE is given by Equations (3.1)-(3.3):
∂NG(m, t)
∂t
+
∂[NG(m, t)R˙(m)]
∂m
= −ΓG(m)NG(m, t)
+2
∫ mmax
m
ΓM(m
′)P (m,m′)NM(m′)dm′ (3.1)
∂NS(m, t)
∂t
+
∂[NS(m, t)R˙(m)]
∂m
= −ΓS(m)NS(m, t) + ΓG(m)NG(m, t) (3.2)
∂NM(m, t)
∂t
+
∂[NM(m, t)R˙(m)]
∂m
= −ΓM(m)NM(m, t) + ΓS(m)NS(m, t) (3.3)
R˙(mmin)NG(mmin, t) = R˙(mmax)NG(mmax, t) = 0 (3.4)
R˙(mmin)NS(mmin, t) = R˙(mmax)NS(mmax, t) = 0 (3.5)
R˙(mmin)NM(mmin, t) = R˙(mmax)NM(mmax, t) = 0 (3.6)
Here m is the cell mass, mmin is the minimum cellular mass for the system, and mmax is
the maximum cellular mass for the system. The growth rate, R˙(m), was set as a quadratic
function of mass:
R˙(m) = aR(mmax −m)(m−mmin) (3.7)
This satisfies the boundary condition on the upper and lower bounds of Equations (3.4)-
(3.6). The same function for mass accumulation was utilized within all three cell phases.
The transition functions out of cell phases G, S, and M are ΓG(m), ΓS(m), and ΓM(m),
respectively, The transition functions were assumed to have the following forms, similar to
those developed for yeast progression [146]:
Γi(m) =

0 m ≤ mci
βi(exp
τi(m−mci)−1) mci ≤ m ≤ mciup
βi(exp
τi(mciup−mci)−1) mciup ≤ m
Here, mci is the critical mass during phase i (where i ∈ {G, S, or M}) representing the
minimal mass necessary for phase transition, and βi, τi, and mciup govern the ultimate
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transition rate value through phase i, sharpness of the transition function relative to the
current cell mass, and upper bound of cellular mass after which the phase transition rate
was constant, respectively. Transition of cells from phase M to G follows cellular division
resulting in two new cells and a division of the original mass defined by the following
symmetric beta distribution:
PM(m,m
′) =
 0 m < mcM , m′ < m1
B(q,q)
1
m
(
m
m′
)q−1 (
1− m
m′
)q−1
mcM ≤ m, m ≤ m′
This function is similar to those used in describing yeast division [146]; however, a higher
value of the constant, q, was selected to represent increased probability towards equal
allocation of cellular mass following cell division for eukaryotic cells. Finally, the three
t = 0 boundary conditions are given by:
NG(m, 0) = NG0(m)
NS(m, 0) = NS0(m)
NM(m, 0) = NM0(m)
A summary of the parameters used for simulations can be found in Table 3.1. The parameters
in the present study were selected to characterize a tumor with an approximate doubling
time of 9 days, representative of Ht29 human colon carcinoma xenograft tumor growth [148].
3.3 AGE-STRUCTURED CELL CYCLE TUMOR GROWTH PBE
This model was adapted from the age structured yeast model developed by Zamamiri et al.
[146]. For the three cell phases, G, S, and M , the cell phase population density is given by
NG, NS, and NM , respectively. The complete PBE is as follows:
∂NG(a, t)
∂t
+
∂NG(a, t)
∂a
= −ΓG(a)NG(a, t) (3.8)
∂NS(a, t)
∂t
+
∂NS(a, t)
∂a
= −ΓS(a)NS(a, t) (3.9)
∂NM(a, t)
∂t
+
∂NM(a, t)
∂a
= −ΓM(a)NM(a, t) (3.10)
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Here, a is the period of time a cell has resided within a given phase. The transition functions
out of cell phase G, S, and M are ΓG(a), ΓS(a), and ΓM(a), respectively, The transition
functions were assumed to have the following forms:
Γi(a) =

0 a ≤ aci
βi
a−aci
(mi−1)aci
aci ≤ a ≤ miaci
βi miaci ≤ a
(3.11)
Here, aci is the critical age during cell phase i (where i ∈ {G, S, or M}) representing the
minimal age necessary for phase transition or cell division onset. βi represents the maximum
transition rate for the cell phase and mi defines the sharpness of the transition function. The
additional constraint, mi > 1, ensures positive growth rates.
Finally, the three age-zero boundary conditions, which account for phase transition or
division, are given by:
NG(0, t) =
∫ ∞
0
2ΓM(a)NM(a, t)da (3.12)
NS(0, t) =
∫ ∞
0
ΓG(a)NG(a, t)da (3.13)
NM(0, t) =
∫ ∞
0
ΓS(a)NS(a, t)da (3.14)
A summary of the parameters used for simulations can be found in Table 3.2. These
parameters were not estimated from data because there are multiple solutions for critical
transition ages within the G-, S-, andM -phases that will provide a specified tumor doubling
rate. Instead, the parameters were selected to characterize a tumor with an approximate
doubling time of 9 days, representative of Ht29 human colon carcinoma xenograft tumor
growth [148]. Furthermore, parameters were chosen to attain a phase fraction ratio (G : S :
M) of 0.50 : 0.30 : 0.20, as observed from cell-cycle experiments [86]. In fact, the mean cell
residence times in both the S- and M - phase are known to be inaccurate based upon cell
cycling dynamics in vitro [86] and are a repercussion of attempting to describe solid tumor
progression with phase fraction distributions observed from in vitro cells.
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Table 3.1: Model, transition function, mass allocation, and division function parameters for
the mass-structured cell-cycle PBE.
Parameter Value Parameter Value
mcG 1.56 10
−9g βG 0.05 1day
mcS 1.78 10
−9g βS 0.5 1day
mcM 2.00 10
−9g βM 0.5 1day
mmin 0.44 10
−9g τG 1.0 110−9g
mmax 2.67 10
−9g τS 1.0 110−9g
mcGup 1.78 10
−9g τM 1.0 110−9g
mcSup 2.00 10
−9g aR 0.105 10−9
g
day
mcMup 2.22 10
−9g q 50
Table 3.2: Model, transition function, and division function parameters for the age-
structured cell-cycle PBE.
Parameter Value Parameter Value
acG 3.75 day βG 4
1
day
acS 2.4 day βS 6
1
day
acM 1.5 day βM 6
1
day
mG 1.6 mS 5
mM 2.4
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3.4 NON-SATURATING PBE MODEL RESULTS AND DISCUSSION
Simulations for the unperturbed age and mass structured cell-cycle PBEs are shown below
in Figures 3.2 and 3.3 for the age model and Figures 3.4 and 3.5 for the mass model. Both
models were initialized with all cells distributed solely within G-phase to better illustrate
growth phase transition and overall tumor growth progression. The age cell-cycle PBE was
simulated with the following initial conditions:
NG(a, 0) = 0.08e
−(a−0.27)2
0.16 (3.15)
NS(a, 0) = 0 (3.16)
NM(a, 0) = 0 (3.17)
Population distributions for each phase (G, S, and M) can be found in Figure 3.3.
Starting at time zero with all cells located within G-phase, the progression of the population
can be observed through each of the cell phases.
Gradually, the distribution of cells spread out over all three phases, eliminating the semi-
discrete increases in population seen every 9 days in Figure 3.2 (top). While the overall tumor
growth rate becomes nearly exponential by day 35, damping oscillations continued to persist
with respect to individual cell phase populations (Figure 3.2, bottom). The persistence of the
oscillations was dependent on both the initial conditions of the system and the magnitude and
structure of the phase transition kernels. Ultimately, an age-structured PBE with structure
defined by Equations (3.8)-(3.10) would attain a steady state phase fraction distribution
similar to that obtained during simulation of lumped cell-cycle models.
It is worth noting that the model parameters used for the age-structured PBE simulation
were not evaluated against experimental data, nor were they constructed using information
regarding cell cycling dynamics. Constructing a model based solely on bulk tumor doubling
time results in a degenerate number of possible solutions where individual cell phases may
compose an arbitrary percentage (0 < fi < 1) of the overall tumor. Information from in vitro
cell cycling studies can be used in place of the above phase transition parameters. However,
observed in vitro cycling times are typically on the order of 1-2 days [9], significantly faster
than the doubling times observed from studies involving solid tumors. Similarly, average G-,
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Figure 3.2: Tumor volume versus time. Top: Total volume starting from an initial cell
distribution given by Equations (3.15)-(3.17). Bottom: Individual cell-cycle phase volumes
for G-phase (NG, dashed), S-phase (NS, dash-dot), and M -phase (NM , dotted) cells.
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Figure 3.3: Cell distribution within G-phase (top), S-phase (middle), andM -phase (bottom)
during unperturbed growth.
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S-, and M -phase transition rates from in vitro studies are approximately 12-24, 4-8, and 4-6
hours, respectively, significantly shorter than the sum of critical ages incorporated within
the age-structured PBE that serve as a lower bound on the doubling time of the modeled
system (7.65 days).
The mass cell-cycle PBE was simulated with the following initial conditions:
NG(m, 0) = 0.56e
−(m−0.45)2
0.018 (3.18)
NS(m, 0) = 0 (3.19)
NM(m, 0) = 0 (3.20)
The overall tumor volume and individual phase progressions are shown in Figure 3.4, and
the density progression over the initial seven days of the simulation are shown in Figure 3.5.
Oscillations in the total tumor volume persisted for a longer period of time than in the
age-structured PBE (out to 60 days, not shown), a result of the chosen model parameters.
Comparing both sets of model predictions, it is worth noting that incorporation of
either mass or age of the cell population allowed for near identical results for overall tumor
volume progression (Figures 3.2 and 3.4). However, both models also produced exponential
tumor growth profiles, which is sufficient for describing blood-borne cancer progression but is
inadequate for describing solid tumor growth. For solid tumors, both model structures need
to be altered to display saturating growth kinetics as the overall population approaches
a maximum value similar that observed from the lumped GM, SCM, and QCM model
structures in Chapter 2.
3.5 MASS-STRUCTURED SATURATING CELL CYCLE PBE
For the saturating model, the ultimate goal was to have the G-phase fraction increase as
the tumor size approaches a model-specific saturating value. This final allotment can be
accomplished by having either the transition rate fromG to S phase or the mass accumulation
rate within Equation (3.1) saturate with increasing total tumor volume.
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Figure 3.4: Tumor volume versus time. Top: Total volume starting from an initial cell
distribution given in Equations (3.18)-(3.20) (m is normalized mass). Bottom: Individual
cell-cycle phase volumes for G-phase (NG, dashed), S-phase (NS, dash-dot), and M -phase
(NM , dotted).
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Figure 3.5: Total cell density distribution for G-phase (dashed), S-phase (dash-dot), and
M -phase (dotted) during unperturbed growth. Density progression is shown starting from
day 0 until day 7.
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3.5.1 Saturating G-Phase Transition Rate
For the case of a saturating transition rate, ΓG(m,NG(m, t), NS(m, t), NM(m, t)), Equa-
tion (3.1) becomes:
∂NG(m, t)
∂t
+
∂[NG(m, t)R˙(m)]
∂m
= −ΓG(m,NG(m, t), NS(m, t), NM(m, t))NG(m, t)
+2
∫ mmax
m
ΓM(m
′)P (m,m′)NM(m′)dm′ (3.21)
The transition function out of cell phase G, ΓG(m,NG(m, t), NS(m, t), NM(m, t)), was
updated as follows:
ΓG(m,Nt(t)) =

0 m ≤ mcG
βG(exp
τG(m−mcG)−1) ln( θ
Nt(t)
) mcG ≤ m ≤ mcGup
βG(exp
tauG(mcGup−mcG)−1) ln( θ
Nt(t)
) mcGup ≤ m
Nt(t) =
∫ mmax
mmin
(NG(m, t) +NS(m, t) +NM(m, t))dm
Here, θ governs the saturation of tumor growth and places a pseudo-maximum on the total
tumor volume for the system. A summary of the parameters used for simulations can be
found in Table 3.3. Parameters were chosen to achieve an approximate tumor doubling time
of 9 days, as before.
Results for the mass-structured PBE with saturating G-phase dynamics are shown
in Figure 3.6 with cell density distributions over the course of the simulation shown in
Figure 3.7. The model was initialized with the same initial conditions from Equations (3.18)-
(3.20). While the model does display saturating growth kinetics, halting further tumor
progression at approximately the θ value of the system (t =120 days), the growth kinetics
up until that point are approximately exponential, inconsistent with the dynamics observed
from the GM, SCM, QCM, and in the literature [69]. This is confirmed in Figure 3.7, where
it is shown that the individual phase distributions, while increasing in overall number, have
the same distribution from day 50 until the overall tumor volume reaches θ. The only period
where this does not hold is during the first 10 days (top four figures in Figure 3.7), where
initial condition effects are still influencing phase density distributions, and after day 110
(bottom four figures in Figure 3.7), where the saturation in G-phase transition rate begins to
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manifest. Despite using the same initial conditions from the non-saturating mass-structured
PBE, this model displayed less extended phase oscillations, likely a result of introducing the
saturating G−phase exit rate [84].
Some concerns regarding the model predictions included the abrupt alteration in growth
dynamics predicted upon reaching the saturating tumor value and the behavior of the model
upon reaching the plateau population (Figures 3.6 and 3.7). The overall tumor volume
increased beyond the specified θ value as cells currently within S- and M -phase would still
complete the cell-cycle despite cessation of G-phase transition. Furthermore, as no limit on
mass accumulation was specified within the model, those cells which can no longer progress
through G-phase continue to accumulate mass, progressing towards the specified maximum
mass of the model. This introduces two problems: (i) model quality begins to degrade as
the entire population converges to to the maximum mass of the system, all within a single
phase; and (ii) if the population would decrease below θ, there would be instantaneous phase
transition as the cell masses in G-phase already exceed the necessary value for progression
through both S- and M -phase. Alternatively, it may be desirable to design the model
structure to saturate mass accumulation rather than phase transition rate to avoid these
problems.
3.5.2 Saturating G-Phase Mass Accumulation Rate
For the case of a saturating mass accumulation rate, Equations (3.2) and (3.3) and the
associated mass accumulation rates remained unchanged. The mass accumulation rate for
G-phase, RG(m,NG, NS, NM), and Equation (3.1) were altered as follows:
∂[NG(m, t)R˙G(m,Nt(t))]
∂m
+
∂NG(m, t)
∂t
= −ΓG(m)NG(m, t)
+2
∫ mmax
m
ΓM(m
′)P (m,m′)NM(m′)dm′ (3.22)
˙RG(Nt(t),m) = amG(mmax −m)(m−mmin) ln
(
θ
Nt(t)
)
(3.23)
Nt(t) =
∫ mmax
mmin
(NG(m, t) +NS(m, t) +NM(m, t))dm
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Table 3.3: Model, transition function, mass allocation, and division function parameters for
the mass-structured saturating cell-cycle PBE with saturating G-phase transition rate.
Parameter Value Parameter Value Parameter Value
mcG 1.56 10
−9g βG 0.70 1day mcGup 1.78 10
−9g
mcS 1.78 10
−9g βS 1.0 1day mcSup 2.00 10
−9g
mcM 2.00 10
−9g βM 1.0 1day mcMup 2.22 10
−9g
mmin 0.44 10
−9g τG 1.0 110−9g q 50
mmax 3.33 10
−9g τS 1.0 110−9g θ 10000 mm
3
aR 0.12 10
−9 g
day
τM 1.0
1
10−9g
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Figure 3.6: Tumor volume (solid) versus time starting from an initial cell distribution given
in Equations (3.18)-(3.20) (m is normalized mass). Individual cell-cycle phase volumes are
shown for G-phase (dashed), S-phase (dash-dot), and M -phase (dotted).
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Figure 3.7: Total cell density distribution for G-phase (dashed), S-phase (dash-dot), and
M -phase (dotted) during unperturbed growth. Cell cycle density plots are shown, starting
from the upper left, for days 1, 3, 5, 7, 10, 20, 30, 40, 50, 60, 70, 80, 110, 120, 130, and 140.
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A summary of the parameters used for simulations can be found in Table 3.4. Parameters
were chosen to achieve an approximate tumor doubling time of 9 days.
Model predictions for the mass-structured cell-cycle PBE with saturating G-phase mass
accumulation are shown in Figure 3.8 with cell-cycle density plots in Figure 3.9. Oscillations
persisted for an extended period of time in this model; this is different from the previously
observed response of the mass-structured model with saturating G-phase transition rate.
These results implied that the saturating mass-accumulation rate model was capable of more
accurately reproducing the exponential growth dynamics observed from the original mass-
structured model. These oscillations persisted throughout the entire tumor progression, a
result of model initial conditions, and it is unlikely that phase oscillations would still be
observable in a solid tumor after such an extensive period of time (oscillations over weekly
periods while a majority of bodily processes oscillate over a daily or more frequent schedule).
The phase density plots (Figure 3.9) reveal that the model takes on the characteristics of
exponential growth (Figure 3.9 days 1 to 90), then gradually accumulated a greater fraction
of the tumor population within G-phase (Figure 3.9 days 90 to 190). Eventually, once the
saturating tumor population is attained, mass accumulation completely halts within G-phase
(Figure 3.9 days 190 to 240). While this model also attained a final tumor volume in excess
of θ, the degree to which it exceeded θ was significantly less (0.001% vs. 15%) than the
mass-structured PBE with phase transition saturation. This resulted from the different
approaches to the plateau population predicted by both models.
While this mass-structured cell-cycle PBE with saturation in G-phase mass accumulation
displayed the desired tumor growth dynamics without any mathematical degeneracy, there
remain problems regarding appropriate parameters for such structures and the incorporation
of treatment effect. Though the model contains the appropriate phases for cycle specific drug
effects, there is no literature evidence relating cell mass and drug concentration to a PD effect.
Furthermore, while there is greater uncertainty regarding average cell mass and cellular mass
necessary for phase transition, the residence time of a cell within S- and M -phase is well
characterized during unperturbed proliferation, likely a result of the mechanistic nature of
DNA replication and cell division.
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Table 3.4: Model, transition function, mass allocation, and division function parameters for
the mass-structured cell-cycle PBE with saturating G-phase mass accumulation rate.
Parameter Value Parameter Value Parameter Value
mcG 1.56 10
−9g βG 0.70 1day mcGup 1.78 10
−9g
mcS 1.78 10
−9g βS 1.0 1day mcSup 2.00 10
−9g
mcM 2.00 10
−9g βM 1.0 1day mcMup 2.22 10
−9g
mmin 0.44 10
−9g τG 1.0 110−9g q 50
mmax 3.33 10
−9g τS 1.0 110−9g θ 10000 mm
3
aR 0.12 10
−9 g
day
τM 1.0
1
10−9g amG 0.10
g
day
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Figure 3.8: Total tumor volume (solid) versus time starting from an initial cell distribution
of NG(m, 0) = 0.40e
−(m−0.49)2
0.014 with NS(m, 0) = NM(m, 0) = 0 (m is normalized mass).
Individual cell-cycle phase volumes are shown for G-phase (dashed), S-phase (dash-dot),
and M -phase (dotted).
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Figure 3.9: Total cell density distribution for G-phase (dashed), S-phase (dash-dot), and
M -phase (dotted) during unperturbed growth. Cell cycle density plots are shown, starting
from the upper left, for days 1, 3, 5, 7, 10, 50, 90, 130, 170, 180, 190, 200, 210, 220, 230, and
240.
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3.6 AGE-STRUCTURED SATURATING CELL CYCLE PBE
Starting from the initial age-structured cell-cycle PBE Equations (3.8)-(3.10), two models
were investigated: (i) a three phase cell-cycle PBE with a lumped G-phase population; and
(ii) a four phase age structured cell-cycle PBE. These representations are analogous to the
SCM and QCM developed previously in Chapter 2.
3.6.1 Three Phase Age-Structured Saturating Cell Cycle PBE
For case (i), Equations (3.8) and (3.13) are updated as Equations (3.24) and (3.25),
respectively:
dNG(t)
dt
= −kGS ln
(
θ
Nt(t)
)
+
∫ ∞
0
2ΓM(a)NM(a, t)da (3.24)
NS(0, t) = kGS ln
(
θ
Nt(t)
)
NG(t) (3.25)
Nt(t) = NG(t) +
∫ ∞
0
(NS(a, t) +NM(a, t))da
Parameters for this model were taken from the literature, when possible, and are shown
in Table 3.5. S- and M -phase transition times were set at 6-8 hours [9, 147] while the value
of kGS was selected to attain an approximate tumor doubling time of 9 days [147]. Overall
tumor volume and individual phase progressions are shown in Figure 3.10 with initialization
at NG(0) = 1 mm
3 and NS(a, 0) = NM(a, 0) = 0. Inclusion of a lumped representation for
G-phase decreased the degree and magnitude of the phase progression oscillations during
the simulation. While it was previously observed that inclusion of a lumped quiescent term
in an age PBE decreases oscillations [84, 86] , this model demonstrates that it may be
a mathematical effect of including a lumped phase representation capable of constantly
supplying cells to the next phase.
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Table 3.5: Model, transition function, and division function parameters for the age-
structured saturating cell-cycle PBE with three cell phases.
Parameter Value Parameter Value
acS 0.25 day βS 25
1
day
acM 0.25 day βM 25
1
day
mS 0.5 day mM 0.5 day
kGS 0.014
1
day
θ 10000 mm3
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Figure 3.10: Total tumor volume progression (solid) starting from an initial cell distribution
of NG(0) = 1.0 with NS(a, 0) = NM(a, 0) = 0, and individual cell-cycle phase volumes for
G-phase (dashed), S-phase (dash-dot), and M -phase (dotted).
71
3.6.2 Four Phase Age-Structured Saturating Cell Cycle PBE
For case (ii), Equations (3.9)-(3.10) remained unchanged while Equations (3.8) and (3.12)
are updated as Equations (3.26) and (3.27):
∂NG(a, t)
∂t
+
∂NG(a, t)
∂a
= −(1 + kGQ)ΓG(a)NG(a, t) (3.26)
NG(0, t) = kQG ln
(
θ
Nt(t)
)
NQ(t) +
∫ ∞
0
2ΓM(a)NM(a, t)da (3.27)
Nt(t) = NQ(t) +
∫ ∞
0
(NG(a, t) +NS(a, t) +NM(a, t))da
In addition, Equation (3.28) was appended to the model to represent the time varying
volume of tumor in a quiescent state:
dNQ(t)
dt
= −kQG ln
(
θ
Nt(t)
)
NQ(t) +
∫ ∞
0
kGQΓG(a)NG(a, t)da (3.28)
Parameters for this model were also taken from the literature when possible and are shown
in Table 3.6. S- and M -phase transition times were set at 6-8 hours while the value of kGQ
and kQG were selected to attain an approximate tumor doubling time of 9 days. Figure 3.11
shows the total tumor and individual phase progression for the four phase age-structured
saturating cell-cycle PBE using these parameters. As before, the inclusion of a lumped ODE
within the model decreased both the degree and magnitude of the system oscillations. The
tumor volume versus time profile was similar to that obtained from the three-phase age-
structured saturating cell-cycle PBE, but, the two models displayed different dynamics in
approaching the plateau volume.
3.6.3 Age-Structured Cell Cycle Model Comparison
As a final comparison, the original age-structured cell-cycle PBE (Equations (3.8)-(3.10))
was updated with the same transition, critical age, and maximum age parameters for S- and
M -phase used in the previous two models. Overall tumor progression predictions for the
three models are shown in Figure 3.12. Though exact overlap was not obtained between the
three models, there is reasonable agreement over the region of exponential tumor volume
progression. Deviation between the saturating and non-saturating models occurs for tumor
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Table 3.6: Model, transition function, and division function parameters for the four phase
age-structured saturating cell-cycle PBE.
Parameter Value Parameter Value Parameter Value
acG 0.5 day βG 100
1
day
kGQ 4.0
1
day
acS 0.25 day βS 75
1
day
kQG 0.030
1
day
acM 0.25 day βM 75
1
day
θ 10000 mm3
mG 1.0 day mS 0.5 day mM 0.5 day
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Figure 3.11: Total tumor volume progression (solid) starting from an initial cell distribution
of NQ(0) = 1.0 with NG(a, 0) = NS(a, 0) = NM(a, 0) = 0, and individual cell-cycle phase
volumes for the quiescent cells (Q, circles), G-phase (dashed), S-phase (dash-dot), and M -
phase (dotted).
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volumes beyond 100 mm3, with additional deviation present between the two saturating
models as the plateau population was approached. This deviation resulted from the manner
in which saturation was included within the model structure, necessitating a lower initial
phase transition rate (kGS) for the three-phase age-structured more in order to maintain an
exponential tumor doubling time of approximately 9 days.
3.7 DOSE SCHEDULE EVALUATION AND DISCUSSION
Extensive evaluation of the linear age-structured cell-cycle PBE in the development of
chemotherapeutic treatment schedules can be found in the literature [80, 81, 82, 83, 84, 85, 86,
147]. These studies evaluated the dynamics of tumor cells grown in vitro, developed models
approximating this growth dynamic, and determined the necessary dosing interval for an
administered therapeutic to attain a maximum effect by taking advantage of explicitly known
cell-cycle dynamics. Within these models, oscillations are induced following treatment; this
results in periods of time where the next dosing will be more or less effective, a phenomena
referred to as resonance chemotherapy. PK drug profiles in such models are typically
incorporated as either being “present” or “absent”, without evaluation of multiple dosing
levels or accurate PK dynamics. Furthermore, drug effect was incorporated within these
models as a bilinear kill term. Although this term is commonly used for approximating the
overall effect between drug exposure and the susceptible population of cells, additional model
information is not used in constructing the drug effect functionality (e.g., cell susceptibility
at certain periods during phase transition, increased likelihood of cell apoptosis based on
period of exposure, etc.).
Studies by Sherer and coauthors have evaluated the extent of dosing necessary to “ensure”
elimination of the tumor based on statistical measures, mainly focusing on the necessary
duration of treatment [127] while studies by Gaffney have evaluated the probability of
success of a treatment accounting for the evolution of drug resistance within the tumor
[85]. Finally, age-structured cell cycle PBE models have also been used to construct
models for the cycling of hematopoietic cells, utilizing a growth structure similar to tumor
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Figure 3.12: Total tumor volume progression for the original age-structured PBE (dash-
dot), three-phase saturating age-structured PBE (dashed), and four-phase saturating age-
structured PBE (solid).
75
progression but with the addition of a quiescent compartment. Together with developed
tumor models, predictions from both the tumor and hematopoietic cell models were combined
to evaluate therapeutic administration schedules for effectiveness against the tumor while
sparing other normal functioning proliferating cells [84, 86]. The results of these experiments
and simulation studies [84, 86] are conclusive that proper timing of doses to elucidate
increased tumor kill is likely not achievable due to the similarities in growth dynamics
observed between tumor and hematopoietic cells grown in vitro. However, these models
neglect that the modeled tumor dynamics may not be representative of the in vivo setting.
Indeed, experiments to validate even the proposed cycling of native hematopoietic cells
have not been performed, though there is conclusive evidence for the cycling of the entire
population following chemotherapeutic treatment (or disease). While it is likely that the
susceptible cell population would be eliminated following treatment with a chemotherapeutic
and oscillations can be induced in cultured cells, there is no experimental evidence for
induced phase fraction oscillations in vivo in either solid tumors or native proliferating cell
populations.
Researchers have investigated the effects of including quiescent cell populations as
an additional lumped ODE [84, 86], however evaluation of age-structured PBEs with
saturating growth dynamics have not been evaluated within the literature. Furthermore, the
incorporation of accurate PK dynamics and multiple chemotherapeutics targeting different
phases of the cell cycle have not been investigated. This latter area requires investigation
as a possible dynamic explanation, at least in part, of the macroscopic observations
of synergism and antagonism observed during combination chemotherapy delivered over
different treatment schedules.
Three case studies were proposed for evaluating treatment outcomes, as measured by
tumor volume. In these cases, the tumor was: (i) the non-saturating age-structured
PBE (Equations (3.8)-(3.10)); (ii) the three-phase saturating age-structured PBE (Equa-
tions (3.9), (3.10), and (3.24)); or (ii) the four-phase saturating age-structured PBE
(Equations (3.9), (3.10), (3.24), and (3.28)). Treatment occurred with two drugs, where
were S-phase and M -phase specific, respectively. The dosing schedules employed for the
three case studies are summarized as follows: Schedule 1 evaluated two drugs having the
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same PK and PD dynamics and parameter values. Dosing of the S-phase drug began on day
42 and was repeated every 7 days through day 70. Dosing of the M -phase therapeutic also
occurred at 7 day intervals beginning between 6 days prior (day 36) and 6 days after (day
48) the initiation of treatment with the S-phase therapeutic. Schedule 2 evaluated a M -
phase therapeutic having PK dynamics that persist for an entire week (e.g., Doc), while the
S-phase therapeutic PK lasted for one day. Dosing of the compounds occurred as described
for Schedule 1. Schedule 3 used the same PK as Schedule 2, however, dosing of the S-phase
drug began on day 42, was repeated daily for 4 more days, and this five day on two day off
schedule was repeated through day 70. Dosing of the M -phase therapeutic was the same as
the previous two schedules.
The schedules were motivated by the following rationale. Schedule 1 results would reveal
if the developed models were more susceptible to treatment during specific phases. Schedule
2 investigates more clinically-relevant PK dynamics for the two drugs, using PK profiles
similar to that observed from common S-phase active camptothecins (plasma half-lives on
the order 2-4 hours) and M -phase active taxanes (plasma half-lives of 12-24 hours); The
PK profiles and dosing schedules for Schedule 3 are similar to preclinical regimens evaluated
for the treatment of SCID mice implanted with Ht29 human tumor xenografts and treated
with 9-nitrocamptothecin (9NC) and docetaxel. Results from this 9NC/Doc animal study
revealed a possible synergistic interaction between 9NC and docetaxel treatment that was
schedule dependent (i.e., statistically-significant improvement in final tumor volume was
achieved if docetaxel was delivered on the fifth day of 9NC treatment versus the first day).
Each of the drugs (D1 and D2) in this simulation study were modeled using two
compartments in series with first order transfer and elimination rates to more accurately
represent PK dynamics observed in implanted xenografts following drug administration.
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The equations for the drugs and phase-specific kill effects are as follows:
dE1(t)
dt
= −τ11E1(t) + u1(t) (3.29)
dD1(t)
dt
= −τ21D1(t) + τ11E1(t) (3.30)
dE2(t)
dt
= −τ12E2(t) + u2(t) (3.31)
dD2(t)
dt
= −τ22D2(t) + τ12E2(t) (3.32)
∂NS(a, t)
∂t
+
∂NS(a, t)
∂a
= −ΓS(a)NS(a, t)− kSNS(a, t)D1(t) (3.33)
∂NM(a, t)
∂t
+
∂NM(a, t)
∂a
= −ΓM(a)NM(a, t)− kMNM(a, t)D2(t) (3.34)
Here, u1(t) and u2(t) are the amounts of the S- and M -phase drug administered, τij is the
transfer rate
(
1
day
)
of input j through state i, and kS and kM are the tumor kill rates (
µM
day
for S- and M -phase cells, respectively). Values for τij and kill rates for the three schedules
can be found in Table 3.7. Representative plots of the drug PK can be found in Figure 3.13.
For each respective dose, 10µM of the drug was delivered as a bolus at the specified time.
While the PK models presented above were only representative approximations of actual
drug PK, and the tumor growth dynamics were not modeled based upon the untreated
control tumor growth dynamics, the focus of these studies was to determine if significant
improvements in final tumor volume were achievable when multiple drugs and realistic PK
profiles were incorporated into nonlinear age-structured PBEs.
The final tumor volumes after 100 days for each of the three models are shown in
Tables 3.8-3.10. The notation in column 1 refers to which day delivery of the M -phase
therapeutic was initiated relative to delivery of the S-phase therapeutic, which was always
initiated on day 42. The organization structure is chosen for comparing treatment outcomes
for individual schedules studies and should not serve as a comparison between individual
model results.
As seen in Table 3.8, equivalent final tumor volumes were predicted at the end of the
simulation for two therapeutics with activity during different cell-cycle phases when the
phase transition rates were equivalent. These results were expected, and they served as
a validation of the model simulations. The general trend of final tumor volumes obtained,
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Figure 3.13: PK profiles for the S-phase chemotherapeutic for Schedule 1 (solid), Schedule
2 (dashed, overlay on first “hump” of Schedule 3), and Schedule 3 (dash-dot). The M -phase
PK profile for all three schedules is the same as the S-phase profile for Schedule 1.
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Table 3.7: PK and PD parameters used for evaluating the treatment of three age-structured
PBEs with S- and M -phase therapeutics.
Model 1 Model 2 Model 3
τ11 1.5
1
day
τ11 1.5
1
day
τ11 1.5
1
day
τ21 1.5
1
day
τ21 1.5
1
day
τ21 1.5
1
day
Schedule 1 τ12 1.5
1
day
τ12 1.5
1
day
τ12 1.5
1
day
τ22 1.5
1
day
τ22 1.5
1
day
τ22 1.5
1
day
kS 1.2
µM
day
kS 1.6
µM
day
kS 2.4
µM
day
kM 1.2
µM
day
kM 1.6
µM
day
kM 2.4
µM
day
τ11 1.5
1
day
τ11 1.5
1
day
τ11 1.5
1
day
τ21 10.0
1
day
τ21 10.0
1
day
τ21 10.0
1
day
Schedule 2 τ12 10.0
1
day
τ12 10.0
1
day
τ12 10.0
1
day
τ22 1.5
1
day
τ22 1.5
1
day
τ22 1.5
1
day
kS 200.0
µM
day
kS 250.0
µM
day
kS 60.0
µM
day
kM 1.2
µM
day
kM 1.6
µM
day
kM 2.4
µM
day
τ11 1.5
1
day
τ11 1.5
1
day
τ11 1.5
1
day
τ21 10.0
1
day
τ21 10.0
1
day
τ21 10.0
1
day
Schedule 3 τ12 10.0
1
day
τ12 10.0
1
day
τ12 10.0
1
day
τ22 1.5
1
day
τ22 1.5
1
day
τ22 1.5
1
day
kS 40.0
µM
day
kS 50.0
µM
day
kS 300.0
µM
day
kM 1.2
µM
day
kM 1.6
µM
day
kM 2.4
µM
day
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Table 3.8: Day 100 tumor volume predicted for the three models treated with Schedule 1.
The first two entries are the final tumor volumes obtained from dosing with only the S-
phase or M -phase therapeutic, respectively. The remainder are combination dose schedule
regimens with the S-phase treatment started on day 42, and theM -phase treatment initiated
the listed number of days prior (-) or after (+).
Schedule 1 Model 1 Model 2 Model 3
Only S-phase 2168.4 mm3 488.6 mm3 524.9 mm3
Only M -phase 2222.1 mm3 488.6 mm3 524.9 mm3
-6 days 629.7 mm3 251.5 mm3 341.4 mm3
-5 days 199.0 mm3 185.4 mm3 289.9 mm3
-4 days 85.5 mm3 144.2 mm3 254.1 mm3
-3 days 92.0 mm3 139.4 mm3 252.5 mm3
-2 days 344.0 mm3 174.2 mm3 290.8 mm3
-1 days 944.5 mm3 254.0 mm3 360.4 mm3
0 days 1416.7 mm3 349.8 mm3 433.2 mm3
+1 days 1013.2 mm3 302.3 mm3 397.8 mm3
+2 days 428.7 mm3 208.8 mm3 322.7 mm3
+3 days 115.5 mm3 151.3 mm3 266.6 mm3
+4 days 115.5 mm3 137.8 mm3 248.7 mm3
+5 days 140.4 mm3 161.3 mm3 269.0 mm3
+6 days 545.0 mm3 218.6 mm3 315.5 mm3
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however, was not expected, with the smallest tumors resulting when theM -phase therapeutic
was administered three or four days prior to administration of the S-phase agent for all three
models. An oscillatory trend in final tumor volume was apparent for the dose schedules
evaluated, with a period of approximately seven days and slight variation depending on
whether the S- or M -phase agent was administered first (e.g., compare final tumor volumes
from -3 days vs. +4 days schedules, -2 days vs. +5 days schedules, etc.). Perhaps most
surprising were the results indicating the highest tumor volumes when both drugs were
administered on the same day. These results were counter to the traditionally accepted
methodology for administering multiple chemotherapeutic agents that advocates the co-
delivery of agents to increase both the overall amount of “cellular stress” and the likelihood
of apoptosis.
A possible explanation for these dosing results was the manner in which the PD effect
was incorporated within the age-structured PBE models. Both of the therapeutics only
affected cells in a specific cell-cycle phase, did not affect any phase transition rates, and
were not designed to display either increased or decreased effect based on the presence on an
additional therapeutic. While there were minimum age requirements before phase transitions
could occur, cells would continue to progress through the cell-cycle even in the presence of
a phase-specific chemotherapeutic, analogous to the results observed during TM dosing [80].
For the two cell-cycle specific chemotherapeutic problem investigated here, the therapeutic
effect of the M -phase agent was reduced following co-administration of the S-phase agent as
cells would undergo apoptosis in S-phase, never reachingM -phase (Figures 3.14-3.16). With
identical PK, the combined PD effects from both agents would be reduced when delivered on
the same day when compared to delivery of the drugs three to four days apart. Furthermore,
the PD structure ignored the possibility of heterogeneous drug susceptibility within the tumor
population, which is a prime clinical motivator for the co-delivery of chemotherapeutics. It
remains to be evaluated whether offsetting delivery of a secondary or tertiary therapeutic
to increase tumor regression would prove advantageous for situations involving resistant cell
populations or is feasible from a monetary perspective.
For Schedule 2, the smallest final tumor volumes were attained when the M -phase
therapeutic was administered either four to five days prior or two to three days after the
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Figure 3.14: Top: Tumor growth profiles predicted for the three-phase saturating age-
structured PBE using the regimen from Schedule 1 with a separation of 0 days (solid)
and +4 days (dashed) between D1 and D2 therapeutic administration. Bottom: S- (0 days,
squares; +4 days, dashed) and M -phase (0 days, diamonds; +4 days, dash-dot) cell cycle
progression.
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Figure 3.15: Top: Tumor growth profiles predicted for the four-phase saturating age-
structured PBE using the regimen from Schedule 1 with a separation of 0 days (solid) and 4
days (dashed) between D1 and D2 therapeutic administration. Bottom: G- (0 days, circles;
+4 days, dashed), S- (0 days, squares; +4 days, dash-dot), and M -phase (0 days, diamonds;
+4 days, dotted) cell cycle progression.
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Figure 3.16: Top: Tumor growth profiles predicted for the three-phase non-saturating age-
structured PBE using the regimen from Schedule 1 with a separation of 0 days (solid) and 4
days (dashed) between D1 and D2 therapeutic administration. Bottom: G- (0 days, circles;
+4 days, dashed), S- (0 days, squares; +4 days, dash-dot), and M -phase (0 days, diamonds;
+4 days, dotted) cell cycle progression.
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Table 3.9: Day 100 tumor volume predicted for the three models treated with Schedule 2.
The first two entries are the final tumor volumes obtained from dosing with only the S-
phase or M -phase therapeutic, respectively. The remainder are combination dose schedule
regimens with the S-phase treatment started on day 42, and theM -phase treatment initiated
the listed number of days prior (-) or after (+).
Schedule 2 Model 1 Model 2 Model 3
Only S-phase 5255.8 mm3 1006.2 mm3 909.1 mm3
Only M -phase 2222.1 mm3 488.6 mm3 524.9 mm3
-6 days 717.3 mm3 332.9 mm3 408.7 mm3
-5 days 320.0 mm3 323.5 mm3 383.4 mm3
-4 days 508.1 mm3 331.5 mm3 393.9 mm3
-3 days 1317.7 mm3 356.0 mm3 431.1 mm3
-2 days 2045.9 mm3 410.9 mm3 483.9 mm3
-1 days 2375.8 mm3 467.8 mm3 517.9.0 mm3
0 days 2168.1 mm3 482.7 mm3 523.0 mm3
+1 days 1169.6 mm3 336.5 mm3 421.0 mm3
+2 days 508.6 mm3 323.6 mm3 384.1 mm3
+3 days 311.8 mm3 330.0 mm3 387.1 mm3
+4 days 783.9 mm3 349.5 mm3 414.4 mm3
+5 days 1600.7 mm3 392.3 mm3 454.4 mm3
+6 days 2212.9 mm3 436.0 mm3 480.1 mm3
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S-phase therapeutic. While different than the results obtained from Schedule 1, these are
conceptually similar, spacing the delivery of the two therapeutics to minimize the duration
of overlapping effect. Simulated results displayed oscillations that repeated every 7 days and
were not dependent on which agent was delivered initially. Also, the results do not indicate
that simply administering the chemotherapeutics at the latest available time would result in
the smallest final tumor volume, a result counter to the optimal control solutions obtained
from single-agent, lumped, tumor progression models [65, 149].
Recovery of the S-phase cells following S-phase active agent took one to two days for
this schedule, as shown in Figure 3.17. For the three-phase saturating model, the simulation
converged to the nominal cell-cycle fraction by 1.5 days following the start of treatment. In
contrast, the four-phase saturating model was slower to damp, taking 3 days to return to
the pseudo-steady state cell-cycle fraction distribution, and it displayed at least one plateau
in the fractional progression (Figure 3.18). For both saturating PBE models, all observed
oscillations in cell-cycle fraction were a direct PD effect, calling into question the ability of
either model to generate the cell-cycle oscillations ideal for resonance chemotherapy. Only
dosing with the three-phase non-saturating age-structured PBE predicted extended cell-cycle
fraction oscillations (Figure 3.19) which persisted for the duration of the study due to the
phase transition parameters selected for the model.
Finally, the results for Schedule 3 indicated that the smallest final tumor volume was
obtained if the M -phase agent was delivered either one to two days prior or five to six
days after initial administration of the S-phase agent (Table 3.10). This corresponds to
administering the M -phase therapeutic on one of the two days during the week where
the S-phase therapeutic was not administered. Again, the projected final tumor volumes
oscillated over a seven day cycle and did not display consistently lower final tumor volumes
for treatments initialized at earlier time points.
Figures 3.20 and 3.21 show the simulation results for the three-phase and four-phase
saturating age-structured PBEs, respectively, with the M -phase therapeutic dosed on either
the initial day the S-phase therapeutic was administered (day 0) or on the fifth day the
S-phase therapeutic was administered (day +4). For the three-phase model there was near
total recovery of the S-phase population between daily therapeutic administrations with
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Figure 3.17: Top: Tumor growth profiles predicted for the three-phase saturating age-
structured PBE using the regimen from Schedule 2 with a separation of 0 days (solid)
and +4 days (dashed) between D1 and D2 therapeutic administration. Bottom: S- (0 days,
squares; +4 days, dashed) and M -phase (0 days, diamonds; +4 days, dash-dot) cell cycle
progression.
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Figure 3.18: Top: Tumor growth profiles predicted for the four-phase saturating age-
structured PBE using the regimen from Schedule 2 with a separation of 0 days (solid)
and +4 days (dashed) between D1 and D2 therapeutic administration. Bottom: G- (0 days,
circles; +4 days, dashed), S- (0 days, squares; +4 days, dash-dot), and M -phase (0 days,
diamonds; +4 days, dotted) cell cycle progression.
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Figure 3.19: Top: Tumor growth profiles predicted for the three-phase non-saturating age-
structured PBE using the regimen from Schedule 2 with a separation of 0 days (solid) and
+4 days (dashed) between D1 and D2 therapeutic administration. Bottom: G- (0 days,
circles; +4 days, dashed), S- (0 days, squares; +4 days, dash-dot), and M -phase (0 days,
diamonds; +4 days, dotted) cell cycle progression.
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Table 3.10: Day 100 tumor volume predicted for the three models treated with Schedule
3. The first two entries are the final tumor volumes obtained from dosing with only the S-
phase or M -phase therapeutic, respectively. The remainder are combination dose schedule
regimens with the S-phase treatment started on day 42, and theM -phase treatment initiated
the listed number of days prior (-) or after (+).
Schedule 3 Model 1 Model 2 Model 3
Only S-phase 1109.4 mm3 670.0 mm3 548.4 mm3
Only M -phase 2222.1 mm3 488.6 mm3 524.9 mm3
-6 days 522.2 mm3 289.2 mm3 334.1 mm3
-5 days 267.3 mm3 277.8 mm3 322.0 mm3
-4 days 101.1 mm3 254.2 mm3 300.6 mm3
-3 days 115.2 mm3 229.9 mm3 285.3 mm3
-2 days 99.2 mm3 223.1 mm3 286.3 mm3
-1 days 201.7 mm3 271.9 mm3 327.5 mm3
0 days 624.6 mm3 327.1 mm3 385.2 mm3
+1 days 646.8 mm3 324.7 mm3 383.3 mm3
+2 days 431.5 mm3 308.4 mm3 363.2 mm3
+3 days 183.2 mm3 274.4 mm3 326.4 mm3
+4 days 115.2 mm3 236.4 mm3 292.1 mm3
+5 days 110.0 mm3 213.5 mm3 272.4 mm3
+6 days 118.4 mm3 250.1 mm3 295.7 mm3
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the trough of the M -phase population increasing as the week continues. In contrast, when
the dosing was separated by four days, the M -phase population was lowest on the day of
drug delivery and does not return to a sufficient volume by the time the S-phase schedule
begins again, limiting the PD effect. Similar results were obtained for the four-phase model,
though neither the population in S- orM -phase completely recovered week-to-week when the
treatments were separated by four days, possibly due to the exchange of cells between the G-
phase and Q-phase populations. For the three-phase non-saturating model, the week-to-week
trough behavior changed as the cycle repeated, initially displaying its lowest point during
days 1-3 of treatment with the S-phase therapeutic, then displaying a downward trough trend
during later weeks. As a whole, the non-saturating model also predicted greater disparity
between treatment regimens which cannot be described solely by the exponential growth
dynamics of the system following treatment. Rather, the rate constants selected (long G-
phase residence time) for this simulation ensured a constant, rapid transition of cells from
G-phase to the other phases, increasing the total number of cells exposed to the therapeutic.
Schedule 3 was demonstrated that delivery of an S-phase therapeutic (9NC) and an M -
phase therapeutic (Doc) yielded final tumor volumes dependent on the delivery schedule of
the two therapeutics [150]. The mouse study demonstrated that for mice dosed daily for five
days with 9NC followed by two days off, with the schedule repeated for an additional week,
tumor volumes at the end of treatment were significantly smaller if Doc was administered
on the fifth day of 9NC treatment (103.7±73.9 mm3) versus the initial day (229.4±160.9
mm3). While the ratio of final tumor volumes achieved during the simulation study was
not as large as that obtained from the PK/PD study (1.4:1 for the three-phase saturating
model and 1.3:1 for the four-phase saturating model versus 2.2:1 experimentally), the results
did demonstrate schedule dependent final tumor volumes. From here, the parameters for
untreated and treated tumor progression could be evaluated for the specific PBE models,
and the actual tumor drug PK could be included for predicting PD effect. Furthermore,
by shortening the window of effect for the M -phase therapeutic (e.g., defining the M -phase
PD parameter as zero if the age within M -phase was less than 5.5 hours), consistent with
the 30-60 minutes duration of cell mitosis, final tumor volume ratios of 1.8:1 and 1.7:1 were
obtained with the three-phase and four-phase saturating age-structured PBEs, respectively.
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Figure 3.20: Top: Tumor growth profiles predicted for the three-phase saturating age-
structured PBE using the regimen from Schedule 3 with a separation of 0 days (solid)
and +4 days (dashed) between D1 and D2 therapeutic administration. Bottom: S- (0 days,
squares; +4 days, dashed) and M -phase (0 days, diamonds; +4 days, dash-dot) cell cycle
progression.
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Figure 3.21: Top: Tumor growth profiles predicted for the four-phase saturating age-
structured PBE using the regimen from Schedule 3 with a separation of 0 days (solid)
and +4 days (dashed) between D1 and D2 therapeutic administration. Bottom: G- (0 days,
circles; +4 days, dashed), S- (0 days, squares; +4 days, dash-dot), and M -phase (0 days,
diamonds; +4 days, dotted) cell cycle progression.
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Figure 3.22: Top: Tumor growth profiles predicted for the three-phase non-saturating age-
structured PBE using the regimen from Schedule 3 with a separation of 0 days (solid) and
+4 days (dashed) between D1 and D2 therapeutic administration. Bottom: G- (0 days,
circles; +4 days, dashed), S- (0 days, squares; +4 days, dash-dot), and M -phase (0 days,
diamonds; +4 days, dotted) cell cycle progression.
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3.8 DISCUSSION AND SUMMARY
This chapter investigated the model development of both non-saturating and saturating PBE
cell-cycle tumor growth models, incorporating either the cell mass or age as intrinsic system
variables. Non-saturating models based on both age and mass were constructed and displayed
exponential bulk tumor progression, which is descriptive of hematological cancers and solid
tumor growth over short periods of time, but is insufficient for describing solid tumor growth
over an extended period of time. To address this shortcoming, two mass-structured PBEs
with either saturating G-phase transition rate or G-phase mass accumulation rate were
investigated. The former model displayed undesirable growth properties, namely exponential
growth up to the saturating population followed by a rapid plateauing effect and subsequent
numeric instability as the number density mass for G-phase cells converged to the upper
bound on the system mass. The latter model, while displaying the desired saturating tumor
growth characteristics, was ultimately set aside due to an inability to relate downstream
PD effects to cell mass. Two saturating age-structured PBEs were then investigated, one
containing a lumped G-phase and age-distributed S- and M -phases for a total of three
phases; the other included a lumped Q-phase and age-distributed G-, S- and M -phases for
a total of four phases. Both models accurately described bulk tumor progression, and could
be updated with parameters for individual tumor lines.
To evaluate whether the increased complexity of these models was capable of describing
multiple chemotherapeutic schedule dependent outcomes, a series of dosing schedules were
simulated. Three dosing schedules involving two cycle-specific therapeutic drugs, PK
dynamics, and PD effects were evaluated against the three age-structured PBE models
developed within this chapter. While the S-phase treatment always started on day 42 of the
simulation, treatment with the M -phase agent began up to 6 days prior or after the S-phase
treatment. Results indicated that age-structured PBEs are capable of generating schedule
dependent differences in final tumor volumes that are not achievable using traditional lumped
models. Furthermore, the simulations indicated that for multi-agent chemotherapies, greater
final tumor volumes resulted when the drugs were administered concurrently and that
separating drug delivery to reduce the extent of PK overlap resulted in the the smallest final
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tumor volumes. These results run counter with how typical chemotherapeutics are currently
delivered in clinical practice and may have resulted from the PD relationship incorporated
for these simulations and failure to include distributed drug sensitivities amongst the tumor
population. The employed model structure was also not capable of achieving the degree
of oscillations necessary for resonance chemotherapy treatment, only manifesting cell-cycle
phase alterations immediately following drug delivery. The four-phase saturating age-
structured model displayed perturbations to the cell-cycle distribution following treatment,
though these perturbations did not result in oscillations of the cell-cycle fractions. These
results were expected as previous papers exploring resonance therapy demonstrated that
the inclusion of a quiescent cell population, gradually declining PD effects, PK transport
dynamics, or any comparable filtering dynamic damped the discrete transitions necessary
for manifesting the cell-cycle fraction oscillations seen during resonance chemotherapy
simulations.
Increased tumor regression over the results obtained during this simulation study
could likely be attained by altering the frequency of drug administration (i.e., resonance
therapy) and the dosing level. However, not only would these schedules with more frequent
administration have results mediated by the quiescent cell population, but uncertainty and
variability regarding phase transition rates could lead to over an prediction of tumor effect.
For dose schedules specifically timed according to the overall cell-cycle transition rate,
slight parameter errors may even result in worse treatments. Further, due to the duration
and gradual elimination of drug effect (as opposed to a sharp transition of drug removal)
compared to the phase transition times incorporated within the models, there were not
sufficient phase oscillations for supporting resonance therapy.
Final tumor volumes obtained following treatment were also independent of when the
schedule was initialized, though, final volume was schedule dependent; similar results
are obtained using lumped models for tumor progression. These results support the
administration of chemotherapeutic on an established schedule regardless of the size of the
tumor when treatment is initiated, a practice that is currently used clinically. However, this
result disagrees with preclinical observations where smaller tumors exhibit larger regression
and likelihood of total elimination. Further, clinical success is correlated with the initial size
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of the tumor, though these clinical results may not coincide with greater tumor regression.
It is clinically recognized that blood flow rate, and hence, drug deposition, is non-uniform in
solid tumors, increasing in heterogeneity as the volume of the tumor increases. To address
this, it is necessary to establish a relationship between plasma PK and the observed tumor
volume for predicting how local drug exposure may change during treatment.
Of concern are the diminished returns in developing more involved tumor models when
the PD effect does not incorporate the additional cell state variables introduced into the
model for describing cell cycle dynamics. Unperturbed bulk tumor progression is already
readily described using any number of deterministic or stochastic tumor growth models found
in the literature [68, 69, 74, 75, 76, 77]. The ability to describe tumor regression following
treatment, however, especially with multiple agents over a set administration schedule,
often leads to inaccurate PD model predictions. The likely cause of these inaccuracies
is the PD effect structure, not only for multi-agent therapies, but also for single agent
treatments. Common practice in tumor modeling, even employed within this dissertation,
is the inclusion of PD effect as a bilinear term, the product of the susceptible population
and drug concentration premultiplied by a constant. This formulation of a kill term, while
applicable to steady state drug exposure experiments conducted in vitro, may introduce error
when extrapolated to an in vivo setting where drug concentrations may vary over orders of
magnitude due to administration methods (i.e., bolus injection versus infusion).
Furthermore, the PD models only assumed elimination of cells based on the susceptible
population and plasma PK, neglecting growth inhibition due to the chemotherapeutic.
Drug effect is a combination of both growth hindrance and apoptosis; however, the
exact contribution of each is neither thoroughly investigated, nor can it be estimated
through macroscopic measures obtained from preclinical (or clinical) trials. The necessary
information could be obtained through in vitro cell cycle transition and tumor cell progression
studies under control and treated conditions obtained at multiple time points. Titrated
conditions mimicking an in vivo PK profile can also be evaluated to assess cell-cycle
progression under concentration conditions similar to those encountered following in vivo
dosing.
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Overall both saturating and non-saturating PBEs offer a unique structure for the
evaluation of single- or multiple-agent chemotherapies. These models, however, are not
suitable for closed-loop controller evaluation of cancer treatment at present due to: (i)
continued reliance on a feedback tumor volume metric; and (ii) the computation time of the
model. In contrast, open-loop schedule evaluation is an ideal application of these models,
allowing for the off-line simulation and evaluation of multiple drug combinations, dosing
schedules, and dosing levels, areas that cannot be explored clinically or even preclinically
due to constraints on financial costs, ethics, and time. The tumor growth progression
portion of these models would need to be updated for individual tumor lines; however, the
variability that exists in bulk tumor growth dynamics can be obtained from concurrent
control experiments, leaving S- and M -phase progression rates largely unaltered while
updating dynamics involving G-phase transitions. Likewise, while individual PK profiles are
drug dependent, this information is typically obtained throughout the course of preclinical
investigations. Finally, the tumor progression model could be appended with a reliable
toxicity assessment model to simultaneously evaluate whether the evaluated dose schedule
has increased or decreased toxicity relative to other schedules and/or changes in predicted
tumor efficacy.
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4.0 MOUSE PBPK MODEL FOR DOC
Docetaxel (Doc) is a semi-synthetic taxane that displays activity against a wide range of
solid tumors and is approved for use in treating metastatic breast, non-small cell lung, and
androgen-independent prostate cancers [151]. It is a cell-cycle-specific chemotherapeutic
agent that promotes tubulin assembly and inhibits depolymerization of assembled tubulin,
which results in blockage of cell-cycle progression during M -phase and leads to apoptosis
[151]. The primary Doc elimination route (>80%) involves metabolism in the liver by the
CYP3A enzyme family, yielding inactive metabolites [152]. The remainder of the parent
compound is eliminated either through fecal (<10%) or renal (<10%) excretion [153, 154].
Typically, Doc is administered as a 1-hour IV infusion every three weeks (q3w regimen) at
60-100
mg
m2 with neutropenia as the primary dose-limiting toxicity [155, 156, 157]. Alternative
schedules, such as administration of Doc once a week for three weeks followed by a week off
(35-40
mg
m2 “weekly” schedule) or every other week are also actively being used or investigated
[7, 8, 157, 158]. These alternative schedules display equivalent efficacy to the q3w schedules
and produce significantly less neutropenia than the q3w schedule. However, these alternative
schedules display cumulative increases in other toxicities such as fatigue, hyperlacrimation,
and nail-toxicity [159]. At present, there is no clear consensus on which schedule is ideal
for treatment; however, the clinical acceptability of weekly schedules offers the possibility
of individualized treatment for those patients who might experience adverse hematological
effects during typical Doc treatment regimens that use the q3w dosing schedule. Further
complicating Doc treatment is the highly variable inter-patient pharmacokinetics (PK)
observed, which are due to a number of patient-specific factors including plasma α1-acid
glycoprotein (AAG) concentrations, serum albumin concentrations, hepatic function, and
body surface area [2, 97].
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The plasma PK of Doc, which have been studied previously in a number of animal species
and humans, display tri-phasic elimination from the plasma following i.v. administration,
appreciable tissue uptake from the plasma, and linear kinetics over various infusion durations
and dosing levels [5, 150, 160, 161, 162]. Distribution studies of radiolabeled Doc in mice
have shown rapid tissue uptake, primarily in the liver, intestine, spleen, and bone marrow,
though radioactivity was detectable in virtually all evaluated tissues [160]. Doc PK in
tissues displayed biphasic elimination with a terminal half-life of 2-4.5 hours compared to
a terminal half-life of 1.2 hours in plasma. Even slower elimination was observed in mice
implanted with adenocarcinoma xenografts, where tumor tissue displayed selective Doc drug
retention relative to normal tissue and a terminal half-life of approximately 22 hours [160].
Other mouse studies have obtained terminal plasma and tissue half-lives significantly longer
than those reported in previous studies, with plasma half-lives ranging from 4.5-8.6 hours
over a Doc dosing range of 5-20
mg
m2 [5, 150]. Tissue half-lives also increased, ranging from
3.2-6.1 hours [5]. This latter study also noted an increase in both plasma and tissue half-lives
with increasing Doc dosing level [5].
More complex models, such as physiologically-based pharmacokinetic (PBPK) models,
utilize knowledge of the anatomy and physiology of the studied species to develop a PK
model that accurately describes plasma, tissue, and, in some cases, tumor concentrations
following drug delivery. A representative illustration of this model structure is shown in
Figure 4.1. These models have found extensive use in toxicity studies [34, 35], anesthetic
therapy [37], treating diabetes [39, 163], and describing chemotherapeutic distribution to
sites of action and regions of susceptible toxicity [5, 41, 42]. Individual tissue compartments
are represented by ordinary differential equations; tissues are included based on PK interest
and available data, while the remaining tissues are combined together into “rapidly” and
“slowly” perfused tissue compartments or as a composite “peripheral” compartment. These
types of models can be applied to drugs that are administered via i.v. injection (into the
venous compartment), orally (into the gastrointestinal tract), via inhalation (necessitating a
pulmonary compartment in addition to the lungs), or via subcutaneous injection (under the
skin).
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System-wide distribution of Doc and construction of an accompanying mouse PBPK
model was previously investigated at dosing levels of 5 and 20
mg
kg
in a study by Bradshaw-
Pierce et al. [5]. Tissue samples for both studies were obtained over 24 hrs, and model
compartments included plasma, liver, kidney, intestine, and total fecal elimination over the
course of the study. The model included nonlinear relationships for the metabolism of
parent compound in the liver, elimination by fecal or urinary excretion, and extended tissue
retention based on tissue specific tubulin content and binding affinity. The goal of the present
study was to use data from Doc distribution following i.v. administration to severe combined
immunodeficient (SCID) mice bearing human SKOV-3 ovarian cancer xenografts to develop
a more extensive mouse PBPK model that included additional normal tissue and tumor
compartments . Furthermore, the model was structured utilizing solely linear dynamics, as
Doc plasma PK in mice has been observed to be linear at the investigated dosing levels.
4.1 MATERIALS AND METHODS
4.1.1 Mouse Doc PK Study
Data for PBPK modeling was obtained from a PK study performed on female C.B.-17
SCID mice bearing SKOV-3 human ovarian cancer xenografts [150, 164]. At 21 days after
xenograft implantation, tumor-bearing mice were stratified into three groups such that group
body weights and tumor volumes were not statistically different. Doc was administered
intravenously to mice at 10
mg
kg
over the course of 10-15 seconds. Mice (n = 3 per time
point) were euthanized by CO2 asphyxiation at 0.083, 0.25, 0.5, 1, 2, 4, 6, 7, 18, and 24
hours after Doc administration. Venous blood was collected from the right ventricle via
cardiac puncture into heparinized syringes and placed on ice until centrifuged at 12,000 × g
for 4 min. After centrifugation, plasma was collected, snap frozen in liquid N2, and stored at
-80 oC until analysis by LC-MS [165]. Similarly, collected tissues (lung, liver, brain, tumor,
spleen, heart, kidney, muscle, and fat) and tumor were removed, weighed, frozen in liquid
nitrogen, and stored at -80 oC until analysis by LC-MS [165].
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4.1.2 Sample Processing and LC-MS Analysis
Plasma samples (100 µL) were mixed with 400 µL of control plasma and 10 µL of 1 µM
paclitaxel internal standard (I.S.). Samples were vortexed and then centrifuged at 21,000 ×
g for 6 min at 4 oC followed by solid phase extraction (SPE) as described previously [165].
Ten µL of the sample were then injected into the LC-MS [165].
Tumor and normal tissue samples were homogenized in phosphate-buffered saline at
pH 7.4 (1:3, w/v) and subjected to acetonitrile protein precipitation using a 200 µL tissue
homogenate aliquot, 10 µL I.S., and 1 mL acetonitrile. Samples were vortexed and then
centrifuged at 21,000 × g for 6 min @ 4 oC. The supernatant was decanted and evaporated
to dryness under nitrogen at 37oC. The dried residues were re-suspended in 1 mL of 0.01 M
ammonium acetate buffer, each at pH 5.0:methanol, (80:20, v/v), which was then processed
by SPE as described previously [165]. Ten µL of the processed tissue sample were then
injected into the LC-MS [165].
4.1.3 Mouse PBPK Model Formulation
The system-wide distribution of Doc was described using a PBPK model, as shown
in Figure 4.1. IV administration is included in the model as an infusion into the
venous compartment, which subsequently distributes throughout the rest of the body. In
PBPK models, tissue compartments are typically treated as either perfusion-limited (one
compartment), as in Equation (4.1),
dCi
dt
=
Fi
Vi
(
Cin − Ci
Pi
)
(4.1)
or diffusion-limited (two compartments), as in Equations (4.2)-(4.3):
dCiv
dt
=
Fi
Viv
(Cin − Civ)− kivefunbCiv +
Vie
Viv
kievCie (4.2)
dCie
dt
=
Viv
Vie
kivefunbCiv − kievCie (4.3)
For the perfusion-limited system (Equation (4.1)), Ci is the drug concentration in tissue i,
Fi is the blood flow rate into tissue i, Vi is the volume of tissue i, and Cin is the inlet drug
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Figure 4.1: PBPK model for the distribution of Doc in plasma, various mouse tissues, and
subcutaneously implanted tumor xenografts.
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concentration for tissue i, which comes from: (i) the venous blood supply in the case of
the lungs; (ii) from the spleen, gut, and arterial compartment for the liver; or (iii) from the
arterial compartment for all other body tissues. Diffusion-limited tissues (Equations (4.2)-
(4.3)) have both a vascular (v) and extra-vascular tissue (e) space (volumes Viv , and Vie ,
respectively), with separate concentrations, Civ and Cie , intratissue transfer rates, kive and
kiev , and an unbound drug fraction (funb) approximated as 15% for mice. Due to the long Doc
retention times observed in tissues, an effect of intracellular Doc binding and transport, all
modeled tissues had improved fits using diffusion-limited compartments. However, a number
of these tissue models were still incapable of simultaneously fitting rapid post-dose dynamics
and Doc retention. To improve model fits, an additional subcompartment was added to each
tissue. The resulting model for tissues that do not eliminate drug is as follows:
dCiv
dt
=
Fi
Viv
(Cin − Civ)− kivefunbCiv +
Vie
Viv
kievCie (4.4)
dCie
dt
=
Viv
Vie
kivefunbCiv − kievCie + kbindoutCib − kbindinCie (4.5)
dCib
dt
= −kbindoutCib + kbindinCie (4.6)
Here, Cib is the drug concentration in the additional “bound” subcompartment, and kbindout
and kbindin are retention rates within the tissue. The binding rate parameters were kept
the same for all investigated tissues to limit the overall number of model parameters. For
drug eliminating tissues, primarily the liver in the case of Doc, Equations (4.5)-(4.6) add a
clearance term, as follows:
dCie
dt
=
Viv
Vie
kivefunbCiv − kievCie + kbindoutCib − kbindinCie − kclliClie (4.7)
dCib
dt
= −kbindoutCib + kbindinCie − kclliClib (4.8)
Here, kclli is the rate of drug clearance from the liver. Note, that clearance was allowed
to occur in both the extravascular space in addition to the bound subcompartment, and
the same parameter was utlized in both tissue spaces due to data limitations regarding
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liver metabolism. Finally, venous plasma and red blood cell (RBC) concentrations were
represented by the following equations:
dCven
dt
=
∑
j FjCje − FtotCven
Vven(1− fhem) +
u
Vven(1− fhem) +
fhem
(1− fhem)krbcplasCrbcv
−kplasrbcfunbCven (4.9)
dCrbc
dt
= −krbcplasCrbc + (1− fhem)
fhem
kplasrbcfunbCven (4.10)
Here, Cven and Crbc are the concentrations in venous plasma and circulating red blood cells,
respectively, fhem is the hematocrit fraction in mice (fhem = 0.45, [1]), Fj and Cj are the
flow rates and extravascular concentrations, respectively, from tissue j, and u represents IV
administration of Doc. Transition rates between plasma and RBCs are given by kplasrbc and
krbcplas, respectively. RBCs were represented as a side compartment to the venous plasma
concentration as shown in Figure 4.1. For the arterial concentration, Equations (4.9)-(4.10)
are left unchanged except for the removal of the drug input term, u, and the use of “art” in
place of “ven”. The overall set of ordinary differential equations governing the PBPK model
can be found in Appendix B.
To reduce the number of parameters requiring estimation, tissue and tumor masses from
the mouse PK study were adjusted based on tissue densities obtained from the literature
[1] and incorporated as the appropriate tissue volumes. Blood flow rates, vascular tissue
fractions fi, and masses for tissues not entirely extracted (fat and muscle) were also obtained
from the literature [1]. These parameters are summarized in Table 4.1. Tumor blood flow
rate was calculated based on the following equation for ovarian xenografts taken from the
literature [166]:
log (tumor blood flow) = −0.808 log (tumor wet weight)− 0.436 (4.11)
Here, the tumor wet weight and tumor blood flow are in units of g and mLg min, respectively.
Vascular and extra-vascular tissue volumes were calculated as Viv = Vifi and Vie = Vi − Viv .
Similarly, the tissue volume and blood flow rate for the other compartment was calculated
as Vo = Vtot −
∑
i6=o Vi and Fo = Ftot −
∑
i6=o,l Fi. The remaining parameters (tissue-specific
exchange rates, plasma-RBC exchange rates, tissue binding rates, and liver clearance rate)
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were estimated by minimizing the weighted sum squared error between model predictions
and mouse PK data, as follows:
min
ρ
(Yact − Ypred(ρ))T W T1 W1 (Yact − Ypred(ρ)) (4.12)
Here, Yact and Ypred are vectors of the actual PK study data and model predictions,
respectively, W1 is a diagonal matrix of the inverse standard deviations from the PK study,
and ρ are the system parameters. The estimated parameters are summarized in Table 4.1.
Parameter estimation and structure selection was accomplished by sequentially adding
tissues while minimizing the weighted sum of squares between the model predictions and
collected experimental data. The inverse square of the variance at individual points was
used as the weights (W T1 W1), and simulations were performed in MATLAB ( c©2007, The
MathWorks, Natick, MA) using the fmincon function. The steps are summarized below:
1. A compartmental model was fit to the Doc plasma data.
2. Parameters for the lung compartment, assuming a perfusion-limited structure, were
estimated, and then the structure was reevaluated as diffusion-limited and as diffusion-
limited with internal binding to assess which structure provided the most accurate
representation of lung Doc PK.
3. RBC binding rates were estimated using the estimated plasma Doc profile as the input.
4. A PBPK model with those compartments deemed essential (RBC, lung, liver, gut, spleen,
tumor, and “other”) was constructed, with each tissue evaluated first as perfusion-
limited. Tissues were then evaluated individually as diffusion-limited then diffusion-
limited with internal binding.
5. Additional tissues were added and evaluated sequentially, in the following order: brain,
kidney, heart, muscle, and fat.
4.1.4 Model Quality Assessment
The quality of the model was determined by calculating the performance error (PE) at
individual data points, the mean performance error (MPE), the mean absolute performance
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error (MAPE), the weighted sum squared error (WSSE), and root mean squared performance
error (RMSPE) for each tissue. The performance error was defined as:
PE =
Yact − Ypred(ρ)
Yact
× 100% (4.13)
Similarly, MPE and MAPE , which represent the bias and accuracy of the predictions,
respectively, are defined as the mean and absolute mean of PE values for a given tissue. The
weighted sum squared error, a measure of the accuracy of tissue predictions with respect to
measurement error is given by Equation (4.12). Finally, RMSPE is defined as,
RMSPE =
1
n
√√√√ n∑
i=1
PE2i (4.14)
where n is the number of data points per tissue.
4.1.5 Parameter Sensitivity Analysis
Sensitivity analysis was performed to identify which of the estimated model parameters and
literature values had the most influence on tissue, plasma, and tumor Doc concentration
estimate on predictions. Each estimated or literature parameter was increased by 0.1% and
the normalized sensitivity (NS) for that parameter with respect to the resulting model output
at each time point was calculated as follows:
NSi,j,k =
∂yi(tj)
∂ρk
ρk
yi(tj)
(4.15)
Here, yi(tj) is the value of the ith model output (concentration) at time tj, and ρk is the
kth model parameter. To calculate the relative sensitivity of the model outputs to changes
in the model parameters over all sampled times, the relative sensitivity (RS) was calculated
as follows:
RSi,k =
1
J
√√√√ J∑
j=1
(NSi,j,k)2 (4.16)
Here J is the total number of samples obtained for the tumor, plasma, and each tissue.
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4.2 RESULTS
The final model fit to SCID mouse plasma, tissue, and tumor data following intravenous
administration of 10
mg
kg
of Doc is shown in Figures 4.2-4.4. The constructed model is able
to describe both the rapid drug absorption after bolus administration and late time drug
retention observed in all tissues. Of particular note is the Doc concentration profile obtained
for the tumor, which displays long-term retention of Doc beyond the 24-hour sample. This
leads to uncertainty in estimating the tumor extravascular to vascular transport rate (ktev) as
minimal dynamic information on drug elimination from the tumor is available from the data.
Also, many of the tissues typically classified as perfusion-limited (i.e., kidney, spleen, and
lung) could not be accurately described using Equation (4.1). One reason that perfusion-
limited tissue approaches were unable to capture the mouse Doc data was the different
dynamic profile obtained for Doc plasma concentrations compared to any of the other
sampled tissues (i.e., plasma concentration falls four orders of magnitude while most tissues
fall three orders of magnitude or less). In addition, improved fits were obtained with the
incorporation of an additional retention subcompartment within each tissue (Equation (4.6)).
As Doc is both lipophilic and binds intracellularly to tubulin, it was not unexpected to
observe long-term Doc retention in a majority of the sampled tissues [151, 167]. However,
given the dynamic profile of plasma Doc concentration (rapid decrease over the first 16
hours) compared to tissue dynamics (rapid initial reduction in concentration over 1 hour
followed by a more gradual decrease over time), the model structure would not be capable
of representing such dynamic behavior without the inclusion of either a nonlinear transport
rate or the addition of another tissue subcompartment with linear transition rates.
Individual compartment accuracy was assessed by evaluating the MAPE, MPE, and
terminal half-lives of individual tissues. Predictions for the heart, spleen, and kidney were
the least accurate fits with MAPE values of 27.9%, 32.9%, and 34.7% and MPE values of
12.4%, 19.1%, and 23.9% respectively. These inaccuracies were a direct result of using a single
set of values for all tissue binding kinetics and could be improved by introducing separate
binding kinetic rates for the muscle and other compartments that displayed long terminal
half-lives. Plasma had the fourth largest MAPE value, which resulted from the 16 and 24
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Figure 4.2: Measured Doc concentration versus time data from tumor-bearing SCID mice
(circles, µ, with ±σ error bars, n = 3 mice per point) compared with mouse PBPK model
predictions (lines) for plasma, liver, tumor, and red blood cells.
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Figure 4.3: Measured Doc concentration versus time data from tumor-bearing SCID mice
(circles, µ, with ±σ error bars, n = 3 mice per point) compared with mouse PBPK model
predictions (lines) for spleen, lung, kidney, and heart.
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Figure 4.4: Measured Doc concentration versus time data from tumor-bearing SCID mice
(circles, µ, with ±σ error bars, n = 3 mice per point) compared with mouse PBPK model
predictions (lines) for brain, “other”, muscle, and fat compartment.
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hour Doc plasma concentration data points having equal values (i.e. the data predicts no
change in Doc plasma concentration over the final 8 hours of sampling). Model predictions
split the difference between these two points resulting in a 5.4% increase in MAPE versus
the same calculation without the two final time points. The remaining tissues have MAPE
values that are within the mean standard error of individual data points and represent a
combination of assay error and individual mouse variability. While the MPEs for plasma,
tumor, and tissues were near zero (range
4.4%− 23.9%
), the model displayed a bias towards overpredicting tissue concentrations. This bias could
similarly be addressed by introducing individual tissue binding rates, or by assigning two
separate sets of tissue binding rates (i.e. specific sets for slowly and rapidly perfused tissues).
Estimated half-lives from the data were 4.7 hours for plasma, 31.2 hours for tumor, and
ranged from 3.4-10.6 hours for the tissues. Similarly, model predicted half-lives were 7.9
hours for plasma, 29.1 hours for tumor, and ranged from 6.1-10.4 hours for the remaining
tissues. The higher tissue half-lives were again a result of using a single set of binding rates
for all tissues, and estimation would be improved by using at least two separate sets of
parameters. The large discrepancy between actual and predicted tumor half-life resulted
from tumor Doc concentration data that was relatively constant over the entire PK study;
half-life estimates could be improved by including tumor concentrations sampled at later
time points (beyond 24 hours) when identifying model parameters.
Parameter sensitivity results for the literature and estimated parameters for all 12
model outputs are shown in Figure 4.5. The ordering of the parameters are the flow rates
(parameters 1-8), tissue volumes (9-21), vascular fractions (22-31), and finally transition
rates entering and exiting each tissue (32-56). Sensitivity analysis revealed that the most
sensitive parameters for each tissue were: the vascular fraction for that tissue, the interstitial-
to-vascular transition rate, and the vascular-to-interstitial transition rate. These results were
not unexpected, as the vascular fraction for a tissue and interstitial-to-vascular transition
rate are not independent system parameters. Furthermore, small alterations to the vascular
fraction can result in large alterations to predicted tissue concentration, especially for
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Table 4.2: PBPK model predicted performance for the incorporated tissues. Half-lives (t 1
2
)
were calculated using the last four data time points (360, 420, 960, and 1440 minutes).
Tissue MAPE MPE WSSE RMSPE t 1
2
data (hours) t 1
2
model (hours)
Plasma 26.4 -0.2 186.6 8.1 4.7 7.0
Tumor 10.6 2.3 16.9 6.7 31.2 29.4
Liver 12.3 5.7 159.7 9.7 4.4 6.9
RBCs 12.6 5.5 68.6 5.4 3.4 5.5
Heart 30.0 9.7 83.2 9.6 6.1 6.4
Kidney 32.3 20.0 48.3 10.5 5.2 6.3
Spleen 43.1 40.7 55.9 12.1 4.5 6.5
Lung 10.3 0.7 109.2 4.6 8.4 7.4
Brain 16.4 -4.1 6.0 10.2 6.8 7.2
Muscle 24.1 1.5 110.1 8.6 10.6 11.2
Fat 19.6 14.3 40.0 7.9 7.0 7.1
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tissues where the vascular fraction is especially small (i.e., muscle and fat) or when there
is concentration-dependent metabolism occurring within a tissue (i.e., liver). Doc plasma
concentration was most dependent on the liver parameters, both estimated and from the
literature, though the hepatic arterial blood flow rate was less important than the venous
flow from the intestine and gut. Of secondary importance to the plasma concentration were
the transition rates and vascular fractions for the muscle and “other” compartment and the
tissue Doc binding parameters.
Figure 4.6 depicts Doc deposition in various tissues as a percentage of the originally
administered dose. Drug was administered to the venous compartment over a 1-min infusion
and rapidly distributed into surrounding body tissues. The liver, in particular, was predicted
to contain 44% of the dose within the first 5 minutes following dosing (not including the
rapid, initial elimination that occurred within the liver). Concurrently, there was rapid
redistribution of Doc from the plasma to red blood cells during early time points; however,
the rate of redistribution decreases rapidly as drug within the plasma is absorbed by systemic
tissues (an effect of maintaining the plasma and red blood cell compartments in equilibrium).
Of the remaining tissues, the only two accounting for substantial (>10%) portions of the total
administered dose were the muscle and “other” compartments, which had peak percentages
of the dose at 20 and 34 minutes, respectively. By the end of 24 hours, the model predicts
that only 2.6% of the original dose remains in the system, predominantly in the muscle (0.8%)
and “other” (1.0%) compartments, with approximately 0.4% in the remaining normal tissues.
Accumulation within the tumor was predicted as 0.6% of the total administered dose, which
remains essentially constant for the entire 24 hour sampling period, falling off to 0.4% at 24
hours.
Finally, comparisons between the Doc PBPK model developed above and a nonlinear
PBPK model for Doc with fewer compartments [5] were evaluated at two separate Doc dosing
levels: 10
mg
kg
and 20
mg
kg
. Tissue concentrations were digitally acquired from Bradshaw-
Pierce et al. at 800% magnification [5]. The PK data from the 5
mg
kg
Doc dose in [5]
was not used in comparisons as the data predictions were in excess of those obtained at
equivalent time points from mice dosed at 10
mg
kg
Doc in this mouse study, possibly a result
of the different mouse species evaluated by the two studies. Furthermore, the human dose
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Figure 4.5: Relative sensitivity plots for liver, lung, tumor, muscle, spleen, heart, fat, kidney,
brain, “other”, plasma, and RBCs. Parameters are arranged in groups: flow rates (1-
8); tissue volumes (9-21); vascular fractions (22-31); and tissue transition rates (32-56).
Parameter ordering within those subgroups follow the ordering from Table 4.1: liver, lung,
tumor, gut, muscle, spleen, heart, fat, kidney, brain, “other”, plasma, RBC binding, and
tissue binding.
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Figure 4.6: Predicted percentage of administered dose in plasma, liver, tumor, muscle, red
blood cells, or the other compartment as a function of time.
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equivalent of 5
mg
kg
Doc in mice is beneath typically administered dosing levels, corresponding
to 17-20
mg
m2 . Tissues investigated by both studies included plasma, kidney, and liver.
Comparisons of the model predictions for the 10 and 20
mg
kg
doses are shown in Figures 4.7
and 4.8 and Table 4.3.
Both models accurately described the data set they were developed to fit. For the 10
mg
kg
data set, the PBPK model developed by Bradshaw-Pierce et al. over predicted the data
slightly at early times and significantly at later times (see MPE and MAPE in Table 4.3).
The PBPK model from this paper, likewise, under predicted data for mice dosed at 20
mg
kg
,
but was capable of describing the kidney data just as well as the Bradshaw-Pierce PBPK
model. The PBPK model developed here was slightly worse at describing the plasma (MAPE
of 39.0 versus 38.4) and liver (MAPE of 64.2 versus 59.1) data for the mice dosed at 20
mg
kg
.
However, the liver PK profile predicted by the Bradshaw-Pierce model, while more accurate
based on these model quality assessment metrics, displayed dynamic behavior between 2-6
hours that was inconsistent with the observed data, a repercussion of including nonlinear
elimination and transport rates within their PBPK model. Still, both models predicted
accurate Doc tissue and plasma PK when extrapolated to dose levels not included during
original model design development.
4.3 DISCUSSION
PBPK models provide a convenient structure for depicting systemic distribution of
chemotherapeutics following administration, provided that sufficient data are available
to support the more involved model structure. Using plasma, tumor, and tissue Doc
concentration versus time data obtained from SKOV-3 bearing SCID mice dosed i.v. at
10
mg
kg
, a mouse PBPK model was constructed with separate compartments for plasma,
tumor, liver, kidney, lung, heart, spleen, brain, muscle, fat, and red blood cells. Due to
the presence of tissue concentration PK with significantly different concentration versus
time profiles from plasma (tissues had bi-phasic elimination while plasma was tri-phasic),
it was necessary to include two tissue subcompartments, corresponding to tissue transport
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Figure 4.7: Plasma (top left), liver (top right), and kidney (bottom left) Doc predictions
from the model developed in Figure 4.1 (dash-dot) and those predicted by a PBPK model
from the literature [5] (solid) compared with actual plasma Doc concentration versus time
data from tumor-bearing SCID mice (circles, µ, with ±σ error bars, n = 3 mice per point)
dosed at 10
mg
kg
.
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Figure 4.8: Plasma (top left), liver (top right), and kidney (bottom left) Doc predictions
from the model developed in Figure 4.1 (dash-dot) and those predicted by a PBPK model
from the literature [5] (solid) compared with actual plasma Doc concentration versus time
data from BALB/c mice (circles) dosed at 20
mg
kg
.
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and tissue retention of Doc, respectively. To minimize the number of parameters requiring
estimation, the same parameter values for Doc retention were used for all tissues. While
this provides a reasonable approximation, two separate sets of parameter values are likely
necessary based upon inspection of tissue half-lives in Table 4.2.
Tissue half-lives reveal that the longest drug retention is predicted within the tumor,
which agrees with previous Doc tumor studies, though the half-life seen from the current
study was significantly longer than that described in others [160]. This increased retention
may be tumor-type specific, however, samples at later time points are required to characterize
the Doc elimination from the tumor appropriately. While the half-lives of Doc in plasma,
tumor, and normal tissues were longer in the current study than those previously reported
in the literature [160], the values agreed with half-lives reported from Bradshaw-Pierce et
al. [5]. This latter study, which was performed more recently and without radiolabeled
Doc, may more accurately represent actual Doc tissue concentrations versus time. Muscle
had the second longest Doc half-life at 10.6 hours. While the Doc Cmax of muscle was 2-15
fold lower than Doc Cmax in other tissues, the Doc concentration at 24 hours in muscle was
similar to that in the majority of other tissues with the exception of tumor. Given the overall
percentage of body weight represented by muscle as compared to other tissues, muscle may
be the primary contributor to terminal Doc retention following dosing.
Comparisons between the mouse PBPK model developed in this chapter and a previous
one [5] agreed well for mouse Doc dosing levels of 10 and 20
mg
kg
, despite using different model
structures. More compartments were included within the PBPK model developed within this
chapter, while the previous PBPK model included intestinal compartment concentrations
and additional routes of elimination, including urinary and fecal excretion, that account
for approximately 10% of drug removal. Furthermore, the previous model [5] has nonlinear
elimination rates and binding relationships within tissues, while the model developed in this
chapter has only linear components. However, our PBPK model also utilized a structure seen
as less desirable in the literature due to the large number of model parameters and uncertainty
associated with the vascular fraction term within the model. Therefore, the ideal model may
depend on the needs of the user, whether a lower-order system with nonlinearities, or a
higher-order linear system is preferred. It is likely, though, that a linear model is sufficient
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for describing Doc PK dynamics in humans, as no nonlinearities over a range of dosing levels
have been observed [161] and the human scale-up model of the previously published PBPK
model did not exhibit any nonlinear behavior regarding patient Doc plasma concentration
predictions. Also, even for patients with altered CYP3A enzyme levels, these alterations
would affect the enzymatic rate of elimination, and not the saturation. Therefore, a linear
elimination rate should be sufficient for describing Doc elimination. Futhermore, for Doc
administration of 5, 10, and 20
mg
kg
, all common tissues (kidney and liver) had similar half-
life values, though plasma half-life was 2-fold greater for the 20
mg
kg
dosing level. Combined
with the extensive preclinical and clinical work performed using Doc, these results suggest
that a linear model may be sufficient for describing systemic Doc distribution.
The incorporation of a tumor compartment within the current Doc PBPK model
structure also represents an extension of the earlier mouse PBPK model [5] and may aid
human scale-up predictions of total tumor Doc exposure. Furthermore, the 3-fold greater
tumor half-life compared to the next longest tissue may explain why similar efficacy is
attainable on weekly versus q3w Doc schedules. Model simulations have demonstrated that
week-to-week tumor accumulation of Doc is predicted to occur (results not shown), and these
findings will be further explored in Chapter 5.
Additional Doc distribution studies from our group have revealed that extended Doc
tumor retention also applies to Pc-3 human tumor xenografts [150]. Measured tumor tissue
Doc concentrations from these xenografts were lower than those obtained from SKOV-3
human tumor xenografts, necessitating a reevaluation of the model parameters for tumor
distribution. Either a reduction in the tumor vascular fraction (ft) from 10% (for SKOV-
3) to 3.1%, or a one-third reduction in the ktve parameter, were necessary to describe the
measured Pc-3 tumor Doc concentrations (Figure 4.9). Finding two parameter alterations
capable of describing the new data was not unexpected based upon the parameter sensitivity
and coupling previously discussed in this Chapter. However, given that Pc-3 xenografts are
typically less vascularized than SKOV-3 xenografts [150], alterations to ft may be suitable for
predicting tumor concentration variation between different tumor lines. Also, Doc samples
in Pc-3 tumor xenografts were obtained out to 72 hours, as opposed to the 24-hour sampling
utilized in the modeling study. While the estimated interstitial-to-vascular transition rate
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for tumor could not be properly estimated due to limited dynamic information in docetaxel
tumor concentration over the 24-hour sampling window, this additional data demonstrates
that the elimination rate predicted by the model may indeed be accurate.
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Table 4.3: PBPK model predictive performance comparison at dosing levels of 10
mg
kg
and
20
mg
kg
.
10
mg
kg
20
mg
kg
Model Tissue MAPE MPE RMSPE MAPE MPE RMSPE
Plasma 26.4 -0.2 8.1 39.0 39.0 15.4
Florian et al. Liver 12.3 5.7 12.5 64.2 7.5 32.9
Kidney 32.3 20.0 13.6 29.7 27.4 14.5
Plasma 61.3 -37.4 48.7 38.4 38.4 14.1
Bradshaw-Pierce et al. [5] Liver 82.4 -82.4 189.5 59.1 -59.1 69.0
Kidney 62.7 8.9 45.2 46.5 36.3 34.6
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Figure 4.9: Measured Doc concentration versus time data from Pc-3 tumor-bearing SCID
mice (circles, µ, with ±σ error bars, n = 3 mice per point) compared with mouse PBPK
model predictions (lines) for the tumor compartment.
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5.0 SCALE-UP OF THE MOUSE DOC PBPK TO HUMANS
Doc, a semi-synthetic taxane, promotes the polymerization of microtubules and induces cell
apoptosis during cell division [151]. It is a potent chemotherapeutic, displaying efficacy across
a wide range of solid tumors, and it is currently approved as treatment against metastatic
breast, non-small cell lung, and androgen-independent prostate cancers [151]. Typical Doc
doses range from 60-100
mg
m2 delivered over 1-hour every three weeks (q3w schedule) or 30-45
mg
m2 delivered over 30-minutes every week for three weeks, followed by a week of no treatment
(“weekly”). These two regimens have drastically different toxicity profiles despite displaying
similar efficacy results [155, 168, 169, 170]. Grade 3 or 4 neutropenia occurs in upwards of
90% of patients treated q3w with 100
mg
m2 Doc [151]. In contrast, the incidence of grade
3/4 neutropenia in patients receiving “weekly” 35-40
mg
m2 doses of Doc was significantly less
(2.5-16%) [155, 159, 171]. However, “weekly” Doc is associated with other serious treatment
side-effects including fatigue, hyperlacrimation, and nail toxicity [172]. Myelosuppression
associated with q3w Doc has been correlated with Doc clearance, however the fact that
similar AUCs are delivered in q3w and “weekly” Doc regimens implies that Doc exposure-
toxicity relationships may not be similar across different dosing schedules.
Docetaxel PK displays high intra-patient variability, predominantly influenced by patient
body weight (partially accounted for using body surface area (BSA) scaled dosing),
extensive protein binding, and metabolic enzyme activity. Elimination routes for Doc
are predominantly metabolic, are mediated by isoforms CYP3A4 and CYP3A5 [173], and
account for >80% of total Doc elimination. Inter-individual variations in expression of
CYP3A isoforms, can substantially influence Doc clearance [174, 175]. Urinary and fecal
elimination comprise the remainder of Doc clearance, with each contributing<10% [153, 154].
An addition factor in Doc elimination is the high plasma protein binding of Doc, which
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may exceed 92% (91%-98%) [8, 176]. This binding percentage is highly dependent on
plasma concentrations of albumin, and to a greater extent, α1-acid glycoprotein (AAG)
serum concentrations. Increased concentrations of serum AAG result in a decreased free
fraction of circulating Doc and, as a result, decreased Doc clearance, according to a linear
relationship developed by Baker et al [8]. Other studies by Baker et al. have demonstrated an
influence of the formulation vehicle, polysorbate 80, on the plasma binding of Doc, resulting
in an increased Doc free fraction at the end of a Doc infusion [177]. As both efficacy and
toxicity are correlated with Doc clearance, the ability to predict individual patient Doc PK,
including clearance, may allow for improvements in treatment efficacy and reduced toxicity.
Furthermore, as Doc exposure (i.e., AUC) does not correlate with toxicity across q3w and
weekly Doc regimens, an understanding of system-wide Doc deposition may provide insight
into how the two regimens can be associated with similar efficacy but differing toxicity.
One PKmodel for predicting patient Doc plasma concentrations in the absence of samples
is the population PK model developed by Bruno et al. [2, 178]. This three-compartment
structure uses set population values for the volume and intra-compartment transition rates.
However, clearance from the plasma compartment is calculated based upon a series of
patient covariates including BSA, albumin, age, hepatic function, and AAG. The primary
advantages of this model are its ability to describe individual PK without the need for sample
processing and its ability to identify those patients whose clearance may significantly deviate
from the population median. Further studies with this model revealed clearance-dependent
correlations with both toxicity and efficacy [2]. Also, investigations into optimal sampling
strategies revealed that as few as two plasma samples, corresponding to the end of infusion
and six hours following the start of infusion, would allow for improved estimates of individual
patient clearance [2].
An alternative model in the literature is the Doc PBPK mouse model developed by
Bradshaw-Pierce et al., and subsequently scaled to humans [5]. This model uses six coupled
nonlinear ODEs to describe Doc deposition within liver, kidney, gut, plasma, rapidly
perfused tissue, and slowly perfused tissue. In addition, elimination pathways for Doc
via metabolism, urinary excretion, and fecal excretion are also included within the model,
consistent with typical elimination percentages observed in patients. This model, developed
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in mice was scaled to humans by adjusting blood flow rates, tissue volumes, and metabolic
parameters, while leaving partition coefficients, tubulin binding affinity, and tissue-specific
tubulin binding capacity unchanged. When model results were compared against actual
patient Doc plasma data for doses of 30, 36, and 100
mg
m2 , the model was capable of describing
Doc plasma PK, but it had a tendency to under-predict Doc concentrations at the end of
the infusion as well as patient data associated with the 30 and 36
mg
m2 Doc doses. Also, while
it is understood that a PBPK model may offer more insight regarding drug deposition than
traditional compartmental PK models, no comparison was made between the PBPK model
predictions and those produced by existing Doc population PK models in the literature.
The goal of the current study was to evaluate how well the tissue-intensive mouse PBPK
model from Chapter 4 could predict human Doc plasma PK after scale-up. The validation
of the scale-up was performed on human Doc plasma data collected from three separate
Phase 1 clinical trials [6, 7, 179] with patients dosed over a range of 35-75
mg
m2 . Furthermore,
human plasma Doc predictions from the scaled tissue-intensive PBPK model were compared
against those predicted by models developed by Bruno et al. and Bradshaw-Pierce et al.
[2, 5]. Estimates of plasma Doc free fraction were made from patient data to assess the
potential improvement resulting from including patient-specific information. Also, the scaled
tissue-intensive PBPK model was updated with model parameters to better describe cardiac
output and tissue distributions observed in elderly patients. Finally, alterations in simulated
tumor Doc concentrations based on changes in dosing level, patient body weight, tumor
volume, (which determines tumor blood flow rate based on Equations (4.11)), and dosing
schedule were investigated using the tissue-intensive PBPK model.
5.1 MATERIALS AND METHODS
5.1.1 Human Doc Clinical Data
Human plasma Doc data were obtained from Phase 1 studies performed at the University
of Pittsburgh Cancer Institute (UPCI) [179] and Memorial Sloan-Kettering Cancer Center
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(MSKCC) [6, 7]. The UPCI study involved 25 patients dosed q3w with 50 (n=7), 60 (n=13),
or 75
mg
m2 (n=5). Drug was administered via IV infusion over 1-hour, and plasma samples
were collected before dosing and at 0.5, 0.92, 1.25, 1.5, 2, 3, 4, 5, 7, 9, 11, 13, 14, 17, and
25 hours following the start of Doc administration. The MSKCC Phase I study samples [6]
were collected at various times (6-9 per patient) out to 50.5 hours from 50 patients dosed
either “weekly” 35 (n = 8) or q3w with 55 (n = 3), 70 (n = 27), or 75
mg
m2 (n = 12). The
MSKCC study in elderly patients [7] involved 20 patients dosed at 35
mg
m2 (n=20) “weekly”.
Infusion duration was 30 minutes with samples (10-11) collected at pretreatment, 0.25 (mid
infusion), 0.48, 0.67, 1, 1.5, 3.5, 8, 24.5, 48.5, and 168.5 hours (approximately one week with
the sample collected prior the following dose). A summary of the patient groups from all
three clinical trials is shown in Table 5.1.
Plasma concentrations of Doc from the two Phase I clinical trials were determined using
a LC-MS assay that was developed by Parise et al. [165]. Plasma samples from the MSKCC
elderly patient study were evaluated using a validated method based on high-performance
LC-MS as described previously [155]. Plasma AAG concentrations values were measured
using an immunoturbidometric method using the Roche AAG Diagnostic Kit on a Cobas
Integra 800 System (Roche Diagnostics, Almeda, CA) as previously described [180].
5.1.2 Human PBPK Model Scale-Up
A structurally equivalent PBPK Doc distribution model was constructed for humans based
upon the mouse PBPK model previously developed in Chapter 4. Blood flow rates and
tissue volumes were based on literature values for humans and subsequently scaled for
individual patient weights [1]. Representative parameters for a 70 kg male are shown in
Table 5.2. Tissues volumes and blood flow rates were adjusted linearly based on actual
patient weight. Tissue vascular fractions were updated, when applicable, to typical values
observed in humans, while liver metabolic rate was left unchanged. The internal transport
rate for Doc in all tissues was uniformly decreased by a factor of 2. This change was
implemented as the unbound fraction of Doc in humans is approximately 5%, which is half
the unbound fraction in mice [8]. Also, the RBC exchange rate was decreased by a factor
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Table 5.1: Patient characteristics from the Phase 1 Doc studies performed at UPCI and
MSKCC. Values are reported as the study median and range.
UPCI [179] MSKCC[6] MSKCC Elderly [7]
Number of Patients 25 50 20
Males/Females 21/4 42/7 8/12
Age (years) 63 (43-78) 60.3 (32-78) 75 (66-84)
Doc Dose (
mg
m2 )
35 — 8 20
50 7 — —
55 — 3 —
60 13 — —
70 — 27 —
75 5 12 —
BSA (m2) 1.72 (1.30-1.93) 1.90 (1.38-2.64) 1.85 (1.49-2.25)
Weight (kg) 88 (52-109) 83 (48-145) —
AAG (
g
L) 1.24 (0.28-2.47) 1.37 (0.60-2.55) —
Albumin (
g
L) 3.7 (2.8-4.5) 4.4 (3.5-5.0) —
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of 40 as the RBC-to-plasma ratio in humans has been determined to be 1:10, versus the 2:1
ratio observed in SCID mice [150, 181]. Model quality was assessed using the methods in
section 4.1.4.
5.1.3 Model Validation
Model comparisons of this tissue-intensive human PBPK model were performed against two
existing Doc models from the literature: (i) a three-compartment population PK developed
by Bruno et al.; and (ii) a five-tissue, PBPK model developed by Bradshaw-Pierce et al.
For the Bruno PK model, the transition rates between compartments were equivalent
for all patients and are summarized in Table 5.3. Clearance (CL, L
hr
) was calculated per
patient using the following equation:
CL = BSA(22.1− 3.55AAG− 0.095AGE + 0.2245ALB)(1− 0.334HEP12) (5.1)
Here BSA is the body surface area of the patient (m2), AGE is the age of the patient
in years, and AAG and ALB represent α1-acid glycoprotein and albumin concentrations
(
g
L) in plasma, respectively. HEP12 is a measure of the hepatic function of the patient
given a default value of 0. For patients with alanine aminotransferase (ALT) or asparatate
aminotransferase (AST) > 60 IU and alkaline phosphatase > 300 IU, HEP12 was assigned
a value of 1. Of the patients enrolled in both Phase 1 clinical studies whose data was used
in scale-up, all had HEP12 values of 0 based on their individual ALT, AST, and alkaline
phosphatase values. Albumin values for 8 of the UPCI patients were not available. In their
place, mean population values from the UPCI patient group were used. AAG values for 18
of the patients from the MSKCC patient group were also not available and were assumed
equivalent to the MSKCC patient group mean for simulation within the Doc population PK
model of Bruno. BSA for 11 of the patients from the elderly MSKCC dataset was unavailable.
Simulations on these patients used a population average BSA of 1.75 m2, however, these
patients were not included when analyzing model performance metrics.
The Bradshaw-Pierce model used the same approach as our model, adjusting tissue
volume and blood flow rates based on the actual weight of the patient. Partition coefficients,
131
Table 5.2: Parameter values from the literature for the human PBPK model (70 kg) [1].
F , V , and f denote tissue blood flow rates, tissue volumes, and tissue vascular fractions,
respectively.
Units Lmin L —
Liver Fli 0.45 Vli 1.80 fli 0.16
Lung Fl 5.60 Vl 0.53 fl 0.30
Tumor Ft 0.03 Vt 0.2 ft 0.05
Gut Fg 1.13 Vg 1.19 fg —
Muscle Fm 0.59 Vm 28.0 fm 0.03
Spleen Fs 0.02 Vs 0.18 fs 0.20
Heart Fh 0.26 Vh 0.33 fh 0.02
Fat Ff 0.74 Vf 15.0 ff 0.03
Kidney Fk 1.24 Vk 0.31 fk 0.24
Brain Fb 0.78 Vb 1.40 fb 0.04
Other Fo 0.36 Vo 15.8 fo 0.05
Blood Ftot 5.60 Vblood 5.53
Table 5.3: Parameter values for the Bruno et al. Doc population PK model [2]. kij are
transition rates from compartment i to compartment j, and Vi is the volume of model
compartment i.
Parameter Value Parameter Value
k12 (
1
hr
) 1.06 k21 (
1
hr
) 1.74
k13 (
1
hr
) 1.28 k31 (
1
hr
) 0.08
V1 (L) 10
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tubulin retention, and binding affinity parameters were left unaltered from their mouse
PBPK model. Parameters pertaining to metabolism and excretion (urinary and fecal) were
altered based on literature values [5].
5.2 RESULTS
5.2.1 Doc Plasma Model Predictions
Doc plasma concentration predictions from the tissue-intensive PBPK were compared to
actual patient Doc concentrations obtained in the three clinical trials. Actual versus
predicted patient Doc plasma concentrations for all three models (Bruno population PK
model [2], Bradshaw-Pierce PBPK model [5], and the tissue-intensive PBPK model) are
shown in Figure 5.2, and a summary of individual model performance based on dosage and
study is shown in Tables 5.4-5.5. Representative patient plots over the evaluated Doc dosing
range are shown in Figure 5.1, and a comprehensive set of individual patient plots can be
found in Appendix C, Figures C1-C11.
Both the PBPK model developed within this dissertation and the original population
model of Bruno were capable of describing Doc plasma AUC and clearance across the range
of investigated doses. However, the Bradshaw-Pierce et al. PBPK model tended to under-
predict the AUC observed for each dosing group. This under-prediction occurred despite the
Bradshaw-Pierce et al. PBPK model having accurate overall performance metrics for both
the UPCI and MSKCC study patients. It should be noted that the fits from both PBPK
models were achieved based solely on the Doc dose, BSA, and body weight, and may be
improved through the inclusion of additional patient-specific metrics.
For all three studies, all three models had difficulty predicting Doc concentrations during
the infusion (highest concentrations), as shown in Figure 5.2. Both the tissue-intensive PBPK
and population PK models were centered around the unity line, however, neither model
predicted the variation in peak Doc plasma concentrations observed within the population
dataset. For the UPCI study, both PBPK models over-predicted the 50
mg
m2 and under
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Figure 5.1: Measured Doc plasma concentration data in humans dosed at 50 (top left),
60 (top right), 75 (bottom left) and 35 (bottom right)
mg
m2 vs. time. Human PBPK model
predictions are from the tissue-intensive PBPK (solid), the Bradshaw-Pierce PBPK (dashed),
and the Bruno population PK (dash-dot) models.
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predicted the 60 and 75
mg
m2 data; based on RMSPE and MPE metrics, model inaccuracies
across all three dosing ranges were consistent. Model predictions for the MSKCC data set
were worse for all three models compared to predictions from the UPCI study, even compared
against results from similar dosing levels (75
mg
m2 ), which was likely a function of fewer total
samples and more sporadic plasma sampling.
For the MSKCC elderly patient data set, neither weights nor gender were available, so
model performance was evaluated for both a 66 kg (woman) and 79 kg (man) person, and
the better performing model was selected as the representation of the patient. The elderly
patient study was better described by the tissue-intensive PBPK model (RMSPE and MPE
of 17.7±7.2 and 27.9±34.3, respectively) compared to predictions from the Bradshaw-Pierce
PBPK (RMSPE and MPE of 19.5 ± 2.0 and 54.7± 22.3, respectively) and Bruno population
PK (RMSPE and MPE of 21.3 ± 6.6 and 51.9± 16.0, respectively) models. Observed Cmax
concentrations from this data set were 1-3 fold higher than those obtained from the other
studies, and hence, Cmax was under predicted by both PBPK models. Overall, this data set
was the worst characterized of the three, both by performance metrics and qualitative fits.
Part of this performance loss was due to the lack of actual patient body weights, but with all
elderly patients, age-related alterations to clearance, cardiac output, and tissue contributions
may also be involved.
Performance error versus sampled time point (Figure 5.3) was also investigated for the
UPCI patients to determine if model predictions were biased towards individual portions of
the sampling schedule. Similar analysis was not performed on the MSKCC data sets as the
number of samples per patient and the time of samples were not equivalent for individual
patients. The tissue-intensive model predicted mean errors per point which over-predicted
the observed concentrations following the end of the infusion, but otherwise demonstrated
unbiased error across the sample set. As mentioned previously, the Bradshaw-Pierce model
under-predicted concentrations during the infusion with a trend towards over-predicting
concentrations as t → 24. Finally, the Bruno model displayed accurate predictions at time
points during and immediately preceding the end of the infusion with predictive accuracy
decreasing at later time points. In addition, the percent error was seen to increase at the later
time points, reaching 30 and 44% at 16 and 24 hours, respectively. This poor performance
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Figure 5.2: Actual versus model predicted human plasma Doc concentrations (tissue-
intensive PBPK model - circles; Bradshaw-Pierce PBPK model - squares; Bruno population
PK model - diamonds) for all patients (top left), UPCI protocol 01-150 (top right), MSKCC
study (bottom left), and the MSKCC study comprised only of elderly patients (bottom
right).
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was not unexpected as the Bruno model also displayed the worst overall predictions of the
UPCI patient group.
5.2.2 Unbound Doc
As mentioned previously, both evaluated PBPK models did not incorporate any patient
specific metrics for predicting Doc plasma concentrations. Inaccuracies in the above model
predictions were partly due to measurement and processing noise, but the majority of
variations between patients can only be captured by introducing additional parameters
consistent with inter-individual variability (i.e., BSA and body weight are significant but
only describe a portion of the overall variability). An important metric in predicting the
efficacy and toxicity of Doc is the unbound fraction present in plasma, which has been
demonstrated to be correlated with patient AAG levels [155]. Both PBPK models specified
a uniform unbound fraction value, however, estimating individual patient free fractions would
improve individual patient predictions.
Unbound fraction of Doc was estimated for each patient with respect to both PBPK
models by minimizing the sum squared error between observed and model predicted Doc
plasma concentrations. For the Bradshaw-Pierce model, lower weights were used for the
concentration time points obtained during the infusion as the model under predicted those
values and uniform weighting for all time points resulted in non-physiological unbound
fraction predictions during the optimization. Estimating free fraction reduced the overall
error predicted by both PBPK models, with updated model performance shown in Tables 5.6-
5.7. Model performance metrics for individual patients from all three studies are shown in
Figures 5.4-5.7. These figures illustrate that there was general improvement in the model
performance metrics when unbound Doc was included as an estimated parameter for the
tissue-intensive PBPK model. The same did not hold true for the Bradshaw-Pierce PBPK
model, however, as the model already displayed a tendency to under predict peak Doc plasma
concentrations, including additional degrees of freedom within this model was not expected
to improve its performance. These figures also reveal that there were some patients that
were not fit well by any of the three Doc PK models discussed in the previous section, nor
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Figure 5.3: Individual patient performance error at sampled time points (circles) and median
performance error for a sampled time point (squares) versus time for the three investigated
models (tissue-intensive PBPK model, left; Bradshaw-Pierce PBPK model, middle; Bruno
population PK model, right) for all 25 patients from UPCI protocol 01-150.
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were they fit by either of the PBPK models when unbound Doc fraction was included as
an additional parameter (i.e., Patient 20 from the UPCI study, Patients 4 and 47 from the
MSKCC study).
The median predicted unbound Doc percentages were 3.7% (0.5-8.9%) and 1.8% (0.5-
4.3%) for the tissue-intensive PBPK and Bradshaw-Pierce PBPK models, respectively.
However, estimating free fraction based on plasma data is not ideal as it would require
substantial sampling and sample processing. Furthermore, the predictions from these
estimates may not be valid. Estimated unbound fractions were compared against those
obtained by two other groups from the literature [8, 109]. The values estimated for the
PBPK models are plotted in Figure 5.8 against individual patient AAG levels, along with
the linear correlation estimated by Baker et al. relating unbound percentage of Doc to
AAG concentrations. Histograms reflecting the unbound fraction distributions are shown
in Figure 5.9. Fits for both PBPK models, while displaying the same trend determined
by Baker et al. (i.e., increasing unbound fraction with decreasing AAG) displayed a lower
slope. Accuracy of the linear fit was also worse, and the estimated unbound fractions versus
AAG may be better represented using an inverse relationship (e.g., unbound Doc = pAAG).
Also, for patients with AAG > 1.5
g
L, unbound percentage was lower for both PBPK models
(tissue-intensive and [5]), with median values of 2.9% (1.4-5.3%) and 1.6% (0.7-2.5%) versus
3.9% (0.5-8.9%) and 1.9% (0.5-4.3%) for patients with AAG < 1.5
g
L.
5.2.3 Simulated Doc Concentration Profiles in Tumors
The inclusion of a tumor compartment in this tissue-intensive PBPK model may have clinical
applicability in predicting Doc concentrations in tumor tissues. As no data were available
regarding Doc concentration in human tumors, simulations were performed to determine
expected tumor Doc concentration versus time profiles under a variety of conditions,
including different dosing levels, different starting tumor volumes, different dosing schedules,
and variations in patient body weight. Initial simulations focused on the case study of a 100-g
tumor subjected to a 1-hour infusion of Doc at 30-90
mg
m2 . All patient BSA were assumed to
be 1.75 m2. The resulting profiles are shown in Figure 5.10 (left), with calculated Cmax and
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Figure 5.4: Model predicted performance metrics (MAPE and RMSPE) for all 25 patients
from UPCI protocol 01-150. Each patient has 5 associated bars: (1) tissue-intensive PBPK
model; (2) Bradshaw-Pierce PBPK model [5]; (3) Bruno population PK model [2]; (4) tissue-
intensive PBPK model estimating unbound Doc fraction; and (5) Bradshaw-Pierce PBPK
model estimating unbound Doc fraction.
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Figure 5.5: Model predicted performance metrics (MAPE and RMSPE) for patients from
the MSKCC clinical trial [6] dosed at either 55, 75, or 35
mg
m2 . Each patient has 5 associated
bars: (1) tissue-intensive PBPK model; (2) Bradshaw-Pierce PBPK model [5]; (3) Bruno
population PK model [2]; (4) tissue-intensive PBPK model estimating unbound Doc fraction;
and (5) Bradshaw-Pierce PBPK model estimating unbound Doc fraction.
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Figure 5.6: Model predicted performance metrics (MAPE and RMSPE) for patients from
the MSKCC clinical trial [6] dosed at 70
mg
m2 . Each patient has 5 associated bars: (1)
tissue-intensive PBPK model; (2) Bradshaw-Pierce PBPK model [5]; (3) Bruno population
PK model [2]; (4) tissue-intensive PBPK model estimating unbound Doc fraction; and (5)
Bradshaw-Pierce PBPK model estimating unbound Doc fraction.
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Figure 5.7: Model predicted performance metrics (MAPE and RMSPE) for patients from
the elderly MSKCC clinical trial [7] dosed at 35
mg
m2 . Each patient has 7 associated bars: (1)
tissue-intensive PBPK model; (2) Bradshaw-Pierce PBPK model [5]; (3) Bruno population
PK model [2]; (4) tissue-intensive PBPK model estimating unbound Doc fraction; (5)
Bradshaw-Pierce PBPK model estimating unbound Doc fraction; (6) tissue-intensive PBPK
model estimating unbound Doc fraction and liver metabolism; and (7) Bradshaw-Pierce
PBPK model estimating unbound Doc fraction and liver metabolism.
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Figure 5.8: Tissue-intensive (square) and Bradshaw-Pierce (circles) PBPK model estimates
for unbound fraction versus actual patient AAG concentrations. Linear regressions for the
tissue-intensive (dash-dot) and Bradshaw-Pierce (dashed) PBPK models are shown plotted
against the linear correlation identified by Baker et al. (solid) [8].
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Figure 5.9: Estimated unbound fraction histograms (n = 48) for the tissue-intensive PBPK
(left) and Bradshaw-Pierce PBPK (right) models.
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Table 5.7: Model performance mean (standard deviation) values for three Doc studies across
multiple Doc dosing levels. a were results obtained by including both unbound Doc fraction
and liver metabolism as model parameters.
Florian et al. Bradshaw et al. [5]
Clinical Trial Doc Dose MPE RMSPE MPE RMSPE
All 35-75
mg
m2 (n=84) 7.8 (29.0) 15.1 (11.6) -37.4 (71.2) 28.0 (20.9)
UPCI [179] 50-70
mg
m2 (n=25) 12.1 (19.2) 9.5 (5.6) -52.1 (51.7) 24.6 (12.6)
50
mg
m2 (n=7) 1.6 (6.7) 7.2 (3.2) -85.8 (58.6) 30.1 (10.6)
60
mg
m2 (n=13) 14.9 (23.6) 9.5 (3.6) -45.1 (50.3) 23.1 (12.1)
75
mg
m2 (n=5) 19.5 (13.4) 12.4 (10.6) -22.8 (6.8) 20.8 (16.2)
MSKCC[6] 55-75
mg
m2 (n=50) 9.6 (31.2) 14.7 (8.0) -46.3 (74.7) 31.6 (25.0)
55
mg
m2 (n=3) 8.2 (8.4) 8.6 (4.1) -68.0 (26.2) 43.0 (16.0)
70
mg
m2 (n=27) -4.9 (28.7) 15.3 (10.0) -76.7 (79.3) 42.0 (28.3)
75
mg
m2 (n=12) 28.5 (25.1) 13.6 (5.2) -6.6 (52.7) 15.3 (8.2)
35
mg
m2 (n=8) 31.0 (28.4) 16.6 (3.1) 4.6 (40.9) 16.7 (8.2)
MSKCC Elderly [7] 35
mg
m2 (n=9) -14.4 (31.6) 33.0 (21.1) 53.2 (8.8) 18.0 (1.2)
Alla 35-75
mg
m2 (n=84) 6.8 (30.6) 15.0 (11.1) 50.1 (22.9) 16.3 (4.3)
MSKCC Elderlya [7] 35
mg
m2 (n=9) 27.9 (34.3) 17.7 (7.2) 54.7 (22.3) 19.5 (2.0)
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AUC0−21 (within this section the subscript with AUC refers to days and not the traditional
units of hours) from the simulations shown in Table 5.8. Both Cmax and AUC0−21 increased
linearly with increasing dose level. This result was expected as the underlying PBPK model
is linear, so that alterations to the dosing level for a specified tumor volume and body weight
should be additive.
The next simulation (Figure 5.10, right) evaluated the effects of body weight on Doc
tumor exposure. Cmax and AUC0−21 increased nonlinearly with increasing body weight. It
should be cautioned that these results may not actually reflect realized increases in tumor
deposition as BSA was kept constant. Furthermore, it should be noted that BSA was
only included within the model for adjusting the total administered dose, and the linearity
of varying dose level has already been validated with the first set of tumor simulations
(Figure 5.10, left). Hence, it is possible to predict Cmax and AUC0−21 for each of the
simulated body weights at any desired BSA (i.e., for a BSA of 2.00 m2 and 90 kg body
weight, Cmax =
(
2.00
1.75
)
0.452 = 0.516).
Changes in tumor concentration as a function of tumor volume (with corresponding
alterations to the tumor blood flow rate) are shown in Figure 5.11 (left). There was a tumor-
size dependent increase in Cmax, with the smallest simulated tumor having the highest Cmax
value. Despite this, the predicted AUC0−21 was relatively constant across all four tumor
volumes and is indeed equivalent when comparing AUC0−∞. Finally, tumor concentration
predictions over 21 days with administration of Doc either every three weeks or every week
are shown in Figure 5.11 (right). There was dose-to-dose accumulation of Doc within the
tumor with “weekly” administered Doc, resulting in a Cmax for the 30
mg
m2 “weekly” Doc
simulation that was greater than one-third of the Cmax from 90
mg
m2 Doc q3w. While dose-
to-dose accumulation of Doc in human plasma has not been observed during “weekly” Doc
treatments (which is consistent with our model simulations), this model predicts that dose-
to-dose accumulation may occur within the tumor.
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Figure 5.10: Simulated Doc tumor concentration versus time plots using the tissue intensive
Doc PBPK model for varying dose levels (left) and body weight (right). Left: Simulated
tumor concentrations assuming a 100 g tumor in 70 kg human treated with 30 (solid), 54
(dashed), 72 (dash-dot), or 90 (dotted)
mg
m2 Doc as a 1-hour infusion. Right: Simulated Doc
tumor concentrations assuming a 100 g tumor in 50 (solid), 70 (dashed), 90 (dash-dot), or
110 (dotted) kg human treated with 72
mg
m2 Doc as a 1-hour infusion.
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Figure 5.11: Simulated Doc tumor concentration versus time plots using the tissue intensive
Doc PBPK model for varying tumor volume (left) and dosing schedules (right). Left:
Simulated tumor concentrations assuming a 5 (solid), 20 (dashed), 100 (dash-dot), or 500
(dotted) g tumor in 70 kg human treated with 72
mg
m2 Doc as a 1-hour infusion. Right:
Simulated tumor concentrations assuming a 100 g tumor in a 70 kg human treated with
either 72 (solid) or 90 (dashed)
mg
m2 Doc as a 1-hour infusion every three weeks or weekly
administration of 30 (dash-dot) or 42 (dotted)
mg
m2 Doc as a 1-hour infusion.
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5.3 DISCUSSION AND SUMMARY
Overall, the tissue-intensive PBPK model was capable of describing Doc plasma distributions
observed following IV infusions of 35, 50, 55, 60, 70, and 75
mg
m2 Doc. Performance of this
tissue-intensive PBPK model was similar to that observed from the population model of
Bruno despite lacking patient-specific measures within the model structure. Furthermore,
both the tissue-intensive PBPK and population PK models were more accurate in predicting
observed AUC across a range of Doc doses compared to a previously developed PBPK
model for Doc. During-infusion Doc concentrations were poorly predicted by all three PK
models, though the predictions for the tissue-intensive PBPK and population PK model
were distributed along the line of unity. A portion of this error likely resulted from
the tissue-intensive PBPK model being developed from data generated with a different
administration schedule (bolus versus infusion), such that no information about infusion
dynamics was included within the mouse model. Polysorbate 80 may also influence Doc
plasma concentration, and hence, distribution dynamics, during the infusion by altering the
unbound fraction of Doc.
Prediction results for the tissue-intensive PBPK model were when the unbound fraction
of Doc was estimated on an individual patient basis. While this is not practical in a clinical
setting, it did establish a theoretical population distribution of Doc unbound fractions.
This distribution qualitatively agrees with the results from Minami et al. [109] and Baker
et al. [8], who reported median (range) unbound fractions of Doc of 4.0 (1.2-22.6) and
4.6 (1.2-8.6), respectively. Individual patient AAG values were plotted against estimated
unbound fractions as previous studies have demonstrated a correlation between the two
measures. However, while Baker et al. observed a linear relationship between unbound
fraction and AAG, estimates of unbound fraction for the tissue-intensive PBPK model were
more representative of a non-linear relationship with AAG < 1.5
g
L predicting patient Doc
unbound fractions of 3.9% (0.5-8.9%) and AAG > 1.5
g
L predicting patient Doc unbound
fractions of 2.9% (1.4-5.3%). Actual Doc unbound fraction data from the modeled patients
are now being pursued in order to validate predicted unbound Doc fractions. Alternatively,
additional patients with both Doc plasma concentration and unbound fraction data can
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be used for evaluating whether unbound fraction is indeed a measure that improves the
predictive performance of both PBPK models.
Attempts to fit the MSKCC elderly patient data set with the existing PBPK models were
largely unsuccessful, with all three models under-predicting observed Doc concentrations
along the entire sampled time course. By altering the tissue-intensive PBPK model to
be more representative of an elderly population (e.g., decreased cardiac output, increased
percent body fat) improvements in the model performance were obtained. Estimates
for patient unbound fraction and body weights were consistent with unbound fraction
distributions from previous studies and a predominantly elderly female data set. Metabolic
rates for this data set were also predicted to decrease, and should be explored further as an
additional patient-specific metric, similar to hepatic function, that can be used for predicting
Doc plasma PK in individual patients.
Using the tissue-intensive PBPK model, tumor Doc concentrations were also simulated
for conditions of changing dosing level, body weight, tumor mass, and dosing schedule. The
model predicts a linear relationship between Cmax and AUC for different dose levels delivered
over the same schedule. Patient body weight reduced the observed tumor concentration Cmax,
though this was likely a result of using a constant BSA regardless of patient body weight.
Tumor-size-dependent Cmax was predicted, though differences in AUC were insignificant at
21 days. This size-dependent effect on Cmax resulted from the tumor volume-blood flow rate
relationship used within the model, where the tumor volume increased disproportionally with
tumor blood flow. The fact that the AUC was relatively constant reflects the fact that the
amount of drug delivered to the tumor remained the same, but due to the increased tumor
volume, a lower whole tumor concentration was observed. Furthermore, as blood flow and
distribution within tumors is heterogeneous, this prediction is representative of delivering the
same amount of drug in localized regions of the tumor. Macroscopically, this would result in
a lower overall observed tumor concentration. Finally, a dose-to-dose accumulation of Doc
was also observed for “weekly” administration versus delivery on a q3w regimen. However,
whether tumor Doc AUC is a valid correlate of treatment efficacy remains to be validated.
While there is no guarantee that model predictions of tissues are accurate, additional
studies are being pursued to validate the model-predicted Doc tumor concentrations using
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a combination of radio-labeled Doc and positron emission topography (PET) in head and
neck cancer patients. At least two time points are necessary, ideally occurring an hour after
infusion (corresponding to radio-labeled Doc) and four or more hours following the initial
sample (necessitating a biopsy). Given the predicted long retention of Doc within a tumor,
these two points should be sufficient for updating the model to describe human tumor Doc
concentrations more accurately if, indeed, discrepancies exist between the model predictions
and sampled data. Alternatively, single biopsy samples from multiple head and neck patients
may be sufficient for updating intra-tumor transition rates given the extended retention time
of Doc observed from implanted human xenografts.
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6.0 DOC NEUTROPHIL TOXICITY MODEL
The degree of inter-patient PD variability observed during chemotherapeutic treatment
is extensive, ranging from tumor regression and elimination to the lack of any treatment
response and/or life-threatening toxicity. The lack of a treatment response has been shown
to correlate primarily with the PK of a patient (i.e., high clearance values as indicative
of lower response rates) and tumor characteristics (i.e., resistance to the therapeutic,
lower exposure due to decreased transport, etc.). On the opposite end of the spectrum
is patient toxicity, primarily manifesting as neutropenia during q3w treatment with Doc.
As treatment related toxicity requires more immediate attention, relationships capable of
predicting patient toxicity prior to the initialization of treatment are highly desirable for
both limiting danger to the patient and ensuring that stoppage of the treatment schedule
can be avoided.
The extent of neutropenia observed during q3w Doc treatment primarily correlates with
decreased drug clearance and the plasma AUC of unbound Doc. Alterations to clearance, in
turn, may result from changes in patient AAG levels and the liver function of the patient.
Completing the circle, and as alluded to within Chapter 5, Baker et al. have demonstrated
that serum AAG and the unbound fraction of Doc are correlated, with increasing unbound
fractions manifesting as serum AAG decreases [8]. Heuristic relationships between the
likelihood of grade 3/4 neutropenia and AAG levels, Cmax of unbound Doc, and hepatic
function have been developed and serve as metrics for predicting probable patient toxicity
following treatment [109]. However, such models are schedule dependent, may even be dosing
level dependent, and provide only an “end point” representation of toxicity rather than
its progression. Furthermore, the AUC measure, while scaling with dose level on a given
schedule, is grossly inaccurate for different administration schedules. Schedules involving
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the “weekly” administration of Doc (35-40
mg
m2 ) have demonstrated a decreased incidence of
neutropenia (2.5-23% versus upwards of 90% in q3w regimens) while overall patient efficacy
has remained equivalent to q3w regimens [151, 155, 159, 171]. As the PK of Doc is linear,
the 3-week inclusive AUC from this treatment is in the range of Doc treatments involving
100
mg
m2 q3w, invalidating the use of exposure-based relationships between the two delivery
schedules [151]. Decreased clearance is still a predictive factor of hematological toxicity, as is
an increase in AUC compared amongst patients treated on the same schedule, however there
is no unifying explanation of patient toxicity across both Doc dosing schedules. Ideally, the
development of a representative PD model for neutrophil progression may address each of
these concerns.
A few PK/PD models have been developed in the literature for predicting the time
course of neutropenia following treatment, with varying levels of complexity ranging from
indirect response models [114, 115] to higher-order models representing the maturation of
hematopoietic stem cells in addition to regulatory cytokines [66]. A recent semi-mechanistic
model developed by Friberg et al. accounts for both the maturation time and overshoot
above baseline neutrophil count observed following treatment [3]. Furthermore, this low-
order (five equation) model has proven effective at describing the time course of neutrophils
and leukocytes following administration of a number of therapeutics (paclitaxel, etoposide,
irinotecan, epirubicin, 2’-deoxy-2’-methylidenecytidine, and permetrexed) including Doc [3,
111, 112]. The study by Friberg et al. [3] investigated neutrophil progression in 601 patients
administered either 75 or 100
mg
m2 Doc over a 1-hour infusion, with Doc plasma concentration
versus time profiles generated using patient-specific metrics and the Bruno population PK
model for Doc [2]. Both a linear and Emax drug effect formulation were evaluated, though
no increase in predictive accuracy was observed from using the Emax model. The results
from this study were later extrapolated to the co-administration of Doc and epirubicin at
75 and 70
mg
m2 , respectively, however no validation of the model at lower dosing levels nor
alternative Doc dosing schedules has been performed in the literature.
The model structure was extended to include various patient-specific covariates, revealing
a strong correlation between AAG and the “slope” value in the drug effect relation (in
addition to estimating a new parameter value 2-fold greater than their previous paper) with
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sex, previous therapy, restricted performance status, and AAG levels having a minor effect
on baseline neutrophil count [106]. This drug effect observation follows from experimental
evidence where Doc clearance may decrease with increasing AAG, but this is accompanied
by a concurrent decrease in the unbound fraction of Doc which induces the PD effect (i.e.,
tumor response, or in this case, the elimination of progenitor cells in the bone marrow).
These studies all focused on q3w Doc, but alternative schedules, such as “weekly” Doc are
gaining interest due to the lower incidence of neutropenia with equivalent efficacy observed
during treatment [151, 155, 159, 171, 172]. The extension of the Friberg et al. model to
“weekly” Doc has not been performed, however.
This chapter takes the model developed by Friberg et al. and evaluates alternative
PD effect terms (log-linear and Hill-relationship) and model structures for the prediction
of neutrophil progression across multiple Doc dosing schedules. Additionally, the two drug
effect relationships originally investigated by Friberg et al. were reevaluated to determine if
they were applicable across multiple Doc dosing regimens and to determine if plasma Doc PK
predictions from the human scaled tissue-intensive PBPK model returned similar parameter
estimates to those obtained using the Bruno population PK model. Using both the original
and updated neutrophil models, simulations for all patients were performed using multiple
dosing levels (28-100
mg
m2 ) and multiple Doc dosing schedules (q3w, “weekly”, every other
week) commonly employed clinically to assess if the appropriate incidences of toxicity were
represented. Patient parameterizations representative of average, high risk, and low risk
were identified from the results, and these patients served as the basis for downstream Doc
dose schedule development. Using a NMPC structure, an objective function was proposed
for maximizing the total amount of drug delivered over a 12 week period, subject to objective
function penalties due to neutropenia. Finally, the estimated Doc schedules were evaluated
against those currently implemented clinically for toxicity and predicted accumulation of
Doc within a tumor compartment.
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6.1 MATERIALS AND METHODS
6.1.1 Patient Data
Neutrophil and leukocyte counts were obtained during the first treatment cycle of two Phase
1 studies performed at UPCI and MSKCC [6, 179] to monitor patient toxicity. While both
Phase 1 studies involved the co-administration of therapeutics (Doc and imatinib for the
UPCI study and Doc and 17-allylamino-17-demethoxygeldanamycin for the MSKCC study),
the additional chemotherapeutic neither altered the observed Doc PK nor had overlapping
toxicity with Doc during the treatment. As such, the PK data and collected neutrophil data
were treated as resulting solely from treatment with Doc. Samples in the UPCI study were
obtained on days 1, 8, 15, and 22. Of the 25 patients enrolled in the study, 21 patients had
all four neutrophil counts recorded, corresponding to Doc doses of 50 (n = 5), 60 (n = 11)
and 75 (n = 3)
mg
m2 . For the MSKCC study, samples were obtained on days 1, 3, 8, 15,
and 22. Of the 50 patients enrolled, 42 patients had 4 or more neutrophil counts recorded,
corresponding to doses of 35 (n = 5, “weekly”), 55 (n = 3, q3w), 70 (n = 17, q3w) and 75
(n = 10, q3w)
mg
m2 . In both studies, patients who displayed any type of Grade 4 or multiple
incidents of Grade 3 toxicity had their Doc dose reduced for future treatments. None of
the patients from these data sets had hematological evaluation after the first four weeks of
treatment.
6.1.2 Model Development
As the primary toxicity associated with Doc is neutropenia, a low-order model of neutrophil
response following administration of Doc was taken from the literature [3]; this model is
shown schematically in Figure 6.1. This model has been validated previously for a number
of chemotherapeutics [3, 111, 112, 182, 183], including Doc [3]; however, the Doc evaluation
was primarily from patients dosed at 100
mg
m2 q3w. The model consists of five differential
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Figure 6.1: Neutrophil model structure for coupling human Doc plasma concentration to PD
effect [3].
equations, as follows:
dP
dt
= ktrP (1− Edrug)
(
Ni
N
)γ1
− ktrP (6.1)
dT1
dt
= ktrP − ktrT1 (6.2)
dT2
dt
= ktrT1 − ktrT2 (6.3)
dT3
dt
= ktrT2 − ktrT3 (6.4)
dN
dt
= ktrT2 − ktrN (6.5)
Here, as seen in Figure 6.1, cell proliferation occurs in compartment 1 (counting from left
to right), maturation occurs in the transit compartments (2-4), and circulating neutrophil
count is represented by compartment 5. Feedback between circulating neutrophil count and
the normal baseline neutrophil value (Ni,
109cells
L ), raised to the power, γ1, was included to
permit an absolute neutrophil count (ANC) count following treatment to exceed the baseline
neutrophil count. The parameter γ1 governs the aggressiveness of the rebound observed
following treatment, with larger values leading to both faster recovery and a greater overshoot
over the baseline neutrophil value. Transfer rates between compartments, elimination from
the circulating neutrophil compartment, and proliferation rate were all modeled using the
same parameter, ktr (
1
day
), to reduce the overall number of model parameters. This
simplification was necessary due to the limited sampling frequency and total number of
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collected data points (4 samples) from individual patients. Rates for some parameters, such
as circulating neutrophil elimination rate, can be found in the literature, but previous results
from Friberg et al. showed that inclusion of such literature parameters did not significantly
increase the accuracy of the model [3]. Based on the model structure and transition rate
parameter, an alternative parameter was defined, as follows:
MTT =
n+ 1
ktr
(6.6)
Here, MTT is the mean transit time for a cell to reach the circulating neutrophil compartment
after leaving the proliferating neutrophil compartment, and n is the number of transit
compartments in the model.
The drug effect (Edrug) was limited to compartment 1; four different functions were
investigated as possible PD terms: (i) linear; (ii) log-linear; (iii) Michaelis-Menten; and (iv)
Hill-relationship:
Edrug = m[Doc] (6.7)
Edrug = α[Doc]
β (6.8)
Edrug =
Emax[Doc]
EC50 + [Doc]
(6.9)
Edrug =
Emax[Doc]
γ2
ECγ250 + [Doc]
γ2
(6.10)
Here, m, α, and Emax are estimated model parameters which scale PK concentration with
units of 1
µM
, 1
µMβ
, and (dimensionless), respectively. β is the slope of the log-linear function,
EC50 (µM) is the concentration at which half the drug effect is obtained, γ2, with value
>1 describes the steepness of transition to Emax within the Hill relationship, and [Doc] is
the patient plasma concentration of Doc (µM). Michaelis-Menten and linear functions have
previously been investigated by Friberg et al. for describing neutrophil progression following
Doc administration. They concluded that the increase in model complexity resulting from
the Michaelis-Menten kinetics was not justified by the small increase in accuracy. However,
these modeling studies were performed on patients administered Doc on a q3w schedule,
and alternative PD relationships may be necessary for describing Doc administration on
alternative schedules.
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Finally, other authors have demonstrated that inclusion of an effect site was necessary for
predicting schedule dependent neutrophil profiles resulting from treatment [183]. Inclusion
of such a compartment within the PD model given by Equations (6.1)-(6.5) is accomplished
by appending the following additional equation:
dF1
dt
= −kfF1 + kf [Doc] (6.11)
and replacing all occurrences of [Doc] within Edrug with F1. The parameter, kf sets the speed
of the response of the filtered plasma concentration of Doc ( 1
day
). Inclusion of an effect-
compartment formulation within the model dampens infusion duration-dependent effects in
the model output. The filtered formulation may also be more indicative of drug concentration
profiles observed within tissues where the drug effect is taking place.
6.1.3 PK/PD Drug Schedule Simulations
The clinically approved Doc regimen calls for drug administration via a 1-hour IV infusion
every three weeks (q3w regimen), however, a repercussion of this regimen is the high incidence
of Grade 3 and 4 neutropenia in treated patients [159]. In an effort to reduce this toxicity,
other Doc dosing regimens have been investigated, most notably once a week for three
weeks followed by a week off (“weekly” regimen), for six weeks with two weeks off, or every
other week. Initial trial results have demonstrated equivalent efficacy between the q3w and
“weekly” dosing regimens, with a significant reduction in Grade 3 or higher neutropenia in
patients treated on the “weekly” Doc regimen [184]. Treatment on every other week Doc
regimens, though limited, has also displayed a reduction in the primary toxicity compared
to the q3w regimen. Efficacy from the every other week regimen, while similar to the q3w
regimen, has not been validated as equivalent because the trail was under powered [158].
Neutrophil progression profile were simulated based on these literature results, the
tissue-intensive human PBPK model developed in the previous section, and the PD model
developed above. Individual patient PK profiles were used for providing the Doc plasma
concentrations, while both patient-specific and population neutrophil parameters were
evaluated. Three different dosing schedules (q3w, “weekly”, and every other week) were
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simulated for each of the patients at dosing levels ranging from 70-100
mg
m2 , 28-40
mg
m2 , and
40-60
mg
m2 , for the three dosing studies, respectively.
6.1.4 PK/PD Drug Schedule Control Algorithm
Nonlinear model predictive control (NMPC) has been employed in a number of industrial
processes [137] and drug dosing applications [58, 79, 185, 186, 187, 188, 189] due to its
readily adaptable structure, which requires a process model, output measurements, and
manipulations at regular intervals. The general form of the NMPC algorithm has three
distinct parts: (i) an objective function; (ii) dynamic model equations; and (iii) constraints.
A typical NMPC formulation would be as follows:
min
∆u(k:k+m−1|k)
‖Γy [R(k + 1 : k + p|k)− Y (k + 1 : k + p|k)] ‖22
+‖Γ∆u∆u(k : k +m− 1|k)‖22 + ‖Γuu(k + 1 : k + p|k)‖22 (6.12)
x˙PK = f(xPK , u) (6.13)
x˙PD = f(xPK , xPD, u) (6.14)
x˙CN = f(xCN , xPK , xPD, u) (6.15)
umin ≤ u(t) ≤ umax (6.16)
xmin ≤ x(t) ≤ xmax (6.17)
The objective function (Equation (6.12)) serves as the metric for deciding the ideal doses
to implement over a predicted horizon in time. For the above two-norm squared objective
function [138], the controller minimizes the sum of three terms. The first is an error term
that calculates differences between predicted future output, Y (k+1 : k+p|k), and a desired
reference trajectory, R(k+1 : k+ p|k), over a horizon of length p. The index, k, denotes the
present time. The second term is a noise-suppression term that penalizes magnitude changes
in the input level, ∆u(k : k +m − 1|k) on the move horizon, m (m ≤ p). Besides reducing
actuator wear, a ∆u formulation of the NMPC algorithm allows for implicit integral action
which ensures the controller will converge to the desired reference trajectory without offset.
The third term penalizes for total manipulated variable use, u(k + 1 : k + p|k). This term
is often omitted in traditional MPC formulations. However, it is a necessary inclusion if the
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input functions solely in disturbance rejection or the total input administered is of concern
(i.e., monetary costs, toxicity).
The state equations, (6.13)-(6.15), corresponding to the PK model, PD model, and
circulating neutrophil state, serve as the dynamic process model that explicitly predicts
future system behavior based on m controller-calculated dosing alterations over the
prediction horizon, p, where m ≤ p. The constraints, (6.16) and (6.17), ensure that both the
input (dosing level) and states (drug within tissues or plasma), respectively, do not exceed
clinically-imposed bounds. In the case of the coupled neutrophil (PD) and Doc plasma (PK)
models, input constraints were set at 0
mg
m2 ≤ u(k+1 : k+p|k) ≤ 100mgm2 . These represent no
delivery of the Doc for a given week and the highest single Doc dose administered clinically
(via the q3w regimen) [151]. Patient toxicity is one of the main causes for treatment failure,
necessitating dose reduction or treatment cessation, thereby motivating the inclusion of
state constraints on patient circulating neutrophil count. While dose alteration criteria vary
depending on the tumor type being treated and the clinician involved, common metrics for
dose reduction include any occurrence of Grade 4 toxicity or week-to-week persistence of
life-threatening Grade 3 toxicities. These can mathematically be posed as constraints as
follows:
B1 ≤ xCN(k + 1 : k + p|k) (6.18)
−M2φi +B2 ≤ xCN(k + i|k) (6.19)
xCN(k + i|k) ≤ M2(1− φi) +B2 (6.20)
φi + φi+1 ≤ 1 (6.21)
where φ is an integer-valued binary vectors ({φi} ∈ {0, 1}, {i ∈ I|1 ≤ i ≤ p}) of length p,
M2 is a large number termed a big-M constraint, and B1 and B2 are state bounds. For
the conditions described above, these would have values of B1 = 0.5 × 109 cellsL (Grade
4) and B2 = 1.0 × 109 cellsL (Grade 3), respectively. Constraining neutrophil counts at
the maximum acceptable limit of neutropenia may be ill-advised, and a less aggressive set
of constraints, maintaining the patient above Grade 3 toxicity and avoiding week-to-week
persistence midway between Grade 2 and 3 toxicities, may be employed (B1 = 1.0×109 cellsL ;
B2 = 1.5× 109 cellsL ).
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Incorporating state constraints may lead to infeasible solutions in an NMPC formulation,
especially if the initial input effect on the system is rapid compared to the subsequent
recovery. Instead, state constraints are placed within the objective function (i.e., relaxed
or softened) to facilitate solutions and appended with a suitably large weighting penalty
[40, 135]. These penalties are typically at least 103 more than the contribution from the sum
of the other objective function terms to ensure that constraints on the circulating neutrophil
count are enforced. The relaxed state constraints were posed as follows:
−M1κ+B1 ≤ xCN(k + 1 : k + p|k) (6.22)
xCN(k + 1 : k + p|k) ≤ M1(1− κ) +B1 (6.23)
−M2φi +B2 ≤ xCN(k + i|k) (6.24)
xCN(k + i|k) ≤ M2(1− φi) +B2 (6.25)
−M3(1− ηi) + 2 ≤ φi + φi+1 (6.26)
φi + φi+1 ≤ M3ηi + 1 (6.27)
where κ and φ are integer-valued binary vectors ({κi, φi} ∈ {0, 1}, {i ∈ I|1 ≤ i ≤ p}) of
length p, η is a binary vector ({ηj} ∈ {0, 1}, {j ∈ I|1 ≤ j ≤ p− 1}) of length p− 1, and M1,
M2 and M3 are large numbers termed big-M constraints, A reference trajectory formulation,
like that in Chapter 2, may not be appropriate as a specific neutrophil trajectory does not
ensure increased Doc delivery and “driving” the neutrophil count of a patient to a specified
value is not a clinically relevant objective. Also, explicit incorporation of the two-norm of
the administered dose was included within the objective function (with a negative weighting
term) to ensure maximum delivery of Doc during the simulation and to preferentially favor
single, large dose administration over multiple small doses. This is consistent with the
viewpoint of the clinician regarding Doc treatment, which is to administer as much drug
to the patient as often as possible subject to patient toxicity [190, 191]. Likewise, the
magnitude change in dosing level is less of a concern to clinicians than is the absolute
amount of drug delivered (dose schedule predictions requiring separate doses at each week,
however, are undesirable due to schedule complexity). The modified form of Equation (6.12),
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the objective function employed in the rest of the chapter, is represented as follows:
min
∆u(k:k+m−1|k)
−‖Γuu(k + 1 : k + p|k)‖22 + Γηη + Γκκ (6.28)
Here, Γy = 0, Γ∆u = 0, and Γu = 0.1. A two-norm formulation for total administered drug
is ideal as it preferentially favors large single doses rather than low doses spread over the
entire treatment regimen. Γη and Γσ are chosen sufficiently large (i.e., > 10
6 and > 107,
respectively), to ensure that the individual contribution from these terms is significantly
greater than the maximum contribution from the drug administration term. Algorithm
predictions were limited to a 12-week treatment horizon with Doc administration possible
once a week at the beginning of each week. Simulations were performed in MATLAB ( c©2007,
The MathWorks, Natick, MA) and optimizations called the fmincon function.
6.2 RESULTS
6.2.1 Neutrophil Model Evaluation
Initially, the model structure from Friberg et al. was left unchanged. Using the original
parameters, neutrophil profiles for the average UPCI patient were simulated and compared
against the actual counts obtained during cycle 1 of treatment (Figure 6.2, dashed). Initial
predictions did not agree well with the patient data, displaying significant overshoot of the
observed neutrophil count at the end of cycle 1 and necessitating a reevaluation of the model
parameters. Because only four points per patient were available, it was assumed that the
collected neutrophil counts would repeat over the following treatment cycles; this assumption
underpredicts the cycle-to-cycle effects of Doc administration. Model parameters were
estimated for each patient by minimizing the weighted sum squared error using the fmincon
function in MATLAB ( c©2007, The MathWorks, Natick, MA). The resulting parameters
were averaged to obtain a parameter set for the entire population, and these are summarized
in Table 6.1 along with the original parameters from the study by Friberg et al.. Neutrophil
profiles using the updated parameter set for the average UPCI patient at each dosing level
are shown in Figure 6.2 (solid).
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Figure 6.2: Patient neutrophil counts obtained during the first cycle of q3w Doc treatment
at 50 (circle), 60 (triangle), and 75 (square)
mg
m2 . Neutrophil profile predictions are based on
the original (dashed) and updated (solid) parameter sets.
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Finally, observed versus predicted individual and population neutrophil predictions are
shown in Figure 6.3. Due to the limited data available for each patient, the model structure
was over parameterized for even this four parameter system, as evidenced by individual
neutrophil predictions lying almost uniformly on the line of unity. The over-fitting of
individual data propagates to increased uncertainty in the population neutrophil model
parameters and less accurate population neutrophil predictions. Estimating parameters for
the entire population simultaneously would likely improve these model predictions, as would
the inclusion of an intra-patient variability model for individual parameters [3].
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Figure 6.3: Individual (left) and population (right) predicted patient neutrophil counts versus
actual patient neutrophil count measurements.
Table 6.1: Parameter values compared for the neutrophil model from the literature [3] and
those estimated using the linear PD effect in Equation (6.7) and patient neutrophil counts
from two Phase I clinical trials.
Friberg et al. Florian et al.
Linear PD effect Linear PD effect
ktr day
−1 1.08 0.84
m 1
µM 8.58 33.3
γ1 0.161 0.187
N0 × 109 cells 5.05 5.09
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6.2.2 Coupled PK and PD Predictions
Typical dosing ranges for the three schedules (q3w, weekly, and biweekly) are 70-100
mg
m2 , 28-
40
mg
m2 , and 40-60
mg
m2 , respectively, and simulated absolute neutrophil count (ANC) profiles
in response to treatment are shown in Figures 6.4a, b, and c, respectively. Grade 2, 3,
and 4 neutropenia are represented as horizontal lines in the figure, with toxicity grades
corresponding to 2.0 ×109 cellsL , 1.0 ×109
cells
L , and 0.5 ×109
cells
L , respectively. At the
lowest q3w dose (70
mg
m2 ), toxicity is predicted to approach Grade 3 neutropenia (nadir
at 1.0 ×109 cellsL ) following the first Doc dose and 1.3 ×109
cells
L (between Grade 2 and 3
neutropenia) on proceeding doses. Likewise, the extent of toxicity at the highest q3w dose
approaches Grade 4 neutropenia (0.5 ×109 cellsL ) following the first dose and 0.8 ×109
cells
L
(between Grade 3 and 4 neutropenia) on proceeding doses. While there is no observable
increase in patient neutropenia from dose to dose, clinical results do not demonstrate nadir
values of increasing magnitude following the first cycle (no clear pattern is observed). Rather,
this behavior is a consequence of perturbing the neutrophil model from its initial conditions
and may not reflect quantitative biological values.
Simulated neutrophil profiles for “weekly” Doc administration display a rapid fall
following the first week of treatment, followed by a less gradual reduction in neutrophil
count after the second dose, then a small rebound and subsequent drop-off in neutrophil
count following the third dose, and finally, neutrophil recovery during the week without
dosing (week four). The nadir for the 28
mg
m2 regimen occurred at 1.5 ×109 cellsL while the
nadir for the 40
mg
m2 regimen was 0.8 ×109 cellsL , though this dose is employed in “weekly”
dosing less frequently than 35
mg
m2 (Grade 3 neutropenia, 1.0 ×109 cellsL ).
Likewise, the profiles for every other week 60
mg
m2 Doc administration display a nadir
following the week of drug delivery (Grade 2 neutropenia, 1.3 ×109 cellsL ), recovery during
the week without Doc dosing (though the recovery does not reach the baseline neutrophil
count), and subsequent repetition of the pattern as dosing continues. The median every
other week regimen, 50
mg
m2 , reaches nadir at 1.7 ×109 cellsL , and the lowest every other
week regimen dose, 40
mg
m2 , predicts a nadir of 2.0 ×109 cellsL (barely classifying as Grade 2
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neutropenia), despite delivering approximately the same Doc over a twelve week period as
the 70
mg
m2 q3w and 28
mg
m2 “weekly” schedules (Grade 3 and 2 neutropenia, respectively).
The median dose level from each regimen is shown in Figure 6.4d for comparison.
Qualitatively, these behaviors are accurate as the weekly and biweekly dosing have higher
nadir values than the q3w regimen. However, the model is not quantitatively predictive for
neutrophil progression in patients dosed “weekly” with Doc with results from the literature
indicating an 2.5-23% incidence of grade 3 and 4 neutropenia during “weekly” Doc treatment
[151, 155, 159, 171, 172, 192]. Furthermore, the decreased toxicity predicted by the “weekly”,
Doc regimen in Figure 6.4d was found to be infusion duration dependent. It should be noted
that while typical “weekly” treatments have an infusion duration of 30-minutes, the above
simulations utilized a 60-minute infusion duration. If the infusion duration was altered to be
representative of clinical practice, model predictions of decreased toxicity under “weekly”
treatment were no longer realized. This indicates a flaw in the underlying PD model
structure.
As an additional comparison, data from the MSKCC study with a patient dosed “weekly”
and the accompanying neutrophil progression prediction is shown in Figure 6.5. While the
model predicts a nadir value of neutrophils that persists for the three weeks of dosing, the
patient data depicts more rapid recovery of neutrophils between treatments and a gradual
decline in the number of circulating neutrophils over the three dosing weeks. In order to
describe weekly dosing quantitatively, the PD model structure must be altered, either at
the feedback or drug effect term, so as to simultaneously describe both the q3w and weekly
dosing schedule. This is needed if model predictions are to be used in subsequent dose
schedule development.
6.2.3 Updated Neutrophil Model
Initial model alterations focused on evaluating alternative PD effect structures within the
neutrophil model as described in Equations (6.7)-(6.10). Parameters were estimated for
the 51 patients available, and the model predicted incidence of grade 3/4 neutropenia was
calculated for the entire population. Neither a Michaelis-Menten nor a sigmoidal formulation
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Figure 6.4: Predicted ANC resulting from administration of Doc at various dose level and
schedule combinations (a) q3w at 70, 85, and 100
mg
m2 (represented by dash-dot, solid, and
dashed lines), (b) “weekly” at 28, 35, and 40
mg
m2 (represented by dash-dot, solid, and
dashed lines), or (c) every other week at 40, 50, and 60
mg
m2 (represented by dash-dot, solid,
and dashed lines). Subfigure (d) compares the median delivered dose for each of the three
regimens, corresponding to q3w 85
mg
m2 (solid), biweekly 50
mg
m2 (dashed), and “weekly” 35
mg
m2 (dash-dot).
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Figure 6.5: Predicted ANC (solid) and representative patient ANC data (circles) versus time.
Doc dose was 35
mg
m2 “weekly”.
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for Edrug allowed for any differences between the predicted incidence of neutropenia on the
two treatment schedules. Separation was achieved using a log-linear PD effect term, but this
only reduced the grade 4 neutropenia (≈10% of the population) while the incidence of grade 3
neutropenia (≈40% of the population) remained outside the range observed in the literature.
Upon closer inspection, is was observed that this separation was only attained for values of
β > 3.0. In essence, selection of such a large parameter value allowed for exploitation of
the small concentration differences observed during the course of the infusion between the
q3w and “weekly” treatment schedules. This concept is further illustrated in Figure 6.6.
For a linear effect structure following treatment with 70
mg
m2 Doc over a 1-hour infusion, the
time course of drug effect was limited to two hours following the start of treatment (infusion
duration and an additional hour). This result was expected as infusion duration dependency
of the model structure had already been established during initial model evaluations using
multiple treatment regimens (Figure 6.4).
As noted in the previous section, the current PD structure is over parameterized, and
attempting to estimate individual patient neutrophil model parameters with more complex
drug effect terms only increased the over parameterization. While the above results did
not predict the desired separation between treatment schedules, this may have resulted from
identifying model parameters on an individual patient basis (i.e., multiple parameter sets for
describing the dataset may exist). To address this question, parameters were evaluated by
randomly pairing two patients from the population, one selected from the group dosed Doc
q3w, the other selected from patients administered Doc “weekly”. Results from this analysis
demonstrated that a subset of patients dosed Doc q3w could be identified concurrently
with patients treated “weekly”. However, closer inspection revealed that only q3w patients
whose baseline was at or below the population average returned model parameters capable
of simultaneously fitting neutrophil profiles from both administration schedules. While this
would seem to be ideal (i.e., the model is predictive at the average population neutrophil
baseline), it should be noted that the limited population data for patients administered Doc
“weekly” (n = 5) possessed an average baseline neutrophil count of 9.5 ×109 cells
µL , nearly
two-fold the value of the actual population baseline count. As such, the model was exploiting
this difference in initial neutrophil count when predicting patient neutrophil progression and
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Figure 6.6: Model predicted progression of each state (P -dashed, T1-solid, T2-dash-dot; T3-
dotted; N -circles) from the Friberg et al. neutrophil model following administration of 70
mg
m2 Doc over a 1-hour infusion on day 0.
175
did not actually predict a reduced incidence of neutropenia for patients administered Doc
“weekly”.
The next neutrophil modeling approach utilized for describing neutrophil progression
on different treatment regimens explored the inclusion of an effect-site compartment in the
model structure (Equation (6.11)) with all four PD effect structures. Due to model over
parameterization, and as the purpose of this compartment was to eliminate the infusion
duration effect on neutrophil count, kf was bounded as 1
1
day
< kf < 20
1
day
(kf = 40
1
day
results in an effect compartment profile that was nearly identical to plasma). Such a
parameter restriction was necessary as arbitrarily large values of kf would behave as if
no filter was incorporated (i.e, effect-compartment Doc concentrations would be equivalent
to plasma Doc concentrations), which is already known to describe q3w but not “weekly”
data. Furthermore, kf values of less than 1
1
day
altered the predicted effect-compartment
concentrations so as to no longer mimic tissue Doc concentrations predicted by the tissue-
intensive PBPK model. A representative plot of these predicted effect-compartment Doc
concentrations for kf values of 1, 5, and 20
1
day
, compared to the original plasma profile and
tissue predictions are shown in Figure 6.7. While these kf values alter the effect profile and do
not match dynamics observed from highly perfused tissues, the dynamics were representative
of tissue dynamics observed from slowly perfused tissues (fat, muscle, and “other”). As the
primary goal of including the effect-compartment was to eliminate the effect of infusion
duration on the predicted neutrophil effect, the kf range above was deemed acceptable.
However, any parameter value within this range would result in model parameters capable
of describing the observed patient neutrophil counts. Furthermore, simultaneous evaluation
of q3w and “weekly” patients would result in the same problem encountered previously.
Hence, three separate values for kf were selected (1, 5, and 20
1
day
), with estimated
population model parameters and predicted population occurrences of Grades 2, 3, and
4 neutropenia summarized in Table 6.2. Of the three evaluated filter parameterizations,
only values of kf = 5
1
day
returned population predicted incidences of grade 3/4 neutropenia
for q3w and “weekly” treatment schedules of Doc consistent with the literature (2.5-23%
versus upwards of 90% in q3w regimens) [151, 155, 159, 171, 172, 192].
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Figure 6.7: Model predicted effect-site concentration as a function of kf value versus time
for a Doc dose of 70
mg
m2 over a 1-hour infusion to a typical patient (kf values of 1, 5, and
20 given by circles, dotted, and dash-dot, respectively). Also shown are the original Doc
plasma concentration (dashed) and selected tissue Doc concentrations (solid) predicted by
the tissue-intensive PBPK model.
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Finally, population predicted neutrophil progression for the original Friberg neutrophil
model (with updated parameters), along with the progressions predicted by the Friberg
model appended with an effect-compartment and PD effects from Equations (6.7), (6.8),
and (6.10) are shown in Figures 6.8 and 6.9. As before, grade 2, 3, and 4 neutropenia,
are represented as horizontal lines in the figure, with toxicity grades corresponding to 2.0
×109 cellsL , 1.0 ×109
cells
L , and 0.5 ×109
cells
L , respectively.
For the updated Friberg model (Figure 6.8, top), median nadir values for the population
were predicted at 0.5 for treatment on both the q3w and “weekly” Doc schedules. Even
the maximum predicted neutrophil counts from the population predicted a nadir of 1.1
×109 cellsL , signifying that the neutrophil model predicts grade 3 neutropenia in almost
the entire population. The inclusion of an effect-compartment within the Friberg model
(Figure 6.8, bottom) allowed for an increase in separation between the two treatment
schedules with median nadir values for both q3w and “weekly” schedules at 0.5 and 0.7
×109 cellsL , respectively. However, the predicted incidence of grade 3/4 neutropenia within
the population differed by only 12%. The incidence of grade 3/4 neutropenia (38/51)
is approximately that observed for q3w treatments in the literature, but the population
predicted occurrence (32/51) exceeds the value from patients dosed “weekly”.
If the PD effect was then altered to either a log-linear or sigmoidal formulation
(Figure 6.9, top and bottom, respectively) further separation between q3w and “weekly”
treatment schedules was achieved. Predicted median nadir values for the log-linear
formulation were 0.5 ×109 cellsL for the q3w schedule and 1.1 ×109
cells
L for the “weekly”
schedule. Similarly, the predicted incidence of grade 3/4 neutropenia was 34/51 and 15/51 for
q3w and “weekly” treatment schedules, respectively, approximately equivalent to the values
observed in the literature. Even further separation between the two treatment schedules was
obtained using the sigmoidal PD effect structure, though the model predicted occurrences of
grade 3/4 neutropenia for “weekly” Doc treatment were beginning to under-predict observed
literature values. In the absence of data for further validating the log-linear and sigmoidal
models with an effect-compartment, both models were deemed reasonable descriptions of
neutrophil progression for treating patients on either q3w or “weekly” Doc schedules, and
dose schedule development was pursued using both model structures.
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Figure 6.8: Median (solid), min (dash-dot), and max (dash-dot) model predicted neutrophil
count progressions for the population using either the updated Friberg neutrophil model
(top) or the Friberg model appended with an effect-compartment having a linear PD effect,
and kf = 5 day
−1 (bottom). Treatment results over a 12 week cycle are shown with Doc
administered q3w at 70
mg
m2 (left) and “weekly” at 30
mg
m2 (right).
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Figure 6.9: Median (solid), min (dash-dot), and max (dash-dot) model predicted neutrophil
count progressions for the population using the Friberg model appended with an effect-
compartment, kf = 5 day
−1, and either a log-linear (top) or sigmoidal (bottom) PD effect
term. Treatment results over a 12 week cycle are shown with Doc administered q3w at 70
mg
m2 (left) and “weekly” at 30
mg
m2 (right).
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6.2.4 Human PBPK Model Reduction
Model reduction tools were applied to the human PBPK model in order to aid subsequent
controller synthesis. As the primary toxicity associated with Doc treatment is neutropenia,
which is commonly represented as a function of plasma drug concentration, and tumor
regression depends on tumor drug exposure, it was necessary to maintain accurate predictions
for both plasma and tumor drug concentrations. All other tissue predictions, while
potentially relevant for other toxicity metrics, are not concentrations that are commonly
obtained in humans; explicit representation of these tissues were removed to reduce model
order. The full model can be employed in subsequent analysis if the predicted concentrations
in other tissues prove informative for treatment or toxicity evaluation.
Using the balmr function from MATLAB ( c©2007, The MathWorks, Natick, MA), Hankel
singular values (HSVs) were calculated for the original 36 ODE PBPKmodel; these are shown
in Figure 6.10. The upper bound on error introduced by truncating the original n-state linear
model, G(jw), to a k-state representation, Gr(jw), is given by [135]:
||G(jw)−Gr(jw)||∞ = 2
n∑
i=k+1
σHi (6.29)
Here σHi is the i
th HSV of the full order model. In a balanced realization, the magnitude
of the HSV serves as a measure of the contribution of an individual state to the overall
process behavior. Convention holds that the total of the sum in Equation (6.29) should not
exceed 0.05-0.10 to ensure the accuracy of the reduced model. Furthermore, the truncation
point is typically selected at a “knee” in the HSV curve. A closer inspection of Figure 6.10
(inset) reveals such a behavior between the 6th and 7th HSVs, and the upper bound on the
truncated error using k = 6 was calculated at 0.020, within acceptable error bounds. As such,
the model was reduced to 6 ODEs, and the resulting structure was used to provide plasma
and tumor Doc concentration predictions when coupled with the PD model developed above.
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Figure 6.10: HSVs for the full 36 ODE human PBPK model. Inset: HSVs for the first 7
states.
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6.2.5 Dose Schedule Development
Doc dose schedule design simulations were performed using model parameters representative
of a median, a high risk of neutropenia, and a low risk of neutropenia patient. Three
different model structures were evaluated for dose schedule development: (i) Friberg model
with updated parameters; (ii) effect-compartment with log-linear drug effect; and (iii) effect-
compartment with sigmoidal drug effect. Previous investigations involving Grade 3 and 4
neutropenia constraints resulted in a Doc treatment schedule which predicted ANCs within
1% of the lower specified toxicity constraint on an every other week basis. When this regimen
was simulated for the entire population, excessive toxicity was predicted and as such the
use of these constraints in algorithm development was rejected. Constraining neutrophil
counts at the minimum acceptable limit of neutropenia was deemed ill-advised, and a less
aggressive set of constraints maintaining the patient above Grade 3 toxicity or week-to-week
persistence midway between Grade 2 and 3 toxicities were employed (B1 = 1.0 × 109 cellsL ;
B2 = 1.5× 109 cellsL ).
NMPC algorithm results (m = 1, and p = 2) for the above constraints using the updated
Friberg model and a low risk patient are shown in Figure 6.11. It should be noted that Doc
doses in this figure and the remaining figures in this chapter are plotted in the traditional
MPC convention (i.e., step profile) while actual Doc administration was limited to a 1-hour
infusion at the start of each treatment week. For the evaluated patient, a nadir value of 1.0
×109 cellsL was attained on week two of treatment. Thereafter, the predicted ANC never fell
below 1.2 ×109 cellsL , despite model predicted Doc administration never going below 36
mg
m2 .
For this patient, total administered Doc over a 12 week period was predicted to be 556
mg
m2 ,
far exceeding administered Doc during any clinically practiced treatment regimen. However,
such dosing is not recommended, not even for patients exhibiting limited neutrophil response
(as in the case of this patient) during the first course of treatment. This Doc treatment result
is an artifact of limited neutrophil progression sampling for this low risk patient, further
supported by the total administered Doc calculated for low risk patients for case (ii) and
(iii) (817 and 703
mg
m2 , respectively).
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Figure 6.11: ANC predictions (top) and input profiles (bottom) for three separate Doc
dosing regimens: 70
mg
m2 q3w (dash-dot); 30
mg
m2 “weekly” (dotted); and dosing constrained
to maximize delivered drug subject to Grade 2 and 3 neutropenia constraints (dashed), for a
low risk patient modeled using the updated Friberg neutrophil model. Neutropenia toxicity
Grade 2, 3, and 4 are represented as horizontal lines (dashed) in the top figure, with toxicity
grades corresponding to 2.0 ×109 cellsL , 1.0 ×109
cells
L , and 0.5 ×109
cells
L , respectively.
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More clinically relevant schedules evaluated for a median and a high risk patient for
case (i) are shown in Figure 6.12. For this case study, total Doc of 307 and 120
mg
m2 were
predicted for the median and high risk patient, respectively, over the treatment cycle. This
corresponds to a 10% increase and a 57% decrease from Doc administered q3w at 70
mg
m2 .
The administration schedule for the median patient displayed a three-level profile, though it
also resembles high dosing for two weeks followed by a week of low dosing similar to regimens
currently being investigated clinically. A similar result was obtained for the high risk patient;
the schedule approaches a two-level formulation as the treatment cycle progresses (starting
on week 6). However, it has already been shown that the neutrophil model used in these Doc
schedule evaluations is not capable of accurately predicting neutrophil progression for both
q3w and “weekly” treatment regimens so Doc schedule calculation and inferences drawn
from this set should be approached with caution.
Case (ii) simulations (Figure 6.13) for the median patient predicted a trough ANC
value of 1.0 ×109 cellsL that repeated every 6 weeks for the controller-calculated treatment
schedule. The treatment schedule for the case (ii) median patient was unique in that
four weeks of high dosing were followed by a two week cessation of treatment. Still, the
developed schedule predicted a total of 340
mg
m2 Doc administered over the treatment cycle,
exceeding that administered during q3w Doc at 70
mg
m2 by 21% while maintaining grade
3 toxicity constraints. As before, the total amount of Doc delivered to the high risk
patient was substantially less (50%) than that administered over a standard q3w 70
mg
m2
regimen. Furthermore, the administration schedule predicted for the case (ii) high risk
patient displayed no perceivable pattern beyond daily low-dose administration similar to
that used during metronomic Doc treatments.
Case (iii) simulations (Figure 6.14) for the median patient predicted a trough ANC
value of 1.0 ×109 cellsL that repeated every 3 weeks during the course of treatment. The
administration schedule for the case (iii) median patient was similar to that obtained for
the case (i) median patient (two-level sequence), with the exception that no drug was
administered every third week. Total Doc administered over this cycle was 367
mg
m2 (31%
increase versus 70
mg
m2 q3w), which was the largest predicted for a median patient of all three
case studies. Likewise, the predicted Doc for a high risk patient was 229
mg
m2 , only 18% less
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Figure 6.12: ANC predictions (top) and input profiles (bottom) for Doc regimen predictions
constrained to maximize delivered drug subject to Grade 2 and 3 neutropenia constraints
(dashed) for a median (left) and high risk (right) patient with the updated Friberg neutrophil
model. Also shown are two standard Doc regimens: 70
mg
m2 q3w (dash-dot) and 30
mg
m2
“weekly” (dotted). Neutropenia toxicity Grade 2, 3, and 4 are represented as horizontal
lines (dashed) in the top figure, with toxicity grades corresponding to 2.0 ×109 cellsL , 1.0
×109 cellsL , and 0.5 ×109
cells
L , respectively.
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Figure 6.13: ANC predictions (top) and input profiles (bottom) for Doc regimen predictions
constrained to maximize delivered drug subject to Grade 2 and 3 neutropenia constraints
(dashed) for a median (left) and high risk (right) patient with a log-linear PD effect and
effect-compartment (kf = 5
1
day
). Also shown are two standard Doc regimens: 70
mg
m2
q3w (dash-dot) and 30
mg
m2 “weekly” (dotted). Neutropenia toxicity Grade 2, 3, and 4 are
represented as horizontal lines (dashed) in the top figure, with toxicity grades corresponding
to 2.0 ×109 cellsL , 1.0 ×109
cells
L , and 0.5 ×109
cells
L , respectively.
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than that administered during q3w at 70
mg
m2 . However, as mentioned in the previous section,
the neutrophil model used for case (iii) slightly under-predicts the incidence of grade 3/4
neutropenia in the population. In those simulations involving a standard “weekly” treatment
schedule, the minimum ANC at 30
mg
m2 (total of 270
mg
m2 Doc) was predicted to be grade
2 neutropenia (Figure 6.9, lower right). The remaining ANCs from other models predicted
grade 3 neutropenia or worse (Figure 6.9, upper right). As such, it was not unexpected
that the case (iii) high risk patient predicted the highest administered Doc total of all the
high risk patient cases, nor that it almost predicted equivalent dosing to that used during
standard treatment regimens.
A final evaluation took the predicted treatment schedules for case (ii) and (iii) from
the median and high risk patients and simulated those schedules for the entire population.
Population predicted median, min, and max ANC are shown in Figure 6.15. The median
ANC for case (ii) now predicted nadir values of approximately 0.5 ×109 cellsL (grade 4
neutropenia), however, this was not unexpected as the simulated schedule delivered 21%more
Doc than the standard q3w schedule (with a similar toxicity profile). Given the likelihood
of grade 4 neutropenia from this treatment schedule, however, it is recommended that an
alternative median patient be used for developing a Doc treatment regimen. For case (iii)
the median patient was now predicted to have a nadir ANC of 0.7 ×109 cellsL with 31% more
Doc delivered than the standard q3w regimen. Finally, both high risk regimens returned
population ANC where the minimum never resulted in grade 3 neutropenia. Again, this was
not unexpected as a representative patient from the high risk group was used for schedule
development and the imposed model constraints highly penalized the occurrence of grade 3
neutropenia.
6.3 DISCUSSION
The semi-mechanistic neutrophil model developed by Friberg et al. [3] was used to describe
patient neutrophil progression following treatment with 50-75
mg
m2 Doc. While parameters
for this model had been evaluated previously, updated model parameters were necessary to
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Figure 6.14: ANC predictions (top) and input profiles (bottom) for Doc regimen predictions
constrained to maximize delivered drug subject to Grade 2 and 3 neutropenia constraints
(dashed) for a median (left) and high risk (right) patient with a sigmoidal PD effect and
effect-compartment (kf = 5
1
day
). Also shown are two standard Doc regimens: 70
mg
m2
q3w (dash-dot) and 30
mg
m2 “weekly” (dotted). Neutropenia toxicity Grade 2, 3, and 4 are
represented as horizontal lines (dashed) in the top figure, with toxicity grades corresponding
to 2.0 ×109 cellsL , 1.0 ×109
cells
L , and 0.5 ×109
cells
L , respectively.
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Figure 6.15: Median (solid), min (dash-dot), and max (dash-dot) model predicted neutrophil
count progressions for the population using the Friberg model appended with an effect-
compartment, kf = 5 day
−1, and either a log-linear (top) or sigmoidal (bottom) PD effect
term. Treatment results over a 12 week cycle are shown with Doc administered according to
the Doc schedule developed for a median (left) and high risk (right) patient.
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properly describe the observed neutrophil progression for patients from the two investigated
clinical studies [6, 179]. Various factors may have contributed to this including different
Doc dosing levels used for model development (previous parameters were developed from
patients dosed either 75 or 100
mg
m2 with a majority of the patients receiving higher doses),
using patient-specific Doc plasma concentrations predicted by the tissue-intensive PBPK
model (previous parameters used the Bruno population PK model for Doc plasma predictions
[2]), and the smaller dataset investigated (58 patients versus 601 from the previous study).
The developed neutrophil model was capable of describing observed neutrophil progression
following Doc treatment on a q3w schedule and initial results indicated that alternate PD
effect terms would allow for prediction of additional Doc treatment schedules. However, it
was discovered that these model results were dependent upon the Doc infusion duration and
if the “weekly” treatment was simulated using a 30-minute infusion, as is practiced clinically,
then the results no longer predicted decreased toxicity for “weekly” Doc treatments.
Initial attempts to adapt the neutrophil model for “weekly” Doc treatment schedules
investigated altering the PD effect term to either a log-linear, Michaelis-Menten, or sigmoidal
formulation. However, none of these PD effect structures were capable of achieving signifi-
cantly different population predictions of grade 3/4 neutropenia for different administration
schedules as observed in the literature. An attempt was made to simultaneously identify
parameters for patients administered Doc q3w and “weekly”. However, due to limited
data on “weekly” patients, in addition to the data for those patients displaying a baseline
circulating neutrophil count bias (nearly two-fold that of the typical population), these
simulations were not able to properly identify patient parameters. Note that additional
“weekly” patient data may allow this, and it will be a topic of future study as data is
available.
Investigating the time evolving states of the neutrophil model, particularly compartment
P where the drug effect was incorporated, it was revealed that nearly the entire Doc drug
effect on proliferating neutrophils was limited to the first two hours of treatment for the q3w
regimen (infusion duration plus one additional hour). This is a failing of the semi-mechanistic
model, as on-board Doc is likely having an effect extending for multiple days. However, due to
the inclusion of multiple filter compartments (three transition states), infrequent neutrophil
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sampling rates, and a slowly progressing patient neutrophil profile, the semi-mechanistic
model was able to predict neutrophil progression results following q3w treatment with Doc
that agreed well with data collected from the literature.
A final evaluation focused on the inclusion of an effect compartment to filter Doc
plasma concentration similar to that used by Hing et al. [183] for describing the effect of
trabectedin on circulating neutrophil count across multiple dose schedules. As the neutrophil
model was already over parameterized prior to the addition of the filter compartment,
acceptable values for the filter constant, kf , were bounded by comparing effect compartment
concentration predictions to those predicted in tissues by the tissue-intensive PBPK model.
Values beneath 1 1
day
, while completely removing the infusion duration effect from the PD
model, returned compartment concentrations with Doc retention dynamics that exceeded
those predicted for tissues. Similarly, values above 40 1
day
returned effect compartment
profiles that were not substantially different from the original plasma profile. As such, this
term was bounded between 1 and 40 1
day
. Using three separate kf parameterizations (1,
5, and 20 1
day
), neutrophil model parameters for the population were identified. Of the
various PD effects investigated, only the log-linear and sigmoidal PD effects were capable of
predicting the observed separation in incidence of grade 3/4 neutropenia between the q3w
and “weekly” Doc treatment. While a number of assumptions were made in constructing this
updated neutrophil model, these alterations were rooted in systems biology. Techniques were
employed that were successful for other authors in describing multiple treatment schedules
[183] and ensuring that the profile predicted within the effect compartment was similar to
predicted Doc tissue profiles. As such, additional data on Doc bone marrow concentrations
(ideally from mouse, which could be scaled to humans) would allow for validation of these
effect compartment predictions. Alternatively, more frequent measurements of neutrophil
count, and additional data from patients dosed “weekly”, may allow for a population analysis
of the model parameters.
Finally, Doc dose schedule control simulations were performed using median, high risk
of neutropenia, and low risk of neutropenia patients. Three different model structures were
evaluated for dose schedule development: (i) Friberg model with updated parameters; (ii)
effect-compartment with log-linear drug effect; and (iii) effect-compartment with sigmoidal
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drug effect. For the objective function, reference trajectory tracking of neutrophil count
was deemed irrelevant as attaining a set neutrophil count is not a clinical goal during
treatment. Rather, initial goals of treatment are to avoid primary toxicities, in this case
neutropenia, while still delivering sufficient drug to attain an efficacious tumor response.
Given the discrete nature of neutropenia toxicity grades and to ensure feasible solutions
during controller simulation, state constraints pertaining to incidence or week-to-week
occurrences of neutropenia grades were “relaxed” and included in the objective function,
premultiplied by a suitably large penalty weight. In addition, objective function weights
(negative) were placed on the two-norm of administered drug to allow for maximization of
total drug delivered over the simulation, subject to toxicity constraints, and to ensure that
dosing predictions favored large dose administrations. This is consistent with the viewpoint
of the clinician regarding treatment, which is to administer as much drug to the patient as
often as possible subject to patient toxicity [190, 191]. Granted, such statements represent
an absolute viewpoint and are easily refuted with results from the literature pertaining
to saturating effects [193, 194]. However, clinical results with Doc indicate that patients
who complete the most weeks of treatment without requiring treatment adjustments are
probabilistically more likely to have longer survival times and a longer duration before tumor
recurrence [190, 191].
Controller simulations were performed in an NMPC formulation with m = 1 and p = 2.
Alternative NMPC parameter selection is also feasible, however, as are controller simulations
over the entire treatment cycle (e.g.,m = 12, p = 14 to ensure that large dosing to the patient
would not be predicted by the algorithm on the final day of treatment [63, 64]). Predictions
for low risk patients for all three evaluated models, while allowing for increased Doc delivery
(556-817
mg
m2 over a 12 week period) are likely artifacts from limited patient neutrophil count
samples and should not imply that such an amount of Doc could be delivered to any patient
over a 12 week interval. Dose schedule predictions for the median patient using each of the
three models allowed for increased administration of Doc over a 12 week period, compared
to a q3w 70
mg
m2 regimen, and these may allow for improved treatment efficacy without an
increase in accompanying toxicity. Doc delivery schedules for high risk patients allowed that
194
patient group to avoid grade 3 occurrences of neutropenia while delivering 38-62% less total
Doc than the schedule for the median patient and 18-52% less total Doc than q3w 70
mg
m2 .
Overall, the NMPC control algorithm using the tissue-intensive PBPK model for PK
predictions and the altered Friberg neutrophil model was capable of returning Doc dosing
schedules that were qualitatively similar with on-going clinical research. Additional “weekly”
patient data is necessary for validating the underlying model, however, the coupled models
are now capable of quantitatively predicting the incidence of grade 3 and 4 neutropenia for
two different Doc treatment regimens. This lends credence to the Doc treatment schedule
predicted by the algorithm. Future algorithm development will focus on the effects of NMPC
parameters m and p on Doc schedule predictions. Also, as the tissue-intensive PBPK model
incorporates a tumor compartment within the model structure, all of the above simulations
also possess model predicted Doc tumor concentration for each of the above schedules. This
would allow for future inclusion of a projected tumor response in addition to a toxicity
measure as presented within this chapter. Furthermore, alterations to the objective function
to include both patient toxicity and a measure of efficacy are being pursued as a topic of
future work.
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7.0 CONTRIBUTIONS
7.1 CONCLUSIONS
The work within this dissertation has presented dose schedule development for chemother-
apeutics, beginning with the classical focus of tumor regression and concluding with
monitoring toxicity effects manifesting during treatment. Each problem possessed similar
components, focusing first on the development of accurate PK models following drug
administration. PK model predictions were used as the driving-force for downstream PD
effect models for both tumor regression and toxicity. Finally, based upon a user supplied
objective function, alterations to established dosing regimens were evaluated, obtaining
solutions which were mathematical solutions to the specified problem, but not always
clinically applicable.
7.1.1 Tamoxifen
NMPC algorithm was developed to dose the chemotherapeutic agent tamoxifen based on
a novel saturating-rate, cell-cycle model (SCM). Using daily tumor measurements, the
algorithm decreased tumor volume along a specified reference trajectory in simulated animals
over 4 months. In mismatch case studies, controllers based on the Gompertz model (GM)
yielded equivalent total drug delivered and elapsed time to t99% reference step convergence
to those obtained using the SCM, though this performance was dependent on the cell-cycle
phase of drug effect. Overall, the NMPC algorithm is suitable for dosing chemotherapeutics
with regular administration schedules and may be adapted for regularly administered
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chemotherapeutics other than tamoxifen. Alterations to the objective function, however,
may be necessary to increase the clinical applicability of predictions from the algorithm.
7.1.2 PBE Models
Both non-saturating and saturating PBE cell-cycle tumor growth models were investigated
incorporating either mass or age as intrinsic system variables. Non-saturating models
displayed exponential bulk tumor progression, which is descriptive of hematological cancers
and solid tumor growth over short periods of time, but is insufficient for describing solid
tumor growth over an extended time period. Saturating mass-structured PBEs, with either
saturating G-phase transition rate or G-phase mass accumulation rates, displayed saturating
growth characteristics, but this may hinder incorporation of a PD effect (i.e., correlations
between cell mass and PD effect are typically not investigated). Two saturating age-
structured PBEs were investigated, one containing a lumped G-phase and age distributed
S- and M -phases for a total of three phases; the other included a lumped Q-phase and age
distributed G-, S- andM -phases for a total of four phases. Both models accurately described
bulk tumor progression, and could be updated with parameters for individual tumor lines.
Three dosing case studies involving two cycle-specific therapeutic drugs with separate
administration schedules, PK dynamics, and PD effects were evaluated against the three
age-structured PBE models developed. While the S-phase treatment always started on
day 42 of the simulation, treatment with the M -phase agent began up to 6 days prior
or after the S-phase treatment. Results indicated that age-structured PBEs are capable
of generating schedule dependent differences in final tumor volumes that are not achievable
using traditional lumped models. Furthermore, the simulations indicated that for multi-agent
chemotherapies, greater final tumor volumes resulted when the drugs were administered
concurrently and that separating drug delivery to reduce the extent of PK overlap resulted
in the the smallest final tumor volumes.
The employed model structure was not capable of achieving the degree of oscillations
necessary for resonance chemotherapy treatment, only manifesting cell-cycle phase alter-
ations immediately following drug delivery. These results were expected as previous papers
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exploring resonance therapy demonstrated that the inclusion of a quiescent cell population,
gradually declining PD effects, PK transport dynamics, or any comparable filtering dynamic
were non-ideal for creating the discrete transitions necessary for manifesting the cell-cycle
fraction oscillations seen during resonance chemotherapy simulations.
Overall both saturating and non-saturating PBEs offer a unique structure for the
evaluation of single or multiple agent chemotherapies. These models, however, are not
suitable for closed-loop controller evaluation of cancer treatment at present due to: (i)
continued reliance on a feedback tumor volume metric; and (ii) the computation time of the
model. In contrast, open-loop schedule evaluation is an ideal application of these models,
allowing for the off-line simulation and evaluation of multiple drug combinations, dosing
schedules, and dosing levels, areas that cannot be explored clinically or even preclinically
(some may even argue in culture) due to constraints on financial costs, ethics, and time.
7.1.3 Docetaxel
Using data obtained from a pharmacokinetic study in mice (n = 30) dosed intravenously
at 10
mg
kg
, a linear PBPK model was developed for Doc. Model compartments included
plasma, tumor, liver, lung, kidney, heart, spleen, muscle, and fat. Tissues were initially
assumed to be perfusion-limited, and then extended to diffusion-limited if the additional
model complexity was justified by a corresponding increase in model quality. Due to a
combination of rapid tissue absorption after the dose and prolonged retention of Doc in
tissues, a third subcompartment was necessary in each tissue to describe the observed data.
Rates into this compartment were kept equivalent for each tissue to limit the overall number
of model parameters. Nonlinear transfer rates into extravascular tissue space could likewise
describe the observed Doc data; however, the focus was on maintaining a linear model
structure because the literature describes Doc plasma kinetics as linear.
The scale up this tissue intensive, linear mouse PBPK model to humans was then
investigated. Model Doc plasma predictions were compared against data from three separate
Phase 1 clinical trials (Doc doses ranging from 35-75
mg
m2 ) and two Doc models available in
the literature: (i) the five-tissue PBPK model of Bradshaw-Pierce et al.; and (ii) the three
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compartment population PK model developed by Bruno et al. Predictive accuracy of the
tissue-intensive PBPK model and population PK model were of the same order despite not
incorporating patient-specific correlates beyond body weight and body surface area within
the PBPK model. Estimating unbound Doc percentage in individual patients improved the
tissue-intensive PBPK model predictions with a mean predicted unbound Doc fraction of
3.7% (0.5-8.9%). While these means and ranges are in agreement with previous studies,
additional validation is required to determine if the predicted unbound fractions correspond
to individual patient values. The elderly patient data was poorly described. By altering
cardiac output and tissue volume percentages for muscle and fat, the tissue-intensive model fit
the data. Finally, simulated tumor concentration profiles revealed that Doc may accumulate
with weekly administration.
The developed tissue-intensive PBPK model and patient-specific Doc plasma concen-
trations were then used as the input to a semi-mechanistic neutrophil model developed by
Friberg et al. Neutrophil model parameter alterations were necessary to describe neutrophil
count progression from the two evaluated clinical studies [6, 195] for patients administered
50-75
mg
m2 Doc q3w over a 1-hour infusion. This neutrophil model was then used to
simulate patient neutrophil progression over alternative Doc treatment schedules (“weekly”
and every other week) as literature results indicate decreased occurrence of grade 3 and
4 neutropenia for these treatment schedules. Initial simulation results indicated decreased
toxicity for “weekly” Doc treatment, however, this reduction in neutropenia was found to be
infusion duration dependent and could not be achieved if Doc for the “weekly” schedule was
administered over 30-minutes as implemented clinically. Neither alterations to the PD effect
term nor simultaneous parameter estimation for patients dosed q3w and “weekly” resulted
in parameters capable of describing both Doc treatment regimens. However, the inclusion
of an effect-compartment with either a log-linear or sigmoidal PD effect term allowed for
population predictions of grade 3/4 neutropenia consistent with results from the literature.
An NMPC algorithm was used to develop Doc administration schedules for three separate
model structures: (i) Friberg model with updated parameters; (ii) effect-compartment with
log-linear drug effect; and (iii) effect-compartment with sigmoidal drug effect. For each of
these models, three separate Doc schedules were developed based upon model parameters
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consistent with median, low risk, and high risk patients. State constraints on ANC were
relaxed and incorporated within the system objective function to avoid infeasible controller
formulations. Predictions for low risk patients for all three evaluated models, while increasing
Doc delivery, are likely artifacts of limited patient neutrophil count samples and should not
imply that such an amount of Doc could be delivered to any patient over a 12 week interval.
Dose schedule predictions for the median patient using each of the three models increased
administration of Doc over a 12 week period compared to a q3w 70
mg
m2 regimen and may
allow for improved treatment efficacy without an increase in accompanying toxicity. Doc
delivery schedules for high risk patients, while delivering 38-62% less total Doc than the
schedule for the median patient and 18-52% less total Doc than q3w 70
mg
m2 , allowed the
high risk patient group to avoid grade 3 occurrences of neutropenia.
7.2 FUTURE WORK
Throughout the course of these studies, a number of methodologies regarding the modeling
and interpretation of experimental data have been encountered. Some have been applied in
the above model development, while many were uncovered after the fact during reflection.
What follows are a number of items to consider during model development for increasing the
downstream relevance of dose schedule design.
7.2.1 Tumor Models
When modeling tumor data, parameters should not be estimated based upon the average
data obtained at individual points. Assuming the PK is identical for each mouse, a necessary
assumption in model development, it is immediately recognizable that the PD term is
nonlinear and the perturbed treatment progression should depend on the initial volume
of the tumor (current models, however, display initial condition independence). Clinical
and preclinical evidence support the premise that treating a smaller tumor is more likely
to result in treatment success. From a modeling standpoint, these would be the tumors
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that displayed a slower overall growth rate, hence, they are less likely to recover following
initial treatment cycles. Developing PD parameters based upon the average tumor volumes
obtained at individual time points over a distributed initial tumor volume range will be
preferentially biased towards under-predicting the actual tumor treatment effect. Taking
this concept one step further, individual tumor growth models should also be developed for
each individual xenograft.
7.2.1.1 Untreated Tumor Growth Evaluation The evolving tumor growth profiles
are dependent upon two system variables: (i) initial condition effects stemming from
implantation of the xenograft fragment, vascularization, and subsequent growth; and (ii)
growth rate defined by the cycling fraction of the tumor (often viewed as S-phase fraction)
that is dependent on a number of environmental factors and ultimately defines the xenograft
doubling time. For initial condition effects, these can be be viewed as time-shifted xenografts
with identical tumor progression trajectories; identical tumor progression parameters should
be sufficient for describing the progression of each of these tumors. For trajectories which do
not appear as time-shifted, these would be categorized as xenografts displaying altered tumor
progression dynamics and require individual parameter identification. While this would
at first seem to be data limited, the identification of models, even for the age-structured
PBEs described above, can be formulated using the following framework: (i) assume a
standard transition rate within both S-phase and M -phase compartments; (ii) evaluate G-
phase transition using tumor progression data from implantation to the start of treatment,
or if this short term progression agrees with that of a control xenograft, the duration of
the study. For the 4-phase saturating model, restrict G-phase to S-phase progression to
literature values, then evaluate parameters for kGQ and kQG, which can not be guaranteed as
unique. Finally, (iii) base the system θ upon the entire set of data. It should be noted that
this approach is non-ideal for G-phase active agents and would require additional information
regarding the G- and Q-phase transition relationship to ensure model accuracy.
7.2.1.2 Inclusion of Natural Apoptosis Another concern is the failure to include
non-drug induced cell apoptosis within the tumor growth model, or, when it is included,
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to ground the function based on experimental observations as opposed to estimating values
which fit the data. As already discussed, the evaluation of individual cell-cycle progression
rates based upon a bulk measure of tumor growth will return multiple solutions, a problem
only compounded by the addition of an overall rate of apoptosis within the model, or
worse, cell-phase dependent rates of apoptosis. Depending on the rate of apoptosis within a
solid tumor, the estimated parameters for tumor growth dynamics may significantly under-
predict the actual rate of proliferation and provide inaccurate tumor progression predictions
during the course of treatment. There have been some modeling attempts to selectively
limit apoptosis to individual phases (i.e., probabilistically most likely during cell division)
[196, 197], however, other authors have had more success in model development by including
equivalent apoptotic rates in every progressing model phase [65]. One may observe apoptotic
rates from proliferating cells in vitro, however, this rate is dependent on the degree of
confluence within the culture and increases as cells form a complete monolayer. Further,
these observations would likely serve as a lower bound on apoptotic rates for solid tumors,
which have additional apoptotic influences due to environmental conditions (i.e., hypoxic
environment, low pH conditions) and the immune system of the host. Whether apoptosis
is a significant factor during unperturbed tumor progression remains unconfirmed, however,
apoptosis following treatment (i.e., PD effect) requires further evaluation to improve both
the model accuracy and applicability to dose schedule development.
7.2.1.3 Accurate PD Terms/Kernels Following treatment, susceptible cells have
their growth trajectory altered, leading to either prolonged phase residence time while the cell
recovers or, if unsuccessful in repairing cellular damage, due to apoptosis. However, almost
all tumor treatment models have an immediate death effect, eliminating the contributions
of affected cells from the overall volume. There is a tendency in these models, however,
to over predict the degree and onset of drug effect, and other authors have investigated
additional model compartments for representing cells undergoing apoptosis [147, 198]. Some
models have included transition rates back and forth between affected and unaffected cellular
compartments [65, 117], though, these multiple state representations encounter the same
difficulties regarding multiple solutions as those discussed in estimating cell-cycle parameters,
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with the additional disadvantage that there is little biological insight for grounding parameter
values within specific bounds. Basse and coauthors included an apoptotic compartment
within a DNA-structured cell-cycle PBE, tracking apoptotic cells based on DNA degradation,
a novel approach for developing a PD effect relationship [198]. Flask experiments involving
cultures of a melanoma cell line (NZM13) exposed to paclitaxel for 72 hours were performed,
with cells collected at 0, 18, 48, 72, and 96 hours and subsequent cell-cycle fraction evaluation
using flow cytometry. Similar approaches can be utilized in constructing more accurate
PD dynamics with different tumor lines and drugs, taking into account the need to titrate
exposure levels (e.g., more accurate representation of PK profile) in addition to exploring
alternative dosing levels.
7.2.1.4 Bulk Tumor Measurement Errors It is important to consider possible errors
when validating a PD effect model based on bulk tumor volume measurements. Previously
in this dissertation (Chapter 2), it has already demonstrated that progression can be
represented by including phase-specific effect within any phase, implying that the current
representations of PD effect are already under-defined. An additional concern is the
reliability of a bulk tumor measurement for gauging the degree of anti-tumor effect following
treatment. For the untreated case, the measurement device, typically digital calibers, have
an accuracy of ± 5% in the measured directions. These errors may result in a 16% error
based on tumor volume calculations using the longest tumor dimension, l, and the second
longest dimension, w, as follows:
V =
lw2
2
This bound on error neglects skin and hair contributions to the measurement, which have
a decreasing effect on measurement error as the overall size of the xenograft increases.
Additionally, caliper measurements can not distinguish necrotic portions of a xenograft which
may have arisen during tumor progression. Following treatment, volume measurement errors
can be compounded due to inflammation and edema resulting from cell apoptosis and necrosis
within a tumor. While apoptotic events are observed rapidly in vitro following treatment
(0-4 hours), regression of the bulk tumor mass may not occur until >4 days following the
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start of treatment. This mismatch of timescale dynamics between PK profile and PD onset is
often neglected during model development or approximated using indirect response models.
Furthermore, preclinical regimens with repeating cycles may display more rapid xenograft
regression during initial or subsequent cycles. Possible explanations of this phenomena are an
increased localization of macrophages, responding to apoptotic cells from the initial cycle, or
acclimation of the tumor mass on follow-up treatments (e.g., decreased inflammation). Better
understanding and inclusion of these bulk tumor altering effects would improve both treated
and untreated tumor growth model quality, allowing for increased accuracy of downstream
schedule development.
7.2.2 Neutrophil Toxicity Model
The neutrophil model investigated herein utilized a structure developed and validated by
Friberg et al. across a number of different chemotherapeutics [3]. Alterations to the model
structure, however, were necessary when evaluating alternative Doc dosing regimens in order
to accurately describe observed clinical neutrophil progression. A number of items remain
to be addressed regarding the validation and clinical relevance of this model structure.
7.2.2.1 Low Dose Model Validation The model developed by Friberg et al. [3] was
adapted with both a Hill function effect term, indicating a threshold drug concentration level
necessary for manifestation of the PD effect, and a filter constant to reduce the effect of Doc
plasma concentration during the infusion on model predictions. However, data from only a
few patients were available for developing this model, and typical baseline neutrophil counts
from these patients were two or more fold greater than typical population baselines. As such,
additional patient data would aid in the validation of both the parameter values and the
model structure. Also, while a comprehensive PBPK model was developed for predicting
human Doc tissue concentrations, the PD effect on hematopoietic stem cells was based
on a filtered circulating Doc plasma concentration. Ideally, the model would be updated
with an additional compartment depicting bone marrow Doc concentrations to provide a
more accurate representation of hematopoietic stem cell exposure to Doc. Alternatively,
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the current structure could be updated to relate the unbound fraction of Doc, based on
the predicted PK profile and patient-specific measures, to downstream PD effect. Karlsson
et al. have explored using a number of metrics for generating a population PD model for
predicting the toxicity effects from Doc treatment, noting only a correlation between patient
AAG and the bilinear effect constant in their PD model [106]. Baker et al. have also found
a significant correlation between the free fraction of Doc to AAG (decreasing free fraction
with increasing AAG levels) and the unbound AUC of Doc in plasma to worst grade of
neutropenia (increased unbound AUC leads to increased toxicity, a correlation not observed
based on total Doc AUC) [8]. As additional patient characteristics (e.g., albumin) also affect
the unbound fraction of Doc without altering AAG levels, unbound fraction may serve as a
more reliable and appropriate metric for predicting patient toxicity.
7.2.2.2 GCS-F Neutrophil Models Therapeutic regimens often include other drugs,
either for increasing the efficacy of treatment or aiding in patient recovery. With Doc
treatments, it is common to have concurrent GCS-F administered to aid in neutrophil
recovery following Doc administration. While the present model did not include an explicit
representation for GCS-F within the model structure, other more involved structures from
the literature can relate administration of GCS-F to increases in neutrophil production [51].
Using such a model, the multi-input problem (Doc and GCS-F administration) could be
evaluated using a NMPC algorithm to determine if the efficacy and patient quality of life
could be improved under different treatment regimens.
7.2.2.3 Objective Function Formulation Objective functions during these studies
were limited to either following a desired tumor trajectory or maximizing the total amount
of Doc delivered subject to toxicity constraints. As illustrated earlier, attempting to follow
a prespecified tumor regression trajectory raises numerous ethical and practical questions,
leaving us no better off than previous solutions generated using optimal control or open-
loop systems analysis. Likewise, maximizing dose subject to toxicity constraints neglects the
repercussions of prolonged neutrophil counts beneath homeostatic levels. Future objective
function formulations can investigate the inclusion of an integrated neutrophil metric or
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time above additional thresholds. Also, the objective function can be extended to include
both tumor regression and toxicity aspects with a weighting preference towards toxicity
constraints as these manifest at earlier points during treatment and may cause the premature
discontinuation of a regimen.
206
APPENDIX A
NOMENCLATURE
Abbreviations
ANC absolute neutrophil count
ALB albumin
AAG α1-acid glycoprotein
AIC Akaike’s information criterion
ALT alanine aminotransferase
AST asparatate aminotransferase
AUC area under the curve
BSA body surface area
CHOP cyclophosphamide/doxorubicin/vincristine/prednisone
CL clearance
Doc docetaxel
ER+ estrogen receptor positive
GCS-F granulocyte colony stimulating factor
GM Gompertz model
GMC Gompertz model controller
GMCS-F granulocyte macrophage colony stimulating factor
HSV Hankel singular value
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HTM 4-hydroxytamoxifen
IV intravenous
9NC 9-nitrocamptothecin
PE performance error
PD pharmacodynamic
PK pharmacokinetic
PBPK physiologically-based pharmacokinetic
MAPE median absolute performance error
MILP mixed–integer linear programming problem
MINLP mixed–integer nonlinear programming problem
MSKCC Memorial Sloan-Kettering Cancer Center
MTT mean transit time
NONMEM nonlinear mixed-effects modeling
NS normalized sensitivity
ODE ordinary differential equation
PBE population balance equation
PET positron emission topography
q3w drug dosing once every three weeks
QCM quiescent cell model
QCMC quiescent cell model controller
RS relative sensitivity
RMSPE root mean squared performance error
SCID severe combined immunodeficient
SCM saturating-rate cell model
SCMC saturating-rate cell model controller
SERM selective estrogen receptor modulator
SSE sum squared error
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UPCI University of Pittsburgh Cancer Institute
WSSE weighted sum squared error
Notation
aci minimum transition age during i-phase
aciup value after which a constant i-phase transition occurs
Bi toxicity bounds for the neutrophil model
Ci concentration in compartment i
Cie extravascular concentration of compartment i
Civ vascular concentration of compartment i
[Doc] plasma docetaxel concentration
Di generic drug concentration for drug i
Edrug drug effect
Ei filtered generic drug concentration for drug i
Emax maximum drug effect
EC50 drug concentration necessary for 50% of Emax
F filtered docetaxel concentration
Fi tissue blood flow rate in compartment i
G(jω) n-state original model
Gr(jω) reduced k-state model
fhem hematocrit fraction
funb unbound plasma fraction
i index variable
j index variable
k time step
kcli metabolic elimination rates in compartment i
kD cell-kill rate
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kf filter rate
ki & kij transition rate constants
kiev extravascular to vascular transition rate in compartment i
kiv vascular to extravascular transition rate in compartment i
kM M -phase cell-kill rate
kS S-phase cell-kill rate
ktr neutrophil transition rate
` length of a tumor during measurement
m manipulated variable moves used in model predictive control
algorithms
mci minimum transition mass during i-phase
mciup value after which a constant i-phase transition occurs
Mi big-M constraints
N0 initial tumor volume; initial neutrophil count
N tumor size; circulating neutrophil count
Ni tumor volume in i-phase (deterministic)
Ni(a, t) cell density in i-phase (age-structured)
Ni(m, t) cell density in i-phase (mass-structured)
Nt total tumor volume (all phases)
n scaling parameter for the linear Edrug formulation
p prediction horizon used in model predictive control algorithms
P proliferating neutrophil compartment
Pi partition coefficient in compartment i
R reference trajectory
R˙(m) mass accumulation rate
t time
Ti neutrophil transition compartment i
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t 1
2
half-life
u input to a system
umin lower bound on the input
umax upper bound on the input
Vi compartment volume
Vie extravascular compartment volume
Viv vascular compartment volume
w width of a tumor during measurement or week in which a
measurement is taken
W1 output weighting vector for parameter estimation
x internal state variable
XG number of cells in the lumped G-phase of the cell-cycle
XG1 number of cells in the G1-phase of the cell-cycle
XM number of cells in the lumped M -phase of the cell-cycle
XQ number of cells in the Q-phase of the cell-cycle
XS number of cells in the S-phase of the cell-cycle
Xi drug mass in compartment i
y outputs
Yact observed output value
Ypred model predicted output value
Greek Letters
α scaling parameter for the log-linear Edrug formulation
β exponent for the log-linear Edrug formulation
βi parameter governing the rate of transition through cell phase i
βi ultimate transition rate through i-phase
∆u change in the input
η binary vector of week-to-week toxicity constraint violations
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Γi weight of the importance of i in the objective function
Γi(a) phase transition rate (age-structured)
Γi(m) phase transition rate (mass-structured)
γ1 rebound effect within the neutrophil model
γ2 Hill coefficient in the sigmoidal drug effect model
κ binary vector of weekly toxicity constraint violations
µ mean
φ binary vector of weekly toxicity constraint violations
ρ parameter vector
σ standard deviation
σHi ith Hankel singular value of the original model
θ plateau population in tumor growth
τi sharpness of the i-phase transition function
τij system time constant, unless specified otherwise
τ pseudo-doubling time for tumor volumes governed by Gom-
pertzian growth
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APPENDIX B
PBPK MODEL EQUATIONS
The complete set of equations for the Doc mouse PBPK model are shown below.
Venous Blood
dCven
dt
=
∑
j FjCje − FtotCven
Vven(1− fhem) +
u(t)
Vven(1− fhem)
+
fhem
(1− fhem)krbcplasCrbcv − kplasrbcfunbCven
dCrbcv
dt
= −krbcplasCrbcv + (1− fhem)
fhem
kplasrbcfunbCven
Lung
dClv
dt
=
Fl
Vlv
(Cven − Clv)− klvefunbClv +
Vle
Vlv
klevCle
dCle
dt
=
Vlv
Vle
klvefunbClv − klevCle + kbindoutClb − kbindinCle
dClb
dt
= −kbindoutClb + kbindinCle
Arterial Blood
dCart
dt
=
1
Vart(1− fhem) (FlClv − FtotCart) +
fhem
(1− fhem)krbcplasCrbca
−kplasrbcfunbCart
dCrbca
dt
= −krbcplasCrbca + (1− fhem)
fhem
krbcplasfunbCart
Gut
dCgv
dt
=
Fg
Vgv
(Cart − Cgv)
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Brain
dCbv
dt
=
Fb
Vbv
(Cart − Cbv)− kbvefunbCbv +
Vbe
Vbv
kbevCbe
dCbe
dt
=
Vbv
Vbe
kbvefunbCbv − kbevCbe + kbindoutCbb − kbindinCbe
dCbb
dt
= −kbindoutCbb + kbindinCbe
Spleen
dCsv
dt
=
Fs
Vsv
(Cart − Csv)− ksvefunbCsv +
Vse
Vsv
ksevCse
dCse
dt
=
Vsv
Vse
ksvefunbCsv − ksevCse + kbindoutCsb − kbindinCse
dCsb
dt
= −kbindoutCsb + kbindinCse
Liver
dCliv
dt
=
1
Vliv
(FliCab + FgCg + FsCsv − (Fg + Fs + Fli)Cliv)− klivefunbCliv
+
Vlie
Vliv
klievClie
dClie
dt
=
Vliv
Vlie
klivefunbCliv − klievClie + kbindoutClib − kbindinClie − kclliClie
dClib
dt
= −kbindoutClib + kbindinClie − kclliClib
Heart
dChv
dt
=
Fh
Vhv
(Cart − Chv)− khvefunbChv +
Vhe
Vhv
khevChe
dChe
dt
=
Vhv
Vhe
khvefunbChv − khevChe + kbindoutChb − kbindinChe
dChb
dt
= −kbindoutChb + kbindinChe
Kidney
dCkv
dt
=
Fk
Vkv
(Cart − Ckv)− kkvefunbCkv +
Vke
Vkv
kkevCke
dCke
dt
=
Vlk
Vke
kkvefunbCkv − kkevCke + kbindoutCkb − kbindinCke
dCkb
dt
= −kbindoutCkb + kbindinCke
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Muscle
dCmv
dt
=
Fm
Vmv
(Cart − Cmv)− kmvefunbCmv +
Vme
Vmv
kmevCme
dCme
dt
=
Vmv
Vme
kmvefunbCmv − kmevCme + kbindoutCmb − kbindinCme
dCmb
dt
= −kbindoutCmb + kbindinCme
Fat
dCfv
dt
=
Ff
Vfv
(Cart − Cfv)− kfvefunbCfv +
Vfe
Vfv
kfevCfe
dCfe
dt
=
Vfv
Vfe
kfvefunbCfv − kfevCfe + kbindoutCfb − kbindinCfe
dCfb
dt
= −kbindoutCfb + kbindinCfe
Tumor
dCtv
dt
=
Ft
Vtv
(Cart − Ctv)− ktvefunbCtv +
Vte
Vtv
ktevCte
dCte
dt
=
Vtv
Vte
ktvefunbCtv − ktevCte + kbindoutCtb − kbindinCte
dCtb
dt
= −kbindoutCtb + kbindinCte
Other
dCov
dt
=
Fo
Vov
(Cart − Cov)− kovefunbCov +
Voe
Vov
koevCoe
dCoe
dt
=
Vov
Voe
kovefunbCov − koevCoe + kbindoutCob − kbindinCoe
dCob
dt
= −kbindoutCob + kbindinCoe
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APPENDIX C
ACTUAL AND MODEL PREDICTED HUMAN DOC PLASMA
CONCENTRATION VERSUS TIME PLOTS
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Figure C1: Measured Doc plasma concentration data in humans from UPCI protocol 01-150
dosed at 50
mg
m2 vs. human PBPK model predictions from the tissue-intensive PBPK (solid),
the Bradshaw-Pierce PBPK (dashed), and the population PK Bruno (dash-dot) model.
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Figure C2: Measured Doc plasma concentration data in humans from UPCI protocol 01-150
dosed at 60
mg
m2 vs. human PBPK model predictions from the tissue-intensive PBPK (solid),
the Bradshaw-Pierce PBPK (dashed), and the population PK Bruno (dash-dot) model.
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Figure C3: Measured Doc plasma concentration data in humans from UPCI protocol 01-150
dosed at 60
mg
m2 vs. human PBPK model predictions from the tissue-intensive PBPK (solid),
the Bradshaw-Pierce PBPK (dashed), and the population PK Bruno (dash-dot) model.
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Figure C4: Measured Doc plasma concentration data in humans from UPCI protocol 01-150
dosed at 75
mg
m2 vs. human PBPK model predictions from the tissue-intensive PBPK (solid),
the Bradshaw-Pierce PBPK (dashed), and the population PK Bruno (dash-dot) model.
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Figure C5: Measured Doc plasma concentration data in humans from a Phase 1 clinical
trial at MSKCC [6] dosed at 55
mg
m2 vs. human PBPK model predictions from the tissue-
intensive PBPK (solid), the Bradshaw-Pierce PBPK (dashed), and the population PK Bruno
(dash-dot) model.
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Figure C6: Measured Doc plasma concentration data in humans from a Phase 1 clinical
trial at MSKCC [6] dosed at 70
mg
m2 vs. human PBPK model predictions from the tissue-
intensive PBPK (solid), the Bradshaw-Pierce PBPK (dashed), and the population PK Bruno
(dash-dot) model.
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Figure C7: Measured Doc plasma concentration data in humans from a Phase 1 clinical
trial at MSKCC [6] dosed at 70
mg
m2 vs. human PBPK model predictions from the tissue-
intensive PBPK (solid), the Bradshaw-Pierce PBPK (dashed), and the population PK Bruno
(dash-dot) model.
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Figure C8: Measured Doc plasma concentration data in humans from a Phase 1 clinical
trial at MSKCC [6] dosed at 70
mg
m2 vs. human PBPK model predictions from the tissue-
intensive PBPK (solid), the Bradshaw-Pierce PBPK (dashed), and the population PK Bruno
(dash-dot) model.
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Figure C9: Measured Doc plasma concentration data in humans from a Phase 1 clinical
trial at MSKCC [6] dosed at 75
mg
m2 vs. human PBPK model predictions from the tissue-
intensive PBPK (solid), the Bradshaw-Pierce PBPK (dashed), and the population PK Bruno
(dash-dot) model.
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Figure C10: Measured Doc plasma concentration data in humans from a Phase 1 clinical
trial at MSKCC [6] dosed at 35
mg
m2 vs. human PBPK model predictions from the tissue-
intensive PBPK (solid), the Bradshaw-Pierce PBPK (dashed), and the population PK Bruno
(dash-dot) model.
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Figure C11: Measured Doc plasma concentration data in humans from a Phase 1 clinical
trial at MSKCC in elderly patients dosed at 35
mg
m2 vs. human PBPK model predictions from
the tissue-intensive PBPK (solid), the Bradshaw-Pierce PBPK (dashed), and the population
PK Bruno (dash-dot) model.
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APPENDIX D
ACTUAL AND MODEL PREDICTED HUMAN DOC PLASMA
CONCENTRATION VERSUS TIME PLOTS (UNBOUND FRACTION)
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Figure D1: Measured Doc plasma concentration data in humans from UPCI protocol 01-150
dosed at 50
mg
m2 vs. human PBPK model predictions from the tissue-intensive PBPK (solid),
the Bradshaw-Pierce PBPK (dashed), and the population PK Bruno (dash-dot) model.
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Figure D2: Measured Doc plasma concentration data in humans from UPCI protocol 01-150
dosed at 60
mg
m2 vs. human PBPK model predictions from the tissue-intensive PBPK (solid),
the Bradshaw-Pierce PBPK (dashed), and the population PK Bruno (dash-dot) model.
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Figure D3: Measured Doc plasma concentration data in humans from UPCI protocol 01-150
dosed at 60
mg
m2 vs. human PBPK model predictions from the tissue-intensive PBPK (solid),
the Bradshaw-Pierce PBPK (dashed), and the population PK Bruno (dash-dot) model.
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Figure D4: Measured Doc plasma concentration data in humans from UPCI protocol 01-150
dosed at 75
mg
m2 vs. human PBPK model predictions from the tissue-intensive PBPK (solid),
the Bradshaw-Pierce PBPK (dashed), and the population PK Bruno (dash-dot) model.
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Figure D5: Measured Doc plasma concentration data in humans from a Phase 1 clinical
trial at MSKCC [6] dosed at 55
mg
m2 vs. human PBPK model predictions from the tissue-
intensive PBPK (solid), the Bradshaw-Pierce PBPK (dashed), and the population PK Bruno
(dash-dot) model.
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Figure D6: Measured Doc plasma concentration data in humans from a Phase 1 clinical
trial at MSKCC [6] dosed at 70
mg
m2 vs. human PBPK model predictions from the tissue-
intensive PBPK (solid), the Bradshaw-Pierce PBPK (dashed), and the population PK Bruno
(dash-dot) model.
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Figure D7: Measured Doc plasma concentration data in humans from a Phase 1 clinical
trial at MSKCC [6] dosed at 70
mg
m2 vs. human PBPK model predictions from the tissue-
intensive PBPK (solid), the Bradshaw-Pierce PBPK (dashed), and the population PK Bruno
(dash-dot) model.
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Figure D8: Measured Doc plasma concentration data in humans from a Phase 1 clinical
trial at MSKCC [6] dosed at 70
mg
m2 vs. human PBPK model predictions from the tissue-
intensive PBPK (solid), the Bradshaw-Pierce PBPK (dashed), and the population PK Bruno
(dash-dot) model.
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Figure D9: Measured Doc plasma concentration data in humans from a Phase 1 clinical
trial at MSKCC [6] dosed at 75
mg
m2 vs. human PBPK model predictions from the tissue-
intensive PBPK (solid), the Bradshaw-Pierce PBPK (dashed), and the population PK Bruno
(dash-dot) model.
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Figure D10: Measured Doc plasma concentration data in humans from a Phase 1 clinical
trial at MSKCC [6] dosed at 35
mg
m2 vs. human PBPK model predictions from the tissue-
intensive PBPK (solid), the Bradshaw-Pierce PBPK (dashed), and the population PK Bruno
(dash-dot) model.
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Figure D11: Measured Doc plasma concentration data in humans from a Phase 1 clinical
trial at MSKCC in elderly patients dosed at 35
mg
m2 vs. human PBPK model predictions from
the tissue-intensive PBPK (solid), the Bradshaw-Pierce PBPK (dashed), and the population
PK Bruno (dash-dot) model.
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